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Abstract 
 As the central repository of biological information and ultimate mediator of all processes 
underlying the activities of living organisms, nucleic acids are the sine qua non for life as we 
know it. Biological research over the past century and more has revealed much of the structure 
and function of nucleic acids, revealing in turn how life begins, changes, reproduces, and ends.  
We glimpse how life has become what it is and perhaps what it may become. 
 This work seeks to understand the ramifications of altering a single nitrogen of the purine 
nucleoside components of nucleic acids. As will be shown, purine analogs lacking the N3 
nitrogen have altered interactions with proteins, water, and other molecules. Replacement of this 
nitrogen with a C-H, C-CH3, or C-CH2OH functionality impacts the structure and biological 
interactions of a DNA duplex containing these alterations in ways not entirely foreseen when this 
work began over ten years ago. The synthetic effort needed to obtain purine nucleosides 
containing each of these modifications is significant. Along the way, new methodologies 
applicable both to the synthesis of purine analogs and natural purine nucleosides are described. 
  
8 
 
Abbreviations and Acronyms 
A  adenosine 
Ac   acetyl 
Ad  adenine  
AIBN   azobis(isobutyronitrile) 
Bn   benzyl 
Boc   tert-butyloxycarbonyl  
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dG  2′-deoxyguanosine 
dm3c3A 3-deaza-3-methyl-2′-deoxyadenosine 
DABCO  1,4-diazabicyclo[2.2.2]octane 
DAP  2,6-diaminopurine 
DBN   1,5-diazabicyclo[4.3.0]non-5-ene 
DBU   1,8-diazabicyclo[5.4.0]undec-7-ene 
DCM  dichloromethane 
DIPEA  diisopropylethylamine  
DMAP  4-(dimethylamino)pyridine 
9 
 
DME  1,2-dimethoxyethane 
DMF   N,N-dimethylformamide  
DMT  4,4′-dimethoxytrityl 
DMSO  dimethylsulfoxide 
DNA  β-D-2′-deoxyribonucleic acid 
dNTP  2′-deoxyribonucleoside 5′-triphosphate 
Et2O   diethyl ether  
EtOAc   ethyl acetate  
equiv   equivalents 
G  guanosine 
Gn  guanine 
h   hour(s) 
Hex   hexanes 
HMDS  hexamethyldisilylazane 
HPLC   high performance liquid chromatography 
HRMS  high-resolution mass spectrum 
M4SA   2,2,3,3-tetramethylsuccinic anhydride 
M4SI   2,2,3,3-tetramethylsuccinimide   
M   molar  
min   minute(s)    
NMR   nuclear magnetic resonance 
NBS   N-bromosuccinimide 
NPE  para-nitrophenylethyl 
PAGE  polyacrylamide gel electrophoresis 
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Pht  phthaloyl  
Piv  pivaloyl 
pyr   pyridine  
Rf   retention factor 
rt   room temperature 
T (or dT) thymidine 
TBAF   n-tetrabutylammonium fluoride 
TBS, TBDMS  tert-butyldimethylsilyl  
TCA   trichloroacetic acid 
TEA   triethylamine 
Tf  triflate (trifluoromethanesulfonyl) 
TFA   trifluoroacetic acid 
TLC   thin layer chromatography 
TMS  trimethylsilyl, also tetramethylsilane 
Tol   para-toluoyl 
Tr   trityl (triphenylmethyl) 
Ts  tosyl 
RNA  β-D-ribonucleic acid 
U  uridine 
UV  Ultraviolet 
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Chapter 1: Introduction 
 
1.1 Brief History of Nucleic Acids Research in Chemistry and Biology 
 From curious prodding at a mysterious substance isolated from the nuclei of cells to the 
soon-to-be routine sequencing of individual genomes to assess disease risk factors and other 
personalized medical information, nucleic acids research has risen from obscurity to prominence 
as a scientific field involving many related disciplines and drawing on immense intellectual and 
monetary resources while advancing at an ever faster pace. Its prominence is merited, for the 
knowledge gained from the study of nucleic acids has not only informed our theoretical 
understanding of life, but also allowed countless breakthroughs with practical applications in 
biology, medicine, agriculture, and many other seemingly unrelated fields. Each new discovery 
not only answers old questions but also opens up the possibility of asking new and sometimes 
more fundamental questions. 
 The name “nucleic acid” comes from Miescher’s isolation in 1868 of an acidic nitrogen 
and phosphorus-containing substance from the nuclei of leukocytes and, later, the sperm cells of 
salmon.1 He called this substance “nuclein,” and it became the object of continuing research 
efforts. The use of dyes capable of staining nuclein and the observation that it formed rod-shaped 
structures during certain stages of cell division suggested that nuclein might have a role in 
inheritance as one generation passed its genetic information to the next. The first direct evidence 
of this role would not come until the Avery-McLeod-McCarty experiment in 1944. This work 
showed that DNA extracted from a virulent strain of the bacterium Streptococcus pneumonia 
transformed a nonvirulent strain of this bacterium to a virulent one. This virulence was shown to 
be transferred by the extracted DNA, and not by protein or any other cellular component. 
12 
 
 Though DNA was shown to be the information-storing agent responsible for inheritance, 
its physical structure and chemical components remained mysterious. Research during the early 
20th century gradually elucidated the nature of these components. Klein and Thannhauser used 
enzymes to degrade nucleic acids into monomers, showing that they were composed of pentose 
carbohydrates linked by a phosphodiester backbone. Isolation of the monomers present in DNA 
 
allowed further purification and characterization. The four monomers (nucleosides) were 
eventually isolated in pure form and chemical structures of each were proposed. The proposed 
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structures of the four nucleosides were verified by total synthesis in 1951 by Todd. This marked 
the increasing interest in DNA by organic chemists as a chemical substance. 
 As shown in Figure 1, DNA, β-D-2′-deoxyribonucleic acid, is composed of a long 
polymer of four different nucleobases each attached to a 2′-deoxyribose sugar with β 
stereochemistry, with each sugar attached to the next by a phosphodiester between the so-called 
3′ and 5′ hydroxyls of the sugar. At this juncture, however, the misassignment of dG and dT as 
existing in their enol rather than keto forms hampered further understanding of how the DNA 
polymer chains arranged themselves in the cell. Gullard had hypothesized that DNA existed with 
hydrogen bonding interactions between dA and dT, and between dG and dC, and this was 
supported by Chargraff’s observation of a consistent 1:1 proportionality between dA and dT and 
between dG and dC. Soon afterward, in 1953, Watson and Crick would make the discovery that 
would revolutionize the field of nucleic acids research and forever alter the study of biology and 
biochemistry.2 Realizing that dG and dC could also reside in the keto form, they constructed 
model structures in which DNA could associate through specific hydrogen bonding interactions.  
 
 
They proposed the Watson-Crick base pairs in which dA pairs with dT and dG pairs with dC. 
Their key piece of evidence came from a crystal structure obtained from their collaborators 
Wilkins and Franklin.3 The X-ray diffraction pattern observed implied a helix with two 
periodicities along the major axis, a major one with a length of 3.4 Å and a secondary one of 34 
Figure 2. Photograph of the X-ray diffraction pattern observed by Wilkins and Franklin. 
14 
 
Å. Using the correct tautomeric forms of dG and dC allowed Watson and Crick to formulate the 
correct three-dimensional structure of DNA, in which two strands form a double helix stabilized 
by base pairs of the heterocycles hydrogen-bonded to each other and sequestered from water on 
the interior of the helix. This structure also suggested a means of replication: unwinding of the 
duplex followed by replication of each strand and re-pairing of the resulting copied, or daughter, 
strands gave a new double-stranded copy of the parent DNA. It would be the work of later 
researchers to prove that this was the case, and to track down the cellular mechanisms for this 
replication. A new era of biochemical research had begun, and it was fueled by the discovery of 
the physical structure of the genetic material common to all living organisms.  
 
1.2 DNA and RNA Structure 
 Though Watson and Crick had proposed the correct secondary structure of DNA, there 
remained many refinements and indeed surprises that were gradually discovered over the next 50 
years. There remain, however, gaps and weaknesses in our modern understanding that are the 
targets of ongoing research.  
 
  Building Blocks and Basics of Duplex Structure 
 The fundamental unit of DNA or RNA is the nucleoside, which is itself composed of two 
units, the nucleobase (or base) and the sugar. In DNA the bases are either adenine, guanine, 
cytosine, or thymine; the sugar is 2′-deoxy-D-ribose. The natural nucleosides are called 2′-
deoxyadenosine (dA), 2′-deoxyguanosine (dG), 2′-deoxycytidine (dC), and 2′-deoxythymidine 
(dT). In RNA uracil replaces thymine to give the nucleoside uridine. The sugar is D-ribose; the 
nucleoside abbreviations are then A, G, C, and U, sometimes used inexactly to designate the 2′-
15 
 
deoxynucleosides. A and G are known as the purines, and C, T, and U are the pyrimidines. There 
exist a number of minor nucleosides modified in the base or sugar that perform many biological 
functions; these are discussed in section 1.5.  
 
 
 Nucleosides attached to one or more phosphate groups are called nucleotides. A single 
phosphodiester bridges each nucleotide unit in all nucleic acids. Together with the sugar the 
phosphates form the “backbone” of nucleic acids. Each phosphodiester bears a negative charge, 
making oligonucleotides overall negatively charged. This allows for a favorable interaction of 
DNA with metal ions and water, as well as imparting a resistance to hydrolysis, making 
phosphates ideal components of nature’s information storage system.4 As shown in Figure 3, 
there are only two possible Watson-Crick base pairs, A-T and G-C. Base pairing is the single 
most important factor in the stability of DNA secondary structures. In other words, the ability of 
a single strand of DNA to form a stable duplex with another strand is mostly dependent on 
complementarity, that is the matching of base pairs between the two strands. The greater the 
complementarity, the more stable the duplex. Since G-C base pairs have three hydrogen bonds 
and engage in more favorable base-base stacking, they add more stability to the duplex than do 
A-T base pairs with their two hydrogen bonds. Mismatches such as A-A or G-T can be tolerated 
Figure 3. The two Watson-Crick base pairs present in DNA. In RNA the A-U base pair replaces A-T. 
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 A few of the many parameters used to describe nucleic acid physical structures must be 
introduced here. These are illustrated in Figures 5, 6, and 75. Base tilt is rotation about the short 
axis through the base pair. Roll is the rotation of the base pair about the long axis normal to the 
helical axis. Propeller twist is the rotation of one base with respect to the other in the same base 
 
 
pair. Rise is the distance between each base pair along the helical axis. Helical twist is the 
rotation around the helical axis. Helical pitch is the distance per helical repeat. Slide and shift are 
displacements of the base pair in the plane normal to the helical axis. Sugar pucker is a 
parameter that describes the orientation of each atom in the sugar ring above or below the plane 
Figure 6. Illustration of propeller twist and tilt. Image taken from Saenger.5 
Figure 5. Illustration of various structural parameters used with nucleic acids. Image taken from 
Saenger.5 
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described by the other four; endo refers to a displacement on the same side of the ring as C5′, 
while exo refers to a displacement on the opposite side. All five atoms of the sugar are never in 
the same plane, and generally all sugars in a given duplex structure will reside in one pucker  
 
  
 
 
most of the time. C2′-endo (or south conformation) is generally favored in DNA, while C3′-endo 
(or north) is favored in RNA. Syn and anti describe the conformation of the glycosyl bond. If the 
base resides above the sugar it is said to be in the syn conformation, and if rotated away from the 
sugar it is anti. The anti conformation is usually favored for purines; the syn conformation is 
almost never observed with pyrimidines because of the steric clash between the O2 carbonyl and 
the sugar.  
Figure 7. Top: The two sugar puckers favored in nucleic acids. Image taken from Saenger.5 
Bottom: Illustration of anti and syn conformations of nucleosides. 
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 With these parameters it is possible to describe precisely the structural features and 
differences between A, B, and Z-form DNA. B-DNA is the most stable structure for a random-
sequence duplex under physiological conditions and is thus the reference point for any 
discussion of DNA structure. It is a right-handed helix about 20 Å in diameter with a rise of 3.4 
Å per base pair and 11 base pairs per helical turn, giving it a moderate pitch or helical repeat of 
35.7 Å. The sugar pucker is C2′-endo and the glycosyl bond is anti.   
 
A B Z 
Helix sense Right-handed Right-handed Left-handed 
Repeating Unit 1 bp 1 bp 2 bp 
Rotation/bp 33.6°  35.9°  60°/2 
Mean bp/turn 10.7 10.5 12 
Tilt 19°  -1.2°  -9° 
Rise/bp 2.3 Å  3.4 Å  3.8 Å 
Pitch 24.6 Å  35.7 Å  45.6 Å 
Propeller twist 18°  16°  0° 
Glycosyl angle anti Anti C: anti, G: syn 
Sugar pucker C3'-endo  C2'-endo  C: C2'-endo, G: C2'-exo 
Diameter 26Å  20Å 18Å 
 
 A-DNA forms under high salt and low water conditions. Many short DNA sequences 
examined in X-ray crystallography crystallize in the A-form, partly as a result of the conditions 
used for crystal growth. It is unknown if A-form DNA exists under cellular conditions, although 
it is thought to be favored for RNA-DNA duplexes and RNA-RNA duplexes. A-DNA exhibits a 
wide, deep major groove. The minor groove is extremely shallow. The helix is wide (26 Å versus 
20 for B-form) and the base pairs have a large tilt of 20° normal to the helical axis.  
 Z-DNA represents a dramatic departure from the A- and B-form. It is a left-handed helix 
in which the minor groove is extremely wide and the major groove almost nonexistent. The 
Table 1. Comparison of A, B, and Z forms of DNA.5 
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repeat unit is two base pairs instead of one. The diameter is narrow at 18 Å and the pitch 
elongated to 45.1 Å. Remarkably, dG residues adopt the syn conformation to make this structure 
possible. Formation of the Z-form is generally disfavored, but certain conditions favor it such as 
alternating purine-pyrimidine sequences (especially poly(dGC)2), negative DNA supercoiling, 
low salt, and the presence of certain cations (all at physiological conditions, 37 °C and pH 7.3-
7.4). Z-DNA can form a junction with B-DNA in a structure that involves the extrusion, or 
unpairing, of a base pair. The Z-DNA conformation has been difficult to study because it does 
not exist as a stable feature of the double helix. Instead, it is a transient structure that can be 
induced by binding with certain proteins that reverts back to B-form afterwards.6 
   
  Other Factors Stabilizing Nucleic Acid Duplexes 
 The favored structure of an oligonucleotide is determined by the counterbalancing of 
many opposing forces, e.g. charge-charge repulsion, steric effects, base stacking, etc. However, 
the forms of DNA described here are not static structures, but rather the equilibrium states of 
dynamic structures. DNA can bend, compress, stretch, and unwind under the influence of 
hydration, salt content, metal ion binding, temperature, protein interactions, the DNA sequence 
itself, and more. A basic overview follows here with an emphasis on points of special relevance 
to the topic of this thesis. 
 The stability of nucleic acids in pure water is lessened,5 and the role of salt content and 
metal binding is quite important. Since DNA is a negatively charged molecule, at a minimum 
counterions are needed to mitigate the charge-charge repulsion of the phosphate groups. 
Additional cations and metal ions are able to bind to and stabilize other structural features of 
nucleic acids. Nucleic acids contain four sites that can bind metal ions: the negatively charged 
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phosphate oxygens, the ribose hydroxyls, the ring nitrogens of the heterocycles, and the 
exocyclic base keto groups.7 Metal ions such as Mg2+, Ca2+, Na+, and K+ are present in the body 
in millimolar concentrations. All of these metals contribute to the stability of the duplex form, 
but some metals can destabilize the duplex. For example, Cu2+ binds strongly to the phosphate 
groups and promotes transition to the random coiled state.7 Other metals such as Pb2+ promote 
nonenzymatic phosphodiester cleavage in RNA.5 While lead is toxic, some DNA-cleaving 
metals have therapeutic potential, the marquee example of which is Cisplatin (cis-
dichloroammineplatinum(II)). Cisplatin coordinates to DNA and attacks guanosine residues at 
N7 and O6.8 It is used in the treatment of a variety of cancers. 
 Not surprisingly, DNA is most stable at physiological pH (7.4). Within the range of 3-10 
it retains normal base pairing and near-normal stability. Protonation of basic sites at acidic pH 
and deprotonation of acidic sites at high pH can contribute to loss of duplex stability by 
disruption of base pairing. Depurination (loss of adenine or guanine from the sugar) becomes 
problematic at acidic pH, while RNA is much more prone to hydrolysis at basic pH. 
 Base stacking, or π-stacking, is another important stabilizing factor. Aromatic compounds 
can stack on top of each other approximately 3 Å apart in an interaction between the p-orbitals of 
the aromatic rings engaged in π-bonding. This interaction is of vital importance to the stability of 
oligonucleotide duplexes. The stability gained by the duplex varies from -3.82 kcal/mol of A-
T/A-T dimers to -14.52 kcal/mol of G-C/C-G dimmers.9 The hydrophobic effect certainly plays a 
role in the aggregation and stacking of oligonucleotide heterocycles in addition to the 
contributions from π-π interactions.10  
 Compression of an oligonucleotide duplex is referred to as positive supercoiling;  
stretching is known as negative supercoiling. DNA under physiological conditions is under slight 
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negative supercoiling. The stiffness of DNA is measured in terms of its persistence length, which 
is defined as the length of DNA beyond which its time-averaged orientation becomes 
uncorrelated by a factor of e. For most sequences this is around 140-150 base pairs or 46-50 nm, 
making DNA a moderately stiff molecule. 
 The supercoiling and bending of DNA becomes vitally important in the cellular 
processing and storage of its genetic material. Given that the DNA of each chromosome (of 
which humans have 46) can extend as much as 10 cm if unwound, a great deal of packaging and 
compression is necessary. DNA is wound tightly around spool-like proteins known as histones, 
which are then further packaged as chromatin and compacted into chromosomes.  
 
  DNA Hydration; Special Features of the Minor Groove 
 Hydration is markedly different in the major and minor grooves of DNA. It is an 
important factor in determining the duplex structure (A-form or B-form) and contributes to the 
overall stability of the duplex by adding additional hydrogen bonding interactions with exposed 
functional groups on the exterior of the duplex. These interactions can be highly ordered or 
relatively disordered—that is, non-specific with a short residence time—depending on the 
location of the interaction. Hydration is often analyzed in terms of shells of hydration, which are 
single layers of H2O molecules surrounding the duplex and engaged in specific interactions. The 
primary shell of hydration is defined as the nearest layer to the duplex engaged in direct 
interactions with functional groups on the surface of the duplex and often with other waters in 
the primary shell. The secondary shell is the next layer of water engaged with the first, and so on. 
Each shell becomes less ordered (at least with respect to its interaction with the duplex), larger, 
and more able to exchange with the bulk solvent as it becomes more distant from the duplex.  
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 As shown in Figure 9, water forms contacts with the N7 and N6 amino group of purines. 
Gumport has examined the importance of hydration in the major groove by designing a 
nucleoside analog that models a water molecule bound to the N7 nitrogen.11 X-ray 
crystallography confirmed that the 7-hydroxymethyl group engaged in an intramolecular 
hydrogen bond with the N6 amino group. The analog was also modeled into a crystal structure of 
24 
 
the tryptophan (trp) repressor/operator complex, showing that the analog places the oxygen of 
the hydroxymethyl group in nearly the same position as the oxygen contributed by the water in 
the protein/DNA complex. In addition to Gumport’s work, a examination of major groove 
hydration in ten different A-form DNA octamers based on crystallographic data found that 
d(CG) base pairs are better hydrated than d(AT) base pairs in terms of total water molecules, 
with 2.5 vs. 1.3; steps with high twist angles are better hydrated than steps with low twist angles, 
with 6.9 vs. 0 water molecules; negative roll angles are better hydrated than positive roll angles, 
with 2.8 vs. 1.8 water molecules; and flanking base pairs are better hydrated than central base  
 
pairs, with 2.6 vs. 2.0 water molecules. These observations are sequence independent, occurring 
for both d(CG) and d(TA) base pairs.12 These phenomena, while important, may not be 
completely applicable to B-form DNA, which has a shallower and wider major groove. A-form 
DNA (vide supra) occurs under relatively dehydrated conditions and may not exist at all under 
physiological conditions. In general, a wider major groove facilitates hydration of individual 
bases by H2O in the plane of each base and a freer exchange of water molecules between 
hydration shells.  
 Though the majority of water molecules and cations in the major groove are relatively 
disordered and non sequence-specific, there are electrostatic factors, or high-occupancy sites, for 
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monovalent cations in the major groove near G-C rich regions as well as in the minor groove 
near A-T rich regions observed in high-resolution structures of DNA.13 A recent compilation of 
high-resolution structures of DNA shows a consensus for monovalent cations within 3.5 Å of O6 
and/or N7 positions of dG.14 Ganguly and co-workers endeavored to model water/cation binding  
 
 
 
and protein side-chain association in the major groove at dG residues through the synthesis of 
dc7G (2′-deoxy-7-deazaguanosine), 2′-deoxy-7-deaza-7-hydroxymethylguanosine, and 2′-deoxy- 
7-deaza-7-aminomethylguanosine15 and examined their effects on the structural parameters of a 
variety of DNA duplexes.16 
 The dc7G substitution decreased the overall stability of the duplex (ΔΔG° = 2.5 and 4.1 
kcal/mol at low and high salt, respectively). The 7-hydroxymethyl substitution behaved in a 
similar fashion to dc7G with a ΔΔG° = 2.3 and 4.9 kcal/mol. Intriguingly, the aminomethyl 
group, which is a restricted cation model (it is protonated under physiological pH), increased the 
stability of 12-mer duplexes by 2.3-2.7 kcal/mol per substitution relative to a control. The 
stabilization was attributed to the tethered NH3+ ion. Clearly, cation binding in the floor of the 
major groove at dG residues is an important stabilizing interaction.  
Figure 10. Guanine N7/O6 bind cations, basic protein side chains, and water in the major groove. 
Figure from reference 16. 
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 In contrast to the major groove, the minor groove’s narrowness in the B-form DNA limits 
the ability of water molecules to exchange rapidly with each other. Being more constrained, 
minor groove hydration tends to be more ordered, with a single line of water molecules filling 
the minor groove floor and hydrating the base pairs.  Hydration of the minor groove in A-T rich 
sequences is ordered enough that a “spine” of ordered water molecules has been observed in 
crystal structures.17,18  Figure 11 shows a crystal structure of the Dickerson dodecamer19 
d(CGCGAATTCGCG)2, a widely-studied self-complementary DNA sequence. The spine is seen 
clearly bridging between the N3 nitrogen of adenines and the O2 carbonyl of thymine in the 
adjacent base pair over a distance of approximately 3.7 Å. This spine is not present in G-C rich 
sequences, largely because the N2 amino group of G blocks access to its N3 nitrogen by water. 
Hydration is less ordered and does not penetrate as deeply into the groove. In addition to the 
spine of hydration, the electrostatic potential is also different in A-T rich sequences.20 The 
importance of the spine of hydration to the stability of A-T rich regions merits further discussion 
and is examined in detail in Chapter 4. 
 Though hydration in the major groove is not generally ordered enough for 
crystallographic study, it nonetheless contains organized and indeed highly conserved regions 
where exact placement of water molecules in the primary shell of hydration is important for 
sequence recognition and protein binding. Shakked and co-workers found that the pattern of 
major groove hydration was crucial for recognition and binding by the trp repressor, and they 
identified 10 conserved hydration sites in the major groove of the trp operator.21 Such groove-
specific hydration sites are even more important for minor groove-binding proteins and 
drugs.22,23 Netropsin, a pyrrole-amidine antibiotic isolated from the actinobacterium 
Streptomyces netropsis,24 is known to bind the minor groove of DNA25 (see Figure 12). 
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 Netropsin binding to the minor groove in B-DNA releases 22-53 water molecules from 
the hydration shell of A-T tracts, and the number of water molecules released depends on the 
Figure 11. Crystal structure of the Dickerson dodecamer showing the spine of hydration in the 
AATT tract of the minor groove.5 
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bonds between the N3 of adenines, the ligand’s indole or benzimidazole NH-groups, and the O2 
carbonyl of thymines. These specific contacts allow netropsin to recognize A-T rich regions to 
cause its biological effects. Non-classical ligands with a linear shape often bind only weakly to 
DNA because they lack the isohelical shape to match the convex structure of the minor groove. 
However, a number of non-classical ligands are able to bind with high affinity, and it is through 
highly-ordered water-mediated contacts with the minor groove that this is possible. 
 As these highlights show, minor groove-binding natural products and ligands are able to 
displace ordered water molecules to take advantage of specific contacts to recognize their 
binding site in a fully sequence-specific fashion. Understanding hydration and cation binding in 
the minor groove may lead to further therapeutic possibilities as well as the rational design of 
modified nucleic acids for other purposes. 
 
1.3 Biological Roles of Nucleic Acids  
 The primary role of nucleic acids is the faithful storage and transfer of genetic 
information. They are a blueprint for not only the replication but also the day-to-day 
management of the cell. The frequency with which certain genetic instructions are carried out 
among all those present in the genome is determined by many factors, many of which remain 
mysterious.6 A full discussion of nucleic acid processing, metabolism, and gene expression is 
beyond the scope of this section, but a few brief details should be sufficient to give a sense of the 
most salient features of this important research area. 
 When transcription of DNA is needed, that is the reading and carrying out of genetic 
“instructions” to make proteins, the DNA is unwound, read, and copied as messenger RNA, or 
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mRNA, which is a temporary copy of DNA. The mRNA is then translated by the ribosome into 
the protein coded by the RNA.  
 The regulation of gene expression is extremely complex. There are a host of DNA-
binding proteins and DNA-modifying proteins that covalently attach chemical modifications to 
DNA such as methyl, acetyl, phosphate, or ubiquitin. Each modification affects the accessibility 
to proteins and hence the expression levels of the gene in which it is placed. Methylation of 
DNA, for example, is an important “off switch” for downregulation of a particular gene.30 The 
study of DNA modification and its effects on expression levels, known as epigenetics, is an 
increasingly active area of research31 as epigenetics has a direct role in certain diseases. 
 The link between DNA structure and function is extremely important, but not always 
clear. Though the biological roles of such structures as junctions, loop, cruciform structures, 
palindromes, and mirror repeats is beyond the scope of this chapter, it is sufficient to note that 
the majority of DNA sequences do not code for protein or any other currently recognized 
purpose. Subtle features such as the curvature of A-T rich sequences32 may have a role in diverse 
biological effects from protein binding to regulation of gene expression.  
 
  Ribozymes  
 In addition to carrying information, many nucleic acids have catalytic functions as well. 
There is a prominent hypothesis based on the idea that RNA may have been the progenitor of 
DNA and carried both information and catalyzed the chemical reactions of the cell. In this 
ancient time there would have been no proteins, and RNA or some other simpler nucleic acid 
would have been the basis of all life. This is known as the RNA world hypothesis.33 Ribozymes34 
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are RNA structures able to catalyze a variety of reactions and may be a holdover from the RNA 
world.  
 
1.4 Chemical Synthesis of Nucleosides and Nucleic Acids 
 It is now generally accepted that nucleosides were among the first organic compounds 
formed on earth, along with various amino acids and carbohydrates, to form the so-called 
primordial soup that may have given rise to the first living organisms. In an interesting 
laboratory model of ancient earth, the purines adenine and guanine were heated with D-ribose in 
seawater, which contains the Lewis acid catalyst MgCl2.35,36 The authors obtained adenosine and 
guanosine in 2.3% and 3% yield, respectively, together with similar yields of the corresponding 
α-nucleosides. The latter were anomerized under UV light to the thermodynamically more stable 
β-adenosine and guanosine for total yields of 5-6%. Pyrimidine nucleosides cannot be produced 
under these conditions and it remains uncertain how these came about in ancient earth. 
 High-yielding chemical syntheses of both naturally-occurring and non-natural 
nucleosides are important for many types of research in many areas. Typical methods for the 
chemical synthesis of the four natural ribo- and four natural 2′-deoxyribonucleosides are shown 
in Schemes 1–3. Historical and alternative methods have been reviewed.37 The sugars and 
heterocycles are generally obtained from natural sources. The sugars are then appropriately 
protected for the coupling reaction according to well-established procedures; some modification 
or protection of the heterocycle is sometimes necessary as well. A further discussion of this topic 
can be found in Chapter 2, section 2.1.  
 Purine ribosides such as adenosine and guanosine are often obtained in good to excellent 
yield and excellent purity using the Silyl-Hilbert-Johnson procedure38 (Scheme 1). The highly 
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polar and insoluble purine such as 1 is first converted by persilylation to the bis- or tri-
trimethylsilyl-protected derivative 2, which exhibits excellent solubility in organic solvents and 
can be distilled and isolated in pure form if desired. The peracylated ribose, typically 3 or the 
corresponding tetraacetate, is ionized by treatment with TMSOTf, or alternatively AgClO4 or 
TMSClO4, in DCE or MeCN at room temperature under inert atmosphere. The persilylated 
 
 
nucleobase can then be added. Alternatively, both silylation and sugar preparation can be carried 
out in a single vessel, avoiding the need to handle the easily-hydrolyzed 2 or 5. Deprotection 
with methanolic ammonia affords the nucleosides 4 and 6. It is important to note that the 
diastereoselective glycosylation of the above scheme results from certain subtleties in the 
ionization of the 1-acyl or 1-halo group of the ribose. The resulting oxonium species I is 
stabilized by the donation of the 2-acyl group’s oxygen lone pair into the empty p orbital of the 
C1 carbon to give 1,2-cyclic acyloxonium cation II. The presence of this highly stabilizing 
interaction blocks the lower face of the sugar such that only attack from the upper face is 
possible, giving the β-nucleosides shown in Scheme 1. Depending on the procedure some N7 
Scheme 1. Synthesis of adenosine and guanosine employing the Silyl-Hilbert-Johnson Method. 
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products—that is, the product resulting from attack by the other imidazole nitrogen—can be 
obtained in addition to the desired N9 products. As shown in Scheme 3, silylated pyrimidines 10 
or 13 react smoothly with 3 or 8 to give uridine38,39 or cytidine,40 respectively. Reaction of the 
heterocycle with the sugar initially gives an intermediate similar to 11, and attack of TMS by the 
associated triflate regenerates the 2-carbonyl en route to the desired product. 
 The synthesis of 2′-deoxyribonucleosides is generally more challenging for reasons 
discussed in detail in Chapter 3. Scheme 4 outlines the two typical methods employed. For many 
purines, the sodium salt method41 provides good yields with the desired β-N9 product highly 
favored. The method works best if oxo or amino functionality is not present. A chloropurine such 
as 15 is usually employed. Deprotonation with NaH or NaOH under phase transfer conditions 
generates the N7/N9 sodium salt 16. The sugar, usually 7, is then added and 17 is obtained as the 
predominant product. 17 is then treated with methanolic ammonia at 80–100 °C to deprotect the 
sugar and displace the chlorine to generate dA. Guanine is not a viable coupling partner for the 
sodium salt method, but dG can be prepared by radical-mediated deoxygenation of protected 
guanosine 18.42 While the Silyl-Hilbert-Johnson Method remains widely employed for the 
Scheme 2. Stabilization of ribose cations; typical sugars used in nucleoside synthesis. 
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preparation of pyrimidine 2′-deoxyribosides, the lack of a C2-O-acyl substituent results in the 
formation of both α and β-anomers. The ratios can be unpredictable and often difficult to  
 
  
reproduce. Yields are often only moderate. Though 7 has become the standard sugar in the 
synthesis of 2′-deoxyribosides, it is rather expensive and unstable. The α-Cl can anomerize, 
especially in polar solvents, sometimes resulting in significant amounts of the α-nucleoside 
products, even under conditions were the 2-deoxyribose 1-carbocation is not generated as the 
coupling partner. Using HgBr2 or AgClO4 under the Silyl-Hilbert-Johnson conditions, dT and dC 
can be produced in good yield with about a 1:1 ratio of β:α nucleosides.43,44 
 Over the last 40 years, chemical synthesis of up to 200-mer oligonucleotide sequences 
has progressed to a routine operation using commercially available reagents with an automated 
DNA synthesizer. The study of nucleic acids and their properties is enabled by the efficient 
Scheme 3. Synthesis of uridine and cytidine by the Silyl-Hilbert-Johnson Method. 
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synthesis of oligonucleotides using current solid-phase methods,45 shown in Figure 13. Using 
nucleoside phosphoramidites bound to controlled-pore glass (CPG) beads, the synthesis of high- 
  
 
purity DNA and RNA oligos allows investigations that were impossible 20 years ago. The 
modern phosphoramidite method46 has five steps: 1) detritylation, 2) coupling, 3) capping, and 4) 
oxidation. Detritylation removes the acid-labile DMT protection on the 5′-OH in preparation for 
coupling. The coupling step uses tetrazole to activate the phosphoramidite of the next nucleotide 
in the sequence. The capping step acetylates any nucleotides that did not react during the 
coupling to prevent the buildup of n-1 sequences, which are difficult to remove from the full-
length product at the end of the synthesis. The oxidation step uses I2 and water to oxidize the 
P(III) of the cyanoethyl-protected phosphite to a P(V) phosphate. Yields of >98% per coupling  
Scheme 4. Synthesis of the four natural 2′-deoxy nucleosides. 
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atoms as the native nucleosides they model, but arranged into a different pattern; others have 
only their shape in common with their namesake. They can be produced synthetically but many 
are biosynthesized by countless organisms. Some are made as antimetabolites to combat viruses 
or bacteria; some are harmless models made to understand some feature of nucleic acid function.  
 Certainly, most nucleoside analogs have a heterocycle, sugar, and perhaps a phosphate or 
phosphate analog as their three components, just as natural nucleosides. Most analogs closely 
mirror one or more natural nucleosides. A brief look at some of the fascinating array of analogs, 
and their purposes, will suffice to give the reader a sense of what nature and humanity have 
combined to produce.  
 Leaving aside the normal modifications and tagging of nucleosides that nature performs, 
there are a large number of naturally-occurring minor bases and antimetabolites. Figure 14 shows 
a few of the nucleosides present in DNA and tRNA, which is used in the ribosome in protein 
synthesis. These often strange-looking variants have important roles in stabilizing certain RNA  
 
  
 
secondary structures and giving tRNAs their necessary mode of action. A survey of some 
common naturally-occurring antibacterial and anticancer nucleosides (Figure 15) shows that very 
small structural variations are all that is needed to differentiate between a harmless natural 
Figure 14. Structures of several minor nucleosides present in tRNA. 
38 
 
substrate and a potent antimetabolite. Nature has evolved a vast array of nucleoside 
naturalproducts for signaling, warfare, and various other purposes. 
 Kool has used nonpolar aromatic isosteres to probe the importance of shape vs. Watson-   
 
 
Crick base pairing as the dominant mode of polymerase recognition of dNTPs47 (Figure 16).  
Surprisingly, many polymerases were able to incorporate the triphosphates of these analogs with 
high efficiency and fidelity, suggesting that the shape of the incoming dNTP and its fit into the  
 
 
Figure 15. Structures of a number of naturally-occurring biocides and anticancer nucleosides. 
Figure 16. Structures of several nonpolar aromatic isosteres used by Kool. Figure from ref. 47. 
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polymerase active site is more important than the exact contacts made to the substrate. Kool’s 
work in the use of size-expanded nucleosides48 to expand the genetic alphabet is an important 
contribution to another field of nucleic acids research, namely the investigation of alternate or 
expanded genetic alphabets.49 This field could have applications in artificial genetic systems or 
bioorthogonal nucleic acids, and perhaps increasing our understanding of the demands inherent 
in a functional genetic system-as-information storage. 
 
1.6 3-Deazapurines: Background and Applications 
 Of special importance to this thesis are the nucleoside analogs in which the N3 nitrogen 
has been deleted and replaced with another chemical functionality. All purine analogs lacking 
this nitrogen can be named as 3-deazapurines (Figure 17); alternatively, this ring system can be 
named using standard IUPAC nomenclature as the imidazo[4,5-c]pyridine ring system. 
Researchers have used both nomenclatures, sometimes in the same publication, but for the sake  
 
 
 
Figure 17. A comparison of the natural purine skeleton with that of 3-deazapurine. The purine 
numbering system is used throughout this discussion. 
40 
 
of clarity the purine numbering system will be used here for ease of comparison with native 
nucleosides and other purine analogs. For this discussion the two ring systems are synonymous, 
meaning that all 3-deazapurine analogs have as their parent ring system a C-H replacing the N3 
nitrogen. This is consistent with the naming systems of the numerous deazapurines in the 
literature: 1-deazapurines,50 7-deazapurines,15-16 etc. 
 A few 3-deazapurines are natural products, for example 2′-deoxy-3-deazaadenosine. This 
analog is found in the green leaves of spinach and the cutaneous glands and liver of sharks and 
amphibians. Its biological purpose in these organisms is apparently not known, but it has 
widespread biological activity in vivo and in vitro. Interestingly, the same imidazo[4,5-c]pyridine 
ring system fully saturated as the 7-hydroxyhexahydro-1H-imidazo[4,5-c]pyridin-4(2H)-one 
(and attached to an aminoglucoside) is part of streptothricin antibiotics.51 Its inhibition of protein 
synthesis hints that it may disrupt the action of the ribosome or become incorporated into tRNAs, 
acting as a nucleoside antimetabolite. The 2′-deoxy-3-deazaadenosine (dc3A) nucleoside exhibits 
anti-inflammatory and antiviral activity, including anti-HIV activity, as does the parent 
heterocycle and simplified analogs where the sugar is replaced by an aliphatic hydroxylated side 
chain.52  Medicinal chemistry produced many structural variants that were investigated 
throughout the 1970s onward.53 Various investigations with 3-deazaguanine, its riboside 3-
deazaaguanosine (c3G), and deoxyriboside dc3G showed a variety of antitumor and antiviral 
activities as well.54 In addition, dc3A is not metabolized like natural purines: it does not undergo 
deamination by adenosine deaminase, nor is it phosphorylated in vivo by adenosine kinase. It is a 
competitive inhibitor of S-adenosyl-L-homocysteine hydrolase as well. In eukaryotes, S-
adenosyl-L-homocysteine hydrolase offers a single way for degradation of S-adenosyl-L- 
homocysteine, a product and potent competitive inhibitor of S-adenosyl-L-methionine (AdoMet)- 
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dependent methyltransferases. De novo phosphatidylcholine synthesis requires three AdoMet-
dependent methylation steps. The disruption of normal levels of methylation and lipid 
biosynthesis is one possible mode of action for dc3A. 
 The replacement of a single G residue with c3G 25 in the Hammerhead Ribozyme 
decreases its catalytic activity by 200-fold, and certain other replacements also impacted its 
activity.55 This serves as a key example illustrating that the N3 nitrogen of purines can thus be 
engaged in critical interactions whose deletion has an enormous impact on their biological 
activity. There is some evidence that DNA polymerases use minor groove contacts to recognize 
their correct substrate,56 perhaps forming the basis for the selective antiviral activity of 3-
deazapurines. Work in this laboratory has shown that removal of minor groove functional groups 
affects the polymerase incorporation of pyrimidine triphosphates as well.57 
 Despite the rich and varied effects of altering the N3 nitrogen of purines, relatively little 
work has been done with 3-deazapurines aside from the parent ring system. To date, 
modifications such as 3-deaza-3-methyl,58 -ethyl,59 -nitro,60 and -halo61 have been synthesized 
and examined as probes of various biological events. The 3-deaza-3-methyl analog 24 (see 
Section 4.2) has been used as an anti-fixed purine analog58 and as a stable analog of an N3-
methyl-adenosine lesion,62 which is the major cytotoxic lesion formed in DNA by methylating 
agents. The importance of 24 to this thesis will be seen in the upcoming chapters. 
Figure 18. Structures of some 3-deazapurine nucleosides compared with dA.  
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 Many possible investigations of 3-deazapurines into their biological activity and effects 
on the structure of DNA remain underexplored. A perspective and outlook on such possibilities 
is found in the concluding section of this thesis (Section 4.5). Clearly, the alteration of the N3 
nitrogen is a biologically important alteration meriting further investigation. The final area in 
which this alteration must be examined is its effect on DNA hydration. The presence of 3-
deazapurines affects the spine of hydration in dramatic ways, and is reviewed and discussed in 
Chapter 4. Synthetic approaches to dc3A and other 3-deazapurines are examined in the following 
chapter. 
43 
 
 
                                                            
1 Miescher, F. in Die hisochemischen und Physioloischem Arbeiten. 1897. 
2 Watson, J. D.; Crick, F. H. Nature 1953, 171 (4356), 737–738. 
3 Franklin, R. E.; Gosling, R. G. Nature, 1953, 172 (4369), 156–157. 
4 Westheimer, F. Nature 1986, 319, 618–624. 
5 Saenger, W. in Principles of Nucleic Acid Structure. Springer-Verlag: New York, 1984. 
6 Nelson, D. L.; Cox, M. M. in Lehninger Principles of Biochemistry Third Edition. Worth: New York, 2000, 338. 
7 For a more complete discussion, see Chapter 8 of reference 5. 
8 Arnesano, F.; Natile, G. Coord. Chem. Reviews 2009, 253(15-16), 2070–2081. 
9 For a more complete discussion, see Chapter 6 of reference 5. 
10 See reference 5, pp. 138–139. 
11 Rockhill, J. K.; Wilson, S. R.; Gumport, R. I. J. Am. Chem. Soc., 1996, 118 (42), 10065–10068. 
12 Tippin, D. B.; Sundaralingam, M. Biochemistry 1997, 36, 536–543. 
13 Howerton, S. B.; Sines, C. C.; VanDerveer, D.; Williams, L. D. Biochemistry 2001, 40, 10023–10031. 
14 Howerton, S. B.; Nagpal, A.; Williams, L. D. Biopolymers 2003, 69, 87–99. 
15 Wang, R.-W.; Gold, B. Org. Lett. 2009, 11, 2465–2468. 
16 Ganguly, M; Wang, R-W.; Marky, L. A.; Gold, B. J. Am. Chem. Soc. 2009, 131, 12068–12069.  
17 Drew, H. R.; Dickerson, R. E. J. Mol. Biol. 1981, 151, 535–556. 
18 Kopka, M. L.; Fratini, A. V.; Drew, H. R.; Dickerson, R. E. J. Mol. Biol. 1983, 163, 129–146. 
19 Wing, R.; Drew, H.; Takano, T.; Broka, C.; Tanaka, S.; Itakura, K.; Dickerson, R. E. Nature 1980, 287, 755–758. 
20 Lavery, R.; Pullman, B.; Zakrzewska, K. Biophys. Chem. 1982, 15, 343–351. 
21 Shakked, Z.; Guerstein-Guzikevich, G.; Eisenstein, M.; Frolow, F.; Rabinovich D.; Joachimiak, A.;  Sigler, P. B. 
Nature 1994, 368, 469–473. 
22 Reddy, B. S.; Sondhi, S. M.; Lown, J. W.  Pharmacol. Ther. 1999, 84, 1–111. 
23 Dervan, P. B.; Burli, R. W. Curr. Opin. Chem. Biol. 1999, 3, 688–693. 
24 Finlay, A. C.; Hochstein, F. A.; Sobin, B. A.; Murphy, F. X. J. Am. Chem Soc. 1951, 73, 341–343.  
25 Zimmer, C.; Wähnert, U. Prog. Biophys. Molec. Biol. 1986, 47, 31–112.  
26 Chalikian, T. V.; Plum, G. E.; Sarvazyan, A. P.; Breslauer, K. J. Biochemistry 1994,  33, 8629–8640. 
27 Boehncke, K.; Nonella M.; Schulten, K.; Wang, A. H. Biochemistry 1991, 30, 5465–5475. 
28 Chen, X.; Ramakrishnan, B; Rao, S.; Sundaralingam, M. Nature Structural Biology 1994, 1, 169–175.  
29 Nguyen, B.; Neidle, S.; Wilson, W. D.  Acc. Chem. Res., 2009, 42 (1), 11–21. 
30 Phillips, T. The role of methylation in gene expression. Nature Education 2008, 1(1).  
31 Suzuki, M.; Bird, A. Nature Reviews Genetics 2008, 9, 465–476.  
32 Meena; Sun, Z; Mulligan, C.; McLaughlin, L. W. J. Am. Chem. Soc. 2006, 128 (36), 11756–11757. 
33 a) Gilbert, W. Nature 1986, 319, 618. b) Joyce, G. G. Nature 2002, 420(6913), 278 – 279. c) Joyce, G. F. Nature 
2002, 418(6894), 214-221. d) Joyce, G. F. Nature 1989, 338, 217-224.  
34 Ribozymes and RNA Catalysis, ed. Lilly, D. M.; Eckstein, F. 2007, RSC Publishing: Cambridge, UK. 
35 Fuller, W. D.; Sanchez, R. A.; Orgel, L. E. J. Mol. Evol. 1972, 1, 249. 
36 Fuller, W. D.; Sanchez, R. A.; Orgel, L. E. J. Mol. Evol. 1972, 67, 25. 
37 Vorbrüggen, H.; Ruh-Pohlenz, C. Handbook of Nucleoside Synthesis. Wiley-Interscience: New York, 2001. 
38 Vorbrüggen, H.; Korlikiewicz, K.; Bennua, B. Chem. Ber. 1981, 114, 1234. 
39 Vorbrüggen, H.; Korlikiewicz, K. Angew. Chem. Int. Ed. Engl. 1975, 14, 421. 
40 Vorbrüggen, H.; Bennua, B. Chem. Ber. 1981, 114, 1279. 
41 Kazimierczuk, Z.; Cottam, H. B.; Revankar, G. R.; Robins, R. K. J. Am. Chem. Soc. 1984, 106, 6379-6382. 
42 De Clercq, E.; Inoue, I.; Kondo, K. EP 381335, 1990 [Chem. Abstr. 1991, 114, 122980n]. 
43 Wittenburg, E. Chem. Ber. 1968, 101, 1095. 
44 a) Kulikowski, T.; Shugar, D. J. Med. Chem. 1974, 17, 269. b) Prystas, M. Collect. Czech. Chem. Commun. 1975, 
40, 1786. 
45 Sudhir Agrawal (ed.) Methods in Molecular Biology 20: Protocols for Oligonucleotides and Analogs: Synthesis 
and Properties. Humana Press: Totowa, NJ, 1993. 
46 Beaucage, S. L.; Caruthers, M. H. Tet. Lett. 1981, 22, 1859-1862. 
47 a) Morales, J. C.; Kool, E. T. J. Am. Chem. Soc., 2000, 122 (6), 1001–1007. b) Morales, J. C.; Kool, E. T.  
Biochemistry, 2000, 39 (10), 2626–2632. 
44 
 
                                                                                                                                                                                               
48 Gao, J.; Liu, H.; Kool, E. T. J. Am. Chem. Soc., 2004, 126 (38), 11826–11831. 
49 a) Liu, H.; Gao, J.; Kool, E. T. J. Am. Chem. Soc., 2005, 127 (5), 1396–1402. b) Liu, H.; Gao, J.; Maynard, L.; 
Saito, Y. D.; Kool, E. T. J. Am. Chem. Soc., 2004, 126 (4), 1102–1109. 
50 Vittori, S.; Volpini, R.; Camaioni, E.; Palu, G.; Cristalli, G. Nucleosides Nucleotides 1995, 14(3-5), 603–606. 
51 a) Chibnall, A. J. Biol. Chem. 1924, 61, 303. b) Ackermann, D.; Mohr, M. Z. Biol. Chem. 1936, 98, 73. 
c) Waksman, S. A.; Woodruff, H. B. Proc. Soc. Exp. Biol. Med. 1942, 49, 207. 
52 a) Gordon, R. K.; Ginalski, K.; Rudnicki, W. R.; Rychlewski, L.; Pankaskie, M. C.; Bujnicki, J. M.; Chiang, P. K. 
Eur. J. Biochem. 2003, 270, 3507–3517. b) Yamada, T.; Komoto, J.; Lou, K.; Ueki, A.; Hua, D. H.; Sugiyama, K.; 
Takata, Y.; Ogawa, H.; Takusagawa, F. Biochemical Pharmacology 2007, 73, 981–989. 
53 a) Montgomery, J. A.; Clayton, S. J.; Thomas, H. J.; Shannon, W. M.; Arnett, G.; Bodner, A. J.; Kion, I-K.; 
Cantoni, G. L.; Chiang, P. K. J. Med. Chem. 1982, 25, 626–629. b) Secrist, J. A. III; Comber, R. N.; Gray, R. J.; 
Gilroy, R. B.; Montgomery, J. A. J. Med. Chem. 1983, 36, 2102–2106. c) Krenitsky, T. A.; Rideout, J. L.; Chao, E. 
Y.; Koszalka, G. W.; Gurney, F.; Crouch, R. C.; Cohn, N. K.; Wolberg, G.; Vinegar, R. J. Med. Chem. 1986, 29, 
138–143. d) Siddiqi, S. M.; Chen, X.; Rao, J.; Schneller, S. W. J. Med. Chem. 1995, 38, 1035–1038. 
54 a) Revankar, G. R.; Gupta, P. K.; Adams, A. D.; Dalley, N. K.; McKernan, P. A.; Cook, P. D.; Canonico, P. G.; 
Robins, R. K. J. Med. Chem. 1984, 27, 1389–1396. b) Mian, A. M.; Khwaja, T. A. J. Med. Chem. 1983, 26, 286–
291. 
55 Seela, F.; Debelak, H.; Andrews, L.; Beigelman, L. Helv. Chim. Acta 2003, 86, 2726–2740. 
56 a) Hendrickson, C. L; Devine, K. G.; Benner, S. A. Nucleic Acids Res. 2004, 32 (7), 2241–2250 and references 
cited therein. b) McCain, M. D.; Meyer, A. S.; Schultz, S. S.; Glekas, A.; Spratt, T. E. Biochemistry 2005, 44, 5647–
5659. 
57 Fraley, A. W.; Chen, D.; Johnson, K.; McLaughlin, L. W.  J. Am. Chem. Soc.  2003, 125 (3), 616–617. 
58 Irani, R. J.; SantaLucia, J. Jr. Nucleosides, Nucleotides & Nucleic Acids 2002, 21 (11–12), 737–751. 
59 a) Aoyagi, M.; Minakawa, N.; Matsuda, A. Tet. Lett. 1993, 34 (1), 103–106. b) Minakawa, N.; Matsuda, A. Tet. 
Lett. 1993, 49 (3), 557–570. 
60 Crey-Desbiolles, C.; Kotera, M. Bioorg. Med. Chem. 2006, 14, 1935-1941 and references cited therein. 
61 Sakthivel, K.; Cook, D. P. Tet. Lett. 2005, 46, 3883–3887. b) Sakthivel, K.; Cook, D. P. Synthesis 2005, 10, 1586–
1590. c) Minakawa, N.; Kawano, Y.; Murata, S.; Inoue, N.; Matsuda, A. ChemBioChem 2008, 9 (3), 464–470. d) 
Minakawa, N.; Kojima, N.; Matsuda, A. J. Org. Chem. 1999, 64, 7158–7172. 
62 Plosky, B. S.; Frank, E. G.; Berry, D. A.; Vennall, G. P; McDonald, J. P.; Woodgate, R. Nucleic Acids Res. 2008, 
36 (7), 2152–2162.  
46 
 
Chapter 2: Novel Synthesis of dc3A and Unsuccessful Approaches to the 
Synthesis of 2′-deoxy-3-deaza-3-hydroxymethyladenosine (dhm3c3A) 
 
2.1 Introduction and Initial Plans for the Synthesis of dhm3c3A 
 As discussed in Section 1.6, 3-deazapurine nucleosides are a class of nucleoside analogs 
that exhibit interesting biological effects and have various potential uses as probes for 
understanding DNA structure and protein binding, but are, thus far, underutilized in these 
applications. At the time this work began, there existed many approaches for the synthesis of the 
3-deazapurine ring system but no generally applicable method for functionalizing the 3-position.  
Methyl, ethyl, halogen, and nitro functionality were the only known substituents at the 3-
position, and each type of functional group required a relatively unique synthesis.  
 We became interested in using 3-deaza-3-methyl nucleoside 41 and 3-deaza-3-
hydroxymethyl derivative 5 as probes of DNA hydration in the minor groove (see Section 4.1) as 
well as evaluating the tolerance of various polymerases for functionality in the minor groove 
besides the natural N3 nitrogen. Preliminary results from this laboratory2 suggested that the 
triphosphate of 4 might be a poor substrate for high-fidelity polymerases while perhaps being an 
acceptable substrate for low-fidelity polymerases such as HIV reverse transcriptase. This would 
give 4 potential applications as a potent antiviral with very low human toxicity in addition to the 
interesting biological applications noted in the concluding section of Chapter 1.  
 Compound 4 is known, and the synthesis of its phosphoramidite and triphosphate was 
relatively straightforward (see Section 4.2). Unfortunately, there was no immediately obvious 
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route to 5. An investigation of the literature suggested a few possibilities. Halogenations of the 
corresponding TBS-protected riboside of 2 are known,3 and the versatility of aryl halides in  
 
 
 
metal-catalyzed and metal-mediated cross-coupling reactions suggested the retrosynthesis shown 
in Scheme 1. 
Figure 1. Structures of some 3-deazapurine nucleosides compared with dA. 
Scheme 1. Retrosynthetic analysis of the 3-deaza-3-hydroxymethyl ring system. 
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 The synthesis of the fully-protected phosphoramidite 10 for solid-phase DNA synthesis 
would depend on the orthogonal protection of the hydroxymethyl group relative to the sugar 
hydroxyls (11). This would be available from Negishi coupling of 3-halo intermediate 12a/b 
preceded by amination of the 6-chlorine or vice versa. As the Negishi coupling of 
acyloxymethylzinc iodides with various 6-halopurines is known to proceed under mild 
conditions4 (in addition there is a bountiful literature of metal-catalyzed couplings of 2-, 6-, and 
8-halopurines),5 it was hoped that the electronics of the 3-deazapurine ring system would allow a 
similar coupling with 12a/b. Glycosylation would lead back to 14a/b. Cyclization of the 
imidazole ring would lead back to highly functionalized pyridine 16a/b. This was not a known 
compound but was considered likely to be available from a variety of approaches including from 
selective chlorination and amination of 18.6b The alternative route would involve carrying known 
3,4-aminopyridine 17 forward to 2 via the known 3-deaza-6-chloropurine 15,6 where the 
precedented halogenation could be performed followed by Negishi coupling. 
 There are numerous methods in the literature that allow access to the imidazo[4,5-
c]pyridine ring system, and in particular to 3-deaza-6-chloropurine 15. In formulating a synthetic 
approach to 11, we considered intermediates along the pathway to 3-deaza-6-chloropurine to find 
a point at which the 3-position could be halogenated. Halogenation of 13 or 2 would allow 
access to the same intermediates (12a/b or 3a–c) for the intended Negishi coupling, maximizing 
flexibility in the synthetic route.  
 Several literature preparations of 15 begin with 2,6-dichloropyridine, including work in 
this laboratory.6c–e While high-yielding, this approach was lengthy and required multiple 
treatments with the pyrophoric metal Raney nickel in a Parr reactor—dangerous and 
inconvenient on large scale—as well as hydrogenation with Pd/C to remove the extra chlorine in 
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the 2-position of the pyridine ring after glycosylation. Another drawback was that installation of 
the 6-amino group required a 48 h treatment with methanolic ammonia at 100 °C in a steel 
bomb. There was also no precedent for halogenations in the desired position on any of the 
intermediates until dc3A 2, limiting the flexibility of the route. The shortest known route to 15 
began with the rather expensive 3,4-diaminopyridine6b and again offered no opportunity for the 
desired halogenations.  
 Other routes were considered, but the required 3-substituted pyridines bearing a 
functionality that could be converted to the hydroxymethyl group, such as cyano, methyl ester, 
  
 
carboxylic acid, or aldehyde, were either not commercially available or were not likely to 
withstand the harsh conditions needed for some of the steps, e.g. nitration with H2SO4/HNO3 at 
100–120 °C, PCl5/POCl3, Raney Ni/H2, or SnCl2/HCl. 
 The reported halogenations of 197 (Scheme 2) allowed us to simplify a synthesis of 15 
that began with 18.6b We chose the inexpensive 4-pyridone 23 as our starting material. 
Combination of several literature reactions and optimization allowed us to assemble a greatly 
improved route to dc3A shown in Scheme 3. 4-Pyridone 23 was nitrated in fuming H2SO4/HNO3 
to afford 248 in 72% yield by neutralization and precipitation with concentrated ammonia. 
Scheme 2. Literature precedent for the desired halogenation in the 3-position7. 
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Sequential treatment with PCl5 in refluxing 1,2-dichloroethane followed by a quench with 
absolute ethanol gave ethoxypyridine 20.9 Mild amination with NH4OAc afforded 199 in  
 
  
excellent yield. The reduction of nitro groups using SnCl2 is a very old reaction with only a few 
mechanistic studies performed;10 in the case of 5-nitropyridines treatment with SnCl2/HCl can 
chlorinate the 6-position in addition to the nitro reduction. This chlorination usually requires heat 
(~90 °C). In our hands the reduction-chlorination of 19 proved capricious under the reported 
conditions,11 giving variable yields and unidentified byproducts. Furthermore, the reported yield 
of 30% and the amount of concentrated HCl needed (100 mL/g) were less than ideal for a large 
scale synthesis. After optimization of conditions we found that 5 mL/g of HCl could be used, and 
that increasing the equivalents of SnCl2 to 4.9 consistently gave 73% yield with 17 as the sole 
isolated product. Condensation with triethylorthoformate/acetic anhydride afforded the crucial 
Scheme 3. Improved synthesis of 15 en route to 2 and 10. 
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nucleobase 15 in 75% yield. Thus, 3-deazapurine 15 is obtained in 5 steps with no 
chromatography and 30% overall yield. Halogenations of 19 were also successful, allowing the 
pursuit of an important alternate route (vide infra). 
The glycosylation to form the 2′-deoxy-β-D-ribonucleoside was next undertaken using a 
published procedure for the synthesis of 2.12 The procedure employed powdered KOH in MeCN 
with TDA-1, tris[2-(2-methoxyethoxy)ethyl]amine,13 as a phase-transfer cryptand with 1.1 equiv 
of sugar 25.14 The desired β-N9 product 13a was obtained in 57% yield with 23% β-N7 product 
13b. Chromatographic separation of the isomers was extremely difficult, but most of 13a 
crystallized in excellent purity from a 1:1 mixture of cyclohexane:EtOAc with the rest purified 
by flash chromatography.  
A few remarks about the 2-deoxysugar 25 are warranted, given the widespread use of this 
rather expensive, unstable synthon in nucleoside chemistry and the fact that routine preparation 
of it was necessary, time-consuming, and difficult. With proper skill and care, however, the 
modified procedure of Lhomme and co-workers14b afforded ample amounts of this important 
sugar as a white crystalline solid in excellent purity. As shown in Scheme 4, commercially 
available 2-deoxyribose is treated with 1% HCl in anhydrous MeOH to form the methyl acetal 
27. Of the mixture of furanose (26) and pyranose (29) forms, the furanose reacts much faster so 
that a mixture containing mostly 27 is obtained as a clear to caramel-colored syrup. Acylation 
with p-toluoyl chloride (apparently the choice of acyl groups affects the subsequent 
crystallization) yields 28. This can be purified by flash column to remove 31 and other 
impurities, but generally an aqueous workup and extensive drying in vacuo is sufficient. The 
semi-solid syrup is dissolved in AcOH and saturated with HCl by addition of AcCl and a small 
amount of H2O. Crystallization of 25 begins almost immediately or over the course of a few 
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minutes, and after a few minutes longer the reaction mixture forms a white, pasty mass. The α 
anomer 25 is crystalline while the β anomer and 32 are not, allowing the buildup of pure 25 from 
the AcOH solution containing all three compounds. Filtration and washing with cold anhydrous 
Et2O affords white, crystalline 25 that must be dried carefully to remove trace acid before 
storage. The sequence gives an overall yield of ~50% from 2-deoxyribose.  
 
 
As mentioned, 25 is rather unstable. If stored in a freezer under dry conditions it is stable 
almost indefinitely, but it is sensitive to heat and moisture. At room temperature in air it 
gradually decomposes to a gray powder. It cannot be re-precipitated or recrystallized—except 
perhaps from the original HCl/AcOH mixture used in its synthesis—and once dissolved, even in 
volatile or nonpolar solvents such as DCM, does not regain its crystalline form. It has several 
decomposition pathways, and begins to anomerize as soon as it is dissolved (Scheme 6). The 
anomerization is much faster in polar solvents, which is always a concern in glycosylations with 
25. The β anomer is about 15% of the mixture in CDCl3 after an hour according to NMR 
studies;14b however some glycosylation reactions can run for hours with no sign of α-nucleoside 
products (these would result from SN2 attack of the nucleobase on the anomerized sugar). The 
Scheme 4. Synthesis of chlorosugar 25. 
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amount of α-nucleoside products obtained from glycosylations with 25 is completely 
 
 
substrate-dependent, but is generally increased in polar solvents, with heating, or in the presence 
of Lewis acids. 
Deprotection of glycosylation product 13a (Scheme 6) with NaOMe/MeOH gave 33 in 
98% yield. Treatment with NH3/MeOH at 80 °C is normally used to both deprotect purine  
a
nucleosides and install the 6-amino group. The imidazo[4,5-c]pyridine ring system is 
considerably more electron-rich than that of purines, and harsher conditions are required. 
Scheme 5. Decomposition pathways of chlorosugar 25. 
Scheme 6. Synthesis of dc3A phosphoramidite 34. 
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Treatment of 33 with refluxing hydrazine followed by reduction with Raney nickel afforded 
dc3A nucleoside 2. This material was used routinely to synthesize the corresponding 
phosphoramidite of dc3A as shown in Scheme 6. Transient protection by O-silylation with excess 
TMSCl at 0 °C in anhydrous pyridine followed by excess BzCl, mild hydrolysis of the TMS 
ethers, and aqueous workup gave the monobenzoylated product in 90% yield. Transient 
protection15 is a standard protocol applicable to almost any nucleoside where selective amino 
protection is desired. Selective protection of the 5′-OH with DMTCl was followed by 
phosphitylation to afford the phosphoramidite 34 for solid-phase synthesis.  
The work described to this point represents a streamlined and cost-effective route to 2 
and its phosphoramidite, which was needed for ongoing studies of DNA minor groove hydration. 
At the time, both 2 and 19 were on hand in gram quantities, enabling subsequent efforts towards 
the synthesis of 2′-deoxy-3-deaza-3-hydroxymethyladenosine (5) and its phosphoramidite. Those 
efforts are described in the following section. 
 
2.2 First Efforts to Elaborate dc3A to dhm3c3A  
For this work the sugar was re-protected as the 3′,5′-bis-tert-butyldimethylsilyl ether in 
an unoptimized yield of 65% (Scheme 7). This compound reacted with NBS or NIS in DMF at 
room temperature to yield 35a and 35b, respectively. When these compounds were subjected to 
the conditions reported for Negishi coupling of 6-chloropurines with alkoxymethylzinc iodides4 
(5 mol% Pd(PPh3)4, 4 equivalents BzOCH2ZnI, THF, room temperature), no reaction took place. 
Increasing the reaction temperature to reflux resulted only in recovered starting material. Mass 
spectral analysis of the crude reaction mixture revealed that some insertion of the catalyst was 
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taking place, but only resulting in dehalogenation of 35a/b. Changing the catalyst to Pd2(dba)3 
yielded similar results. With DMF as the solvent, increasing the reaction temperature to 100 °C 
only resulted in slow decomposition of the starting material and some dehalogenation. The 
amino group of 35a and b were then protected as the N6-bis(Boc) derivatives. These also failed 
to react. Changing the coupling partner to PivOCH2ZnI was similarly fruitless. Meanwhile, a 
commercial sample of 9-benzyl-6-chloropurine reacted smoothly under all the above conditions. 
 
 
 There were two possibilities for the failure of 35/37 to react. Either (1) the electronics of 
the ring system were so different from normal purines that catalyst turnover was impossible, or 
(2) the 3-position was sterically hindered by the presence of the sugar, making catalyst insertion 
sluggish and/or hindering turnover.  
  
Scheme 7. Attempted Negishi couplings. 
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2.3 Use of Test Substrates to Probe the Reactivity of the imidazo[4,5-c]pyridine Ring 
System toward Lithiation and Negishi Coupling 
 Given the difficulties above, it was necessary to determine why the Negishi coupling was 
failing and attempt an alternate route if no other workable solution could be found. Encouraged 
by the reactivity of substrates similar to ours (Scheme 8) found in the patent literature,16 we 
began by synthesizing 3-deaza-3-bromo-6-chloropurine 14a according to the route shown in 
Scheme 9. 
 
 
 Bromination of 19 with Br2 in AcOH/NaOAc afforded 21 in 57% yield with some 
recovered starting material. The reduction-chlorination with SnCl2 proceeded in 90% yield with 
no chromatography needed; the subsequent condensation afforded novel nucleobase 14a. This 
could be coupled with 25 to give a separable mixture of regioisomers in a nearly 1:1 ratio; no 
sign of α-nucleoside products was observed. The desired 12a was tentatively assigned as the 
slightly more polar compound obtained in a slightly lesser yield. N9 glycosylated nucleosides are 
generally more polar and more crystalline than the N7 or corresponding α-nucleosides; this is 
true of 3-deazapurines such as 2 and 4 as well. 
Scheme 8. Literature precedent for Pd-catalyzed couplings with the imidazo[4,5-c]pyridine ring system. 
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 Two additional test substrates were acquired by benzylation of 14a with K2CO3 and BnCl 
in DMF. The N9 and N7 regioisomers were obtained in nearly equal amounts, with the more 
polar isomer tentatively assigned as the N9 product. The robust benzyl group served to simplify 
the substrate, ruling out the influence of the sugar on the reaction, and the performance of N7 
compound 39 in the coupling would determine if the sugar was blocking access of the catalyst to 
the bromine in the 3-position. 
  
 
Compounds 12a, 38, and 39 were submitted to the Negishi coupling conditions. To our 
disappointment all of them failed to react. In each case, starting material was recovered 
unchanged, even after refluxing in THF for 12 h. The failure of 39 ruled out the hindrance of the 
sugar as the reason for the failure of the coupling. The differing electronics of 12a vs. 35a also 
had no impact on the reaction; in fact, 12a was less reactive, as there was no sign of any catalyst 
insertion taking place with Pd(PPh3)4 as the catalyst.  
Scheme 9. Synthesis of additional substrates for Negishi coupling and lithiation. 
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 We next turned our attention to lithium-halogen exchange followed by quench with an 
appropriate electrophile as an alternative route (Scheme 10). Lithiation with alkyllithium or 
magnesiation with alkyl Grignard reagents has been used effectively with 6- and 2-halopurines, 
but the reaction course can be dependent on temperature, as lithiated purines can rearrange to the 
more stable 8-lithiated species.17 The reactivity of an aryllithium species can be sensitive to 
sterics and is, in general, highly dependent on the electronics of the aryl ring as well.18 
 
 
 Treatment of 12a, 37a, or 38 with 1–2 equiv of either n-butyllithium or s-butyllithium did 
result in clean lithium-halogen exchange, but all substrates failed to react with either DMF or 
Scheme 10. Lithium-halogen exchange as an alternate route to 5. 
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ethyl formate; only the corresponding proton-quenched products were obtained after workup. 
This was confirmed by a quench with D2O to yield the deuterium-containing product. 37a was 
also reacted with 1.1 equiv s-BuLi followed by 1.5 equiv Fe(CO)5, which has been used in 
systems where other electrophiles were not reactive enough toward the lithiated species;19 again, 
only proton-quenched starting material was recovered.  
 
2.4 Conclusion 
 The surprising intractability of the imidazo[4,5-c]pyridine ring system to a variety of 
reactions has been noted by other authors.20 The work described in this chapter, though not 
successful in terms of its ultimate goal, resulted in the most efficient and high-yielding synthesis 
of 2 to date. The large body of literature—including half a dozen different syntheses, many 
biological studies, and medicinal chemistry—in which this analog has been employed (Section 
1.5) speaks to the importance of this advance.  
 In retrospect, it seems likely that changing the catalyst to either the air-stable and robust 
PdCl2(PPh3)2 or Pd(P(t-Bu)3)2, which undergoes Ar-X insertion more quickly because loss of a 
bulky P(t-Bu)3 ligand is energetically favorable, would result in a successful Negishi coupling. 
Certainly other conditions such as additives, ligands, and solvents could have been tried as well. 
However, the need to explore other methods along the initial route to 5 was obviated by the rapid 
success of a route employing a radical bromination as its key step (Chapter 4), which soon 
provided a straightforward solution to the difficulties encountered in this chapter. 
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2.5 Experimental Details and Supporting Information 
  General Information 
 All reactions were carried out under an inert atmosphere with dry solvents under 
anhydrous conditions unless noted otherwise. Dry tetrahydrofuran (THF), diethyl ether (Et2O), 
N,N-dimethylformamide (DMF), pyridine (pyr), acetonitrile (MeCN), and dichloromethane 
(DCM) were obtained by passing commercially available pre-dried, oxygen-free formulations 
through activated alumina columns. Dry methanol (MeOH) was obtained by distillation from 
Mg(OMe)2. Yields refer to chromatographically and spectroscopically (1H NMR) homogeneous 
materials, unless otherwise stated. Reagents were purchased at the highest commercial quality 
and used without further purification, unless otherwise stated. Reactions were monitored by thin-
layer chromatography (TLC) carried out on 0.25 mm Silicycle TLG-R10011B-323 60 Å plates 
using UV light as visualizing agent and ceric ammonium molybdate (CAM) stain and heat as 
developing agents. Dynamic Adsorbents silica gel (60 Å, particle size 32-63 µm) was used for 
flash column chromatography. Difficult separations were carried out using “chromatospec silica 
gel” (E. Merck Chromatospec silica gel (60 Å, particle size 15-40 µm). NMR spectra were 
recorded on Varian VNMRS 400, VNMRS 500, VNMRS 600, or INOVA 500 instruments and 
calibrated using residual undeuterated solvent (CDCl3: δH = 7.26 ppm, δC = 77.16 ppm, acetone-
d6: δH = 2.05 ppm, δC = 29.84, DMSO-d6: δH = 2.50 ppm, δC = 39.52 ppm, methanol-d4: δH = 
3.31 ppm, δC = 49.00 ppm) as an internal reference. The following abbreviations are used to 
designate the multiplicities: s = singlet, d = doublet, t = triplet, q = quartet, quin = quintet, m = 
multiplet, br = broad. High-resolution mass spectra (HRMS) were recorded on a Waters LCT 
Classic or JEOL AccuTOF mass spectrometer using ESI (electrospray ionization) or DART 
(direct analysis in real time). 
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  Methods 
4-Hydroxy-3-nitropyridine (24)8. Fuming nitric acid (58 mL, >99.5%) was slowly added to 
fuming sulfuric acid (49 mL, 26-29.5% free SO3) at 0 °C. This was followed by the addition of 
4-hydroxypyridine (20 g, 210 mmol) portionwise over 15 min.  The reaction was slowly heated 
until the exothermic evolution of N2O4 occurred. The heat source was removed and after the 
reaction slowed, the mixture was heated to 120 °C for 1 h. The reaction mixture was cooled to 
ambient temperature and poured slowly over ice. The mixture was neutralized with conc. 
NH4OH and chilled overnight. Yellow crystals were collected by filtration and washed with a 
small amount of ice water to yield 24 (21.3 g, 72%). 1H NMR (400 MHz, DMSO-d6) δ 8.78 (s, 
1H); 8.52 (s, 1H); 7.76 (d, J = 7.6 Hz 1H); 6.46 (d, J = 7.6 Hz, 1H).  HRMS (ESI-TOF): calcd 
for C5H5N2O3: 141.03002, found: 141.02987.  
4-Ethoxy-3-nitropyridine (20)9. To PCl5 (50.1 g, 237 mmol) dissolved in dichloroethane (180 
mL) was added 4-hydroxy-3-nitropyridine (27.7 g, 197 mmol) and the solution was refluxed for 
7 h. After the reaction was complete (verified by TLC, 7:3:1 EtOAc:MeOH:28% aq. NH3), the 
mixture was cooled to 0 °C and 111 mL of absolute ethanol was added slowly via a syringe with 
vigorous stirring. A thick, white slurry formed with an increase in temperature. The slurry was 
stirred at 0 °C for 20 min and then refluxed for 1 h. The flask was cooled at 4 °C for 2–3 h, 
filtered and washed with cold ethanol to yield white crystals of 20 as the HCl salt (32.24 g, 80% 
(87% reported)) after drying in vacuo. 1H NMR (400 MHz, DMSO-d6): δ 9.10 (s, 1H); 8.91 (bs, 
1H); 8.74 (d, J = 6.4 Hz, 1H); 7.56 (d, J = 6.4 Hz, 1H); 4.39 (q, J = 6.8 Hz, 2H);  1.38 (t, J = 7.2 
Hz, 3H). HRMS (ESI-TOF): calcd for C7H9N2O3: 169.06132, found: 169.06137.  
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4-Amino-3-nitropyridine (19)9. Ammonium acetate (14.7 g, 191 mmol) was dissolved in water 
(24 mL) and 4-ethoxy-3-nitropyridine hydrochloride (9.81 g, 47.9 mmol) was added. The 
solution was refluxed for 4–8 h. The reaction was monitored by TLC (10:1 EtOAc:triethylamine) 
and additional ammonium acetate was added if necessary. When the reaction was complete, the 
mixture was cooled to ambient temperature and adjusted to pH 8 with NH4OH and stirred for 1 h 
at 0 °C. The resulting precipitate was filtered and dried overnight to yield 19 as a yellow powder 
(6.58 g, 97%). 1H NMR (400 MHz, DMSO-d6) δ 8.97 (s, 1H); 8.13 (d, J = 6.0 Hz, 1H); 7.93 (bs, 
2H); 6.89 (d, J = 6.0 Hz, 1H). HRMS (ESI-TOF): calcd for C5H6N3O2: 140.04500, found: 
140.04663. 
3,4-diamino-2-chloropyridine (17)11,21. To 25 mL of conc. HCl was added SnCl2 (33.1 g, 175 
mmol) followed by 4-amino-3-nitropyridine (5.0 g, 35.7 mmol) added portionwise to the 
solution over 10 minutes. The reaction was then refluxed for 1.5 h, after which TLC (9:1 
DCM:MeOH) of a neutralized aliquot extracted with EtOAc showed complete conversion. The 
reaction was then cooled to ambient temperature and poured over 400 mL of crushed ice. The 
solution was neutralized with 7 M NaOH and diluted with 200 mL of water to dissolve most of 
the thick white precipitate that formed.  Additional NaOH was added to maintain the pH at ~12.  
The slurry was extracted with ethyl acetate (4 x 100 mL), dried over MgSO4, and evaporated in 
vacuo to yield 17 as a white to rose-colored solid that was used without further purification (3.78 
g, 73%). 1H NMR (400 MHz, DMSO-d6): δ 7.28 (d, J = 5.2 Hz, 1H); 6.43 (d, J = 5.2 Hz, 1H); 
5.76 (s, 2H); 4.66 (s, 2H). HRMS (ESI-TOF): calcd for C5H7ClN3: 144.03285, found: 
144.03290. 
4-chloro-1H-imidazo[4,5-c]pyridine (15)6a. Under inert atmosphere triethylorthoformate (33.3 
mL, freshly distilled over sodium) and acetic anhydride (33.3 mL, fractionally distilled) were 
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added to a flask containing 3,4-diamino-2-chloropyridine (6.67 g, 46 mmol). The reaction was 
then heated at reflux with stirring for 1 h, cooled to ambient temperature, and concentrated in 
vacuo. The resulting yellow solid was dissolved in minimal 10% NaOH and heated to 95 °C for 
10 minutes. The solution was then neutralized to pH 6 with acetic acid and cooled at 4 °C 
overnight. White crystals of 15 (5.33 g, 75%) were collected by filtration, washed with cold 
water and dried in vacuo. 1H NMR (400 MHz, DMSO-d6): δ 8.44 (s, 1H); 8.01 (d, J = 5.6 Hz, 
1H); 7.60 (d, J = 5.6, 1H). HRMS (ESI-TOF): calcd for C6H4ClN3H+: 154.01720, found: 
154.01638. 
3-Bromo-4-amino-5-nitropyridine (21). To a flask containing 4-amino-3-nitropyridine 19 (1.30 
g, 9.27 mmol) in 2.3 mL AcOH was added dropwise 0.715 mL Br2 dissolved in 1.5 mL AcOH. 
The temperature was increased to 50 °C and allowed to stir for 24 h. The reaction was 
neutralized with 1 M NaOH to pH 7. An orange solid separated during the neutralization. The 
mixture was filtered and the solid washed with 2 mL water to obtain 21 as an orange solid (1.16 
g, 57%). MS (ESI-TOF): calcd for C5H3BrN3O2H+, found: 216.95. 
5-bromo-2-chloropyridine-3,4-diamine (16a). To 10 mL of conc. HCl was added SnCl2 (1.0 g, 
5.27 mmol) followed by 4-amino-3-nitropyridine (490 mg, 2.23 mmol) added portionwise to the 
solution. The reaction was then refluxed for 1.5 h, after which TLC (9:1 DCM:MeOH) of a 
neutralized aliquot extracted with EtOAc showed complete conversion. The reaction was then 
cooled to ambient temperature and poured over 40 mL of crushed ice. The solution was 
neutralized with 7 M NaOH and diluted with 20 mL of water to dissolve most of the thick white 
precipitate that formed.  Additional NaOH was added to maintain the pH at ~12.  The slurry was 
extracted with ethyl acetate (4 x 10 mL), dried over MgSO4, filtered, and evaporated in vacuo to 
yield 16a as a white to rose-colored solid that was used without further purification (541 mg, 
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90%). 1H NMR (400 MHz, DMSO-d6): δ 7.28 (d, J = 5.2 Hz, 1H); 6.43 (d, J = 5.2 Hz, 1H); 5.76 
(brs, 2H); 4.66 (brs, 2H). MS (ESI-TOF): calcd for C5H4BrClN3H+, found: 220.94. 
3-deaza-3-bromo-6-chloropurine (14a). To a flask containing 16a (541 mg, 2.42 mmol) was 
added triethylorthoformate (distilled from sodium). The mixture was heated to reflux for 6 h and 
allowed to cool to room temperature. Volatiles were removed in vacuo and the residue purified 
by flash chromatography eluting with 95:5 DCM:MeOH to afford 14a as an off-white solid (374 
mg, 67%). 
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Chapter 3: Use of Tetramethylsuccinimide (M4SI) as a 
Directing/Protecting Group for Purine Glycosylations: Highly 
Regioselective Synthesis of Purines and Purine Analogs Including the 
First Route to 2,6-Diaminopurine 2′-Deoxyriboside and 2′-
Deoxyisoguanosine by Direct Glycosylation 
3.1 Introduction 
 One of the most challenging aspects of nucleoside synthesis is the glycosylation step. 
When possible, it is often easier to begin the synthesis of a nucleoside analog with a natural 
nucleoside; achieving a high-yielding and selective glycosylation and separating the desired  
 
 
product from any regioisomers and anomeric products that may be present can be challenging. 
These general issues are clearly at their worst in the synthesis of purine 2′-deoxynucleosides, 
Scheme 1. The four possible purine coupling products for the reaction of 6-chloropurine with 2-
deoxy-3,5-di-O-(p-toluoyl)-β-D-erythro-pentofuranosyl chloride. The naturally-occurring β-N9 
product is usually desired. 
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because (1) there are theoretically four possible products (Scheme 1), and (2) control of the 
relative ratios is sometimes more substrate-dependent than under the control of the reaction 
conditions. There are several methods for purine glycoslyation, and each affords good to 
excellent selectivity for some substrates, but a general method applicable to the synthesis of all 
purine 2′-deoxyribonucleosides remains elusive. Certainly the most common method employed 
with simple heterocycles such as 6-chloropurine 1 is the sodium salt method;1 the most common 
sugar employed is 2-deoxy-3,5-di-O-(p-toluoyl)-α-D-erythro-pentofuranosyl chloride2 2, as 
discussed in Section 2.1. The glycosylation of 1 gives the desired 3 in 57% yield with 13% β-N7 
product 4 with none of the possible α-nucleoside products observed. 
 Leaving aside the approach of ribosylation followed by removal of the 2′ hydroxyl by, for 
example, Barton radical deoxygenation,3 there are several common methods for the direct 
synthesis of purine 2′-deoxyribosides. These are shown in Scheme 2. Adenine (5) can be 
converted to its sodium salt with NaH in acetone, which reacts with 2 to form protected 2′-
deoxyadenosine (6) in 48% yield with 8% α-N9 product.4 The authors note that the low 
solubility of the sodium salt of 2 in non-polar solvents such as DCM causes it to react with 2 
more slowly, increasing the anomerization of the sugar and leading to more α-N9 product. On 
the other hand, polar solvents such as EtOAc or DMF dissolve the sodium salt but increase the 
anomerization rate of the sugar, again resulting in more α-nucleoside product. The best  
 
                                                            
1 Kazimierczuk, Z.; Cottam, H. B.; Revankar, G. R.; Robins, R. K. J. Am. Chem. Soc. 1984, 106, 6379-632. 
2 a) Rolland, V.; Kotera, M.; Lhomme, J. Synthetic Commun. 1997, 27, 3505-3511. b) Hoffer, M. Chem. Ber. 1960, 
93, 2777–2780. 
3 a) Robins, M. J.; Wilson, J. S. J. Am. Chem. Soc. 1981, 103, 932–933. b)  Lessor, R. A.; Leonard, N. J. J. Org. 
Chem. 1981, 46, 4300–4301. c) Kawasaki, A. M.; Wotring, L. L.; Townsend, L B. J. Med. Chem. 1990, 33, 3170–
3176. 
4 Kawakami, H.; Matsushita, H.; Naoi, Y.; Itoh, K.; Yoshikoshi, H. Chem. Lett. 1989, 235–239. 
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Scheme 2. Selected examples of purine glycosylations including the sodium salt method (compounds 5, 
7), the metal salt procedure (9), the transglycosylation method (11), and phase-transfer conditions (14). 
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selectivity is obtained in acetone or MeCN. 2,6-dichloropurine (7) performs well in the sodium 
salt procedure, reacting with 2 to form desired product 8 in 68% yield as the only observed 
product.1 Compound 9 illustrates the metal salt procedure, one of the first glycosylation methods 
developed for nucleosides, in which the purine is converted to a heavy metal salt, typically Ag or 
Hg, and reacted directly with the sugar. The desired product 10 is only obtained in 25% yield 
with 16% α-N9 product,5 a remarkable decrease from the 57% yield obtained with 1 or 68% with 
7. This method also has the drawback that isolating the pure product requires the oftentimes 
difficult removal of the highly toxic heavy metal salts formed in the reaction. The 
transglycosylation method (11→13) takes advantage of the fact that nucleoside formation in the 
presence of a Lewis acid is a reversible process. Lewis acids such as HgBr2, TMSClO4 or 
TMSOTf are effective in promoting this type of glycosylation. In the case of 2-deoxyribose 
sugars significant or predominant amounts of the α-nucleoside product is usually obtained 
besides the desired product. 11 reacts with silylated nucleobase 12 to afford 27% 13 and 36% of 
the corresponding α-N9 product.6 Alkali halides can also catalyze glycosylations. Treatment of 
silylated N2-acetyl guanine 14 with KI and a crown ether in 1:1 MeCN:PhMe affords 16 in 90% 
yield as a 7:3 mixture of α:β anomers7. This result underscores the difficulty of producing dG in 
good yields, at least by chemical methods; its poor solubility in organic solvents makes the 
sodium salt procedure untenable, and there are few other reports of direct glycosylations of 
guanines to produce dG.8  
 The sodium salt procedure is the preferred method for the glycosylation of most simple, 
acidic heterocycles, in particular chloropurines such as 1. Yields are generally moderate to good. 
                                                            
5 Keller, F.; Bunker, J. E.; Brown, L. H. J. Org. Chem. 1966, 31, 3840. 
6 Yamaguchi, T.; Saneyoshi, M. Chem. Pharm. Bull. 1984, 32, 1441. 
7 Baud, M. V.; Chavis, C.; Lucas, M.; Imbach, J.-L. Tet. Lett. 1990, 31, 4437. 
8 Vorbrüggen, H.; Ruh-Pohlenz, C. Handbook of Nucleoside Synthesis. Wiley-Interscience: New York, 2001. 
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Aminopurines such as adenine (5) can sometimes perform well in this method, but small factors 
can impact the results. Scheme 3 shows several different conditions that were investigated for the 
reaction of N6-benzoyladenine 174 with 2. While N9 products were obtained with complete  
 
 
selectivity, the ratios of α:β anomers varied widely under the influence of solvent, temperature, 
and counterion. The sodium salt 17 reacted in 1,2-dimethoxyethane (DME) after 1 h at room 
temperature to form predominantly 18 in a 46% total yield of 5:95 α:β anomers. When a cooled 
mixture of MeCN/THF and an extended reaction time of 10 h was used, the α anomer became 
the major product (52%) with a lesser amount of β product (18%). With K+ or Li+ counterions 
and MeCN as the solvent and a 24 h reaction time at room temperature, yields of 18% total with 
Scheme 3. Influence of counterions, solvent, reaction time, and temperature on the product ratios 
of glycosylations. 
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a 57:42 α:β and 17% with a 71:29 α:β ratio were obtained, respectively. These results highlight 
some interesting trends observed in glycosylations with the sodium salt method. Longer reaction 
times generally favor the α product. The sugar 2 anomerizes most quickly in polar solvents9, so 
longer reaction times mean that more β-2 will be present. The reaction may also be reversible 
under the sodium salt conditions, particularly with excess 2 present. More β-nucleoside would 
form initially, but could equilibrate over time to form more α product. The influence of the 
cation is clear but less easily explained. Since the reaction generates 1 equiv of KCl or LiCl as a 
byproduct, the solubility of the salt in MeCN may play a role: the salts could play a role in the 
anomerization of the sugar, for example. The reactivities of the purine K salt or Li salt could also 
determine the rate of reaction and thus the different α:β ratios observed.  
 In the above examples, both sterics and electronics favor glycosylation at N9, making the 
coupling a question of the rate of glycosylation vs. the rate of the anomerization of 2. The 
electronics of many purines are altered in such a way that glycosylation at N9 is no longer 
favored. The 3-deaza-3-substituted purines represent a problematic class of heterocycles in 
which neither electronics nor sterics favor glycosylation of the N9 nitrogen (Scheme 4). In the 
course of our work the poor coupling yield for 2110 and other 3-deaza-3-substituted purines (See 
Section 3.3) became a stumbling block for material throughput in our efforts to synthesize 
dhm3c3A (5, Section 2.1). Large-scale glycosylations of 21 typically resulted in 25-30% yields of 
22, which was also quite difficult to separate from N7 product 23. The difficult amination of 22 
required an overnight treatment with hydrazine followed by a 6 h reaction with Raney nickel and 
only resulted in a 50-60% yield. In attempting to improve this glycosylation, we first examined  
                                                            
9 a) Kotick, M. P.; Szantay, C.; Bardos, T. J. J. Org. Chem. 1969, 34, 3806. b) Hubbard, A. J.; Jones, A. S.; Walker, 
R. T. Nucleic Acids Res., Symp. Ser. 12 1984, 6827. 
10 Irani, R. J.; SantaLucia, J. Jr. Nucleosides, Nucleotides & Nucleic Acids 2002, 21 (11–12), 737–751. 
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Scheme 4. Attempts to improve the poor coupling performance of 3-deaza-3-methylpurines. 
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alternate coupling conditions, then alterations to 21 such as installing the amine before coupling 
and protecting the amine to make the 6-position more bulky and thus increase the yield of N9 
product. Coupling of 21 by persilylation using N,O-bis(trimethylsilyl)-acetamide (BSA) 
followed by sugar coupling with TMSOTf as a Lewis acid catalyst resulted in a 50% yield of N9 
products, but unfortunately as an inseparable 1:1 mixture of α:β nucleosides. Coupling of 6-
amino-3-deaza-3-methylpurine 24 under phase-transfer conditions using KOH and 5 mol% of 
cryptand TDA-1 (tris[2-(2-methoxyethoxy)ethyl]amine)11 gave a much higher ratio of N9:N7 
products, but with only a 23% isolated yield of 25. This low yield could not be increased, and the 
likely reason was the low solubility of 24 in organic solvents (soluble in MeOH, H2O, or DMSO, 
slightly soluble in MeCN, insoluble in EtOAc). In an effort to increase the solubility of 24 we 
used either benzoyl (27) or isobutyryl (30) protection. While these were more soluble in organic 
solvents, the coupling of 27 resulted in a 52% yield of a nearly 1:1 mixture of 28:29 with 20% 
starting material recovered. Compound 30 coupled in a similar yield and the products were 
nearly inseparable. Clearly our purine analogs containing amino groups or amides did not 
perform well in the glycosylation, and no substrate attempted to this point offered an 
improvement over 21. While none of these results were satisfactory, it is important to note that 
more of the desired N9 product consistently was obtained with increasing size of the substituent 
at the 6-position. We reasoned that a directing/protecting group with sufficient steric bulk placed 
in the 6-position would yield exclusively N9 product. Such a substrate would offer a significant 
improvement over the current methodology, not only for 3-deaza-3-substituted purines but 
perhaps unmodified purines as well. Such an improvement would be an important contribution to 
the field of nucleoside synthesis, since often it is necessary to settle for a glycosylation yield that 
is rather poor when considered in the overall context of organic synthesis, due to the lack of 
                                                            
11 a) Winkeler, H.-D.; Seela, F. J. Org. Chem. 1983, 48, 3119. b) Soula, G. J. J. Org. Chem. 1985, 50, 3717. 
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alternatives or the difficulty of the coupling itself. The use of a protecting/directing group in the 
6-position could also increase the solubility of the purine coupling partner and increase the yield 
of the glycosylation. 
 Conceptually, such a method already existed. Bulky groups in the 6-position of purines 
are known to influence the N9:N7 ratios of alkylations12 and glycosylations,13 just as we 
observed for the 3-deaza-3-methyl substituent. The work of Robins and co-workers in this area 
was particularly helpful. Adenine (5, Scheme 5) reacts with azine reagent 3114 to yield 6-(1,2,4-  
 
 
triazol-4-yl)purine 3215. They found that completely regioselective N9 alkylation of the sodium 
salt of 6-(1,2,4-triazol-4-yl)purine was possible using methyl iodide or a variety of alkyl or 
                                                            
12 Breipohl, G.; Will, D. W.; Peyman, A.; Uhlmann, E. Tetrahedron 1997, 53, 14671–14686. 
13 Geen, G. R.; Grinter, T. J.; Kincey, P. M.; Jarvest, R. L. Tetrahedron 1990, 46, 6903–6914. 
14 Naik, A. D.; Marchand-Brynaert, J.; Garcia, Y. Synthesis 2008, 1, 149–154. 
15 Samano, V.; Miles, R. W.; Robins, M. J. J. Am. Chem. Soc. 1964, 116, 9331–9332. 
Scheme 5. Robins’ work with 6-(1,2,4-triazol-4-yl)purine and 6-(2-substituted-imidazol-1-yl)purine 
alkylations and glycosylations. 
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benzyl halides in DMF16. Unfortunately, 32 and similar purines are highly polar and insoluble in 
solvents besides DMF (and MeCN to a lesser extent), so they perform poorly in glycosylations. 
Mintas17 and others18 investigated 6-pyrrole-substituted purines, but the 6-pyrrole group was not 
a completely effective directing group, and it was also difficult to remove17 as it is much more 
basic than 1,2,4-triazole. Robins and co-workers investigated 6-(imidizol-1-yl)purine derivatives 
for their performance in alkylations16 and glycosylations.19 As shown in Scheme 5, 6-
chloropurines such as 7 are easily reacted with various imidazoles to afford the 6-(imidazol-1-
yl)purines. It was shown by X-ray crystallography that the coplanar orientation of the 6-
imidazole and purine rings was favored, placing the 5-C-H bond of the imidazole ring above the 
N7 of the purine. Stabilizing π-electron interactions and the possibility of a non-classical 
hydrogen bond were cited as the cause for this observation. The coplanar C-H bond served to 
block access to N7, proving more effective than the corresponding 4,5-diphenylimidazole 
derivative. The 2-alkylimidazole-substituted purines were more lipophilic than 32 and 
participated in glycosylation reactions to afford exclusively N9 products. The ratio of α:β 
products was poor, however. The use of a binary solvent mixture of 1:1 MeCN:DCM slowed the 
rate of anomerization of 2 while solvating the purine such that exclusively β-N9 product was 
isolated in some cases.  
 Deprotection of the imidazole blocking group was difficult.19b For 6-(2-substituted-
imidazol-1-yl)-2-chloro-2′-deoxyadenosine nucleosides treatment with NH3/MeOH at 80 °C for 
15 h in a pressure vessel gave 2-chloro-2′-deoxyadenosine (Cladribine, an anticancer agent), but 
                                                            
16 Zhong, M.; Robins, M. J. J. Org. Chem. 2006, 71, 8901–8906. 
17 Dzolic, Z.; Kristafor, V.; Cetina, M.; Nagl, A.; Hergold-Pavelic, J.; Balzarini, J.;De Clercq, E.; Mintas, M. 
Nucleosides, Nucleotides, and Nucleic Acids 2003, 22, 373–389. 
18 Alarcon, K.; Martelli, A.; Demeunynck, M.; Lhomme, J. Tet. Lett. 2000, 41, 7211–7215. 
19 (a) Zhong, M.; Nowak, I.; Cannon, J. F.; Robins, M. J. J. Org. Chem. 2006, 71, 4216–4221. 
b) Zhong, M.; Nowak, I.; Robins, M. J. J. Org. Chem. 2006, 71, 7773–7779. 
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separation of the imidazole from the nucleoside was problematic. For purines lacking the 2-
chloro substituent, ammonolysis was more difficult. However, alkylation of the imidazole moiety 
with BnI followed by ammonolysis for 11 h at 60 °C effected the displacement. Benzylation 
followed by ammonolysis afforded Cladribine in >90% optimized yield from the fully-protected 
glycosylation product. 
 
3.2 Initial Approaches 
 Application of the Robins 6-(imidazol-1-yl) directing group to the synthesis of 3-deaza-3-
substituted purine nucleosides required the reaction of a substituted imidazole with a 6-chloro-3-
deazapurine such as 21 (Scheme 6). Though 6-chloropurines react with imidazoles at 65 °C in 
DMF, 21 failed to react with 2-isopropylimidazole even at reflux. Looking for an alternative 
method of installing the imidazole directing group, we treated 21 with anhydrous hydrazine at 
reflux for 24 h then reduced with Raney nickel in H2O to obtain 60–87% of adenine analog 24. 
The yield of this reaction was variable, with 10–30% starting material typically recovered, and 
the nature of the reaction made it impossible to monitor. With 24 in hand we briefly examined 
construction of the imidazole ring onto the exocyclic amine of 24. There are few reports of this 
transformation, however, and our efforts were unsuccessful. Azine reagent 31 did react with 24 
to afford the 6-(1,2,4-triazol-4-yl)-3-deaza-3-methylpurine 34. Reaction of this extremely 
insoluble compound with NaH in MeCN followed by 2 resulted in a highly N9-selective 
glycosylation, but 35 was only isolated in 23% yield.  No sign of the α-N9 product was observed. 
34 was more soluble in DMF, but extremely low conversion was observed, with 35 the major 
product but small amounts of N7 isomer present as well. This was not unexpected given Robins’ 
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observation that 32 did not perform well as a glycosylation partner.19 However, we were gratified 
to find that the triazole of 35 could be selectively deprotected after a few hours in 7 M 
NH3/MeOH at room temperature, leaving the sugar hydroxyls still protected. Such a selective  
 
 
deprotection was necessary for our synthetic approach to dhm3c3A and other 3-deaza-3-
substituted purines.  
 Unable to proceed with the 1,2,4-triazole directing group, we turned our attention to 
cyclic anhydrides. These would react with aminopurines to produce cyclic imides whose 
Scheme 6. Attempts to apply the Robins methodology to 3-deaza-3-substituted purines. 
78 
 
solubilities should be improved relative to 6-(1,2,4-triazol-4-yl)purines. Given our lack of 
success with amide-containing purines (Scheme 4), bidentate amino protection would also result 
in a better glycosylation partner. We examined the phthaloyl group first, since it is commercially 
 
 
available and was examined as a protecting group for phosphoramidites.20 Phthalic anhydride (1–
1.5 equiv) reacted slowly with 24 in acetic acid (~50% conversion after 48 h) to produce 36 as 
well as the uncyclized amide 37 in a 1:1 ratio as judged by 1H NMR. The two products were an 
inseparable mixture on silica gel, and removal of any unreacted anhydride was also difficult. 
Recrystallization also failed to separate 36/37. The addition of additives such as BF3•OEt2 or 
DMAP sped the reaction to some degree, but the yield remained around 50%. The complete 
                                                            
20 Beier, M.; Pfleiderer, W. Helv. Chim. Acta 1999, 82, 633-644. 
Scheme 7. Initial examination of phthalimide as a directing/protecting group. 
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insolubility of 24 in benzene or toluene made the use of a Dean-Stark apparatus impossible. The 
use of anhydrous pyridine with 2.0 equiv of anhydride at reflux resulted in complete conversion 
and ~86% yield of 36/37. It was also found that refluxing the product mixture in excess SOCl2 
for 2 h completely transformed the amide into 36 in quantitative yield, presumably via the 
conversion of the acid of 37 into the acid chloride, which is highly reactive and cyclizes quickly. 
 The solubility of 36 in MeCN was reasonably good, and using the sodium salt method a 
62% yield of coupling products was obtained. The ratio of N9:N7 was 1:1.1 with a small amount 
of both α-nucleoside products obtained. Repetition of this reaction revealed, however, that as 
high a ratio as 1:1 of α:β products was obtained in some cases. The reason for this lack of 
reproducibility is not clear. Examination of the phthaloyl group as a directing/protecting with 
other purines revealed additional shortcomings (see the next section), in particular its lack of 
stability—it was removed in 5–15 min at room temperature in 3 M NH3/MeOH. This is 
surprising given that phthaloyl-protected aliphatic amines typically require hydrazine for 
removal. Though its ease of deprotection might seem to be a desirable trait, it proved to be rather 
labile during reactions where we required it to remain intact. In fact, phthaloyl protection of 
adenine itself only proceeded in ~40% yield under the optimized conditions for 24, and the 
amide could not be efficiently cyclized to the imide. With the promising but less-than-optimal 
results using the phthalimide directing/protecting group, we turned our attention to cyclic 
aliphatic anhydrides. We began with cis-1,4-cyclohexanedicarboxylic anhydride21 (Scheme 8), 
which is obtained by refluxing a mixture of cis and trans dicarboxylic acids in acetic anhydride 
followed by distillation. The polyanhydride is obtained initially and depolymerizes smoothly 
                                                            
21 Hall, H. K., Jr. J. Am. Chem. Soc. 1958, 80, 6412-6420.  
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under high temperature. Our attempts to use this anhydride are discussed in the following 
section. Synthesis of tetramethylsuccinic anhydride,22 abbreviated throughout this work as M4SA  
 
 
(changing to tetramethylsuccinimide, M4SI, after reaction with an amine), began with the 
widely-used radical initiator AIBN 43. Slow addition of AIBN over 14 h to hot heptane resulted 
in homocoupling of the radical fragments to afford dinitrile 44 after a simple filtration to remove 
polymeric material. 44 was suspended in aqueous H2SO4 and heated for 2 h with vigorous 
stirring to obtain the anhydride in excellent yield. No chromatography is needed, and considering 
the usefulness of M4SI as a protecting group (see the following section) the effort to prepare this 
non-commerically available compound is merited.  
                                                            
22 Whitesides, G. M.; Hackett, M.; Brainard, R. L.; Lavalleye, J. P. P. M.; Sowinski, A. F.; Izumi, A. N.; Moore, S. 
S.; Brown, D. W.; Staudt, E. M. Organometallics 1985, 4, 1819-1830. 
 
Scheme 8. Synthesis of cyclic anhydrides cis-1,4-cyclohexanedicarboxylic anhydride 42 and 
tetramethylsuccinic anhydride (M4SA). 
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 The use of the corresponding acid chlorides of all three directing/protecting groups was 
also examined. Since acid chlorides are more reactive than anhydrides, and considering the long 
reaction times and excess anhydride needed to achieve full conversion (vide infra), we 
endeavored to prepare each acid chloride and compare its performance to the anhydride. It is 
often possible to generate acid chlorides from the corresponding acid in situ or isolate them by 
distillation. Phthaloyl chloride is commercially available and was redistilled prior to use. Full 
conversion of 24 was observed with only 1.3 equiv of phthaloyl chloride, but surprisingly a 
similar mixture of 36/37 was obtained in 84% yield; consequently the anhydride was preferred 
for ease of handling. The acid chloride of 40 was prepared in situ using a variety of methods, but 
failed to react under any conditions, as described in the following section. We attempted to 
convert tetramethylsuccinic anhydride (M4SA) to its acid chloride by refluxing with PCl5 in 
DCE, but this was unsuccessful. Only unchanged anhydride was recovered in nearly quantitative 
yield. This was unexpected, as succinic anhydride forms the acid chloride using PCl523  (SOCl2 
gives the anhydride) as does d,l-dimethylsuccinic acid.24 Hydrolysis of M4SA in AcOH/H2O to 
the acid—with the aim of converting to the acid chloride in a separate step—was also 
unsuccessful. Given that M4SA performs well in reactions with a variety of purines, we did not 
pursue additional approaches to the acid chloride. 
                                                            
23 Cason, J.; Reist, E. J. J. Org. Chem. 1958, 23, 1492-1496. 
24 Dervan, P. D.; Jones, C. R. J . Org. Chem, 1979,  44 (13), 2116-2122. 
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 Syntheses of purine 2′-deoxynucleosides are challenging, particularly because the 
glycosylation step must be both regioselective and diasterioselective.  Reaction yields of the 
naturally-occurring β-N9 products are often low to moderate. Most preparations of purine 2′-
deoxynucleosides employ the sodium salt method,1 which typically uses a 6-chloropurine 
heterocycle and 2-deoxy-3,5-di-O-(p-toluoyl)-β-D-erythro-pentofuranosyl chloride.2,3 For 
example 6-chloropurine (1a, Table 1) reacts to form 57% β-N9 nucleoside and 13% β-N7 with 
no α-isomers detected.1 Treatment with NH3/MeOH deprotects the sugar and displaces the 6-
chlorine to form 2′-deoxyadenosine. Small changes in the sterics or electronics of the heterocycle 
can impact the ratio of coupling products. The favorable coupling ratio for 1a (N9:N7 = 4.7:1) 
largely reverses itself for the 6-chloropurine derivative 2a containing a 3-deaza-3-methyl 
substituent (N9:N7 = 1.0:2.2).4 The products of 1a and 2a can be separated by flash 
chromatography, but this is not always the case. Many substrates produce significant amounts of 
β-nucleoside products, further complicating purification and lowering yields.   
 Robins has described the use of purines bearing a 2-alkylimidazole5,6 or triazole6 in the 6-
position to achieve highly regio- and diastereoselective glycosylations using the sodium salt 
method.  However, the purine coupling partners must be prepared from the corresponding 
oxopurines or the often expensive chloropurines. In addition, removal of the 2-alkylimidazole 
was reported to be difficult with most purines.6 Related studies include the regioselective N9 
arylation of purines.7 
 We attempted to use the Robins method in our work with 2a and other 3-deaza-3-
substituted purines, but the 6-(2-alkylimidazolyl) derivatives of 2a and 3a could not be prepared, 
largely because displacement of the 6-chlorine of 3-deazapurines requires harsh conditions (i.e. 
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refluxing hydrazine followed by Raney nickel reduction4,8). Furthermore, the glycosylation 
products of 3a could not be separated easily, leading us to seek an alternative procedure. 
 Here we describe 2,2,3,3-tetramethylsuccinimide (M4SI) as a new directing/protecting 
group for the synthesis of β-N9 nucleosides with high regio- and diastereoselectivity. 
 We reasoned that 6-aminopurines protected with a cyclic imide might perform well as 
glycosylation partners. The cyclic imide would (i) protect the amino group from side reactions, 
(ii) block the undesired glycosylation at N7, and (iii) be removed by mild base to expose the 
amino group, with or without deprotection of the sugar, as needed. We first examined phthaloyl 
protection of adenine using phthalic anhydride. Phthalimide has been reported as a protecting 
group in DNA synthesis9,10  and 15N-phthalimide has been used for the introduction of isotopic 
nitrogen into nucleosides.11,12 The N6-phthalimide derivative of adenine could be prepared (1b), 
although the yield was poor (~40%) under all conditions examined. It participated in 
glycosylation reactions to give almost exclusively the N9 regioisomer but in only 36% isolated 
yield. Deprotection with NH3/MeOH at room temperature removed the phthalimide in less than  
Figure 1. Structure of adenyl-N6-tetramethylsuccinimide from x-ray diffraction methods. (a) face view, (b) 
edge view. 
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15 minutes and the sugar toluoyl esters after several hours.  The amine could be re-protected as 
needed for DNA synthesis, but that approach was less than ideal.  
 We then considered aliphatic anhydrides that might exhibit better hydrolytic stability,  
beginning with 1,4-cis-cyclohexanedicarboxylic anhydride.13 Unfortunately this compound 
polymerizes easily and attempts to prepare simple imides from ammonia or methyl amine have 
failed.  Attempts to prepare the cyclic imide from adenine in this work also failed. 
 
 The third compound we considered was tetramethylsuccinic anhydride (M4SA).  Upon 
formation of the imide with adenine (Figure 1) the methyl groups should partially shield the N7 
nitrogen from glycosylation.  The cyclic anhydride M4SA is readily obtained in two steps14 from  
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AIBN. M4SA reacted smoothly with adenine and other purines in refluxing pyridine in the 
presence of 2-3 equiv of DBU (Scheme 1). Surprisingly, no reaction took place without base, and 
other bases such as Et3N and proton sponge failed to promote the reaction. A small amount of the 
amide was always present due to incomplete cyclization, but this could be converted to the cyclic 
imide with refluxing SOCl2, resulting in 78–81% yields of the purine-N6-tetramethylsuccinimide.  
 
It is important to convert the residual amide into the cyclic imide since the amide (Scheme 1) 
does not function well as a blocking group. We obtained the structure of the M4SI of adenine by 
x-ray crystallography and two views are shown in Figure 1.  In the "face view" (Figure 1a) the 
87 
 
four methyl groups can be observed positioned "umbrella-like" above the N7 edge of the adenine 
ring system. The distance between the imide carbonyl oxygen and the N7 nitrogen is 3.1 Å, and 
that to C5 is 3.0 Å. These distances likely prevent a coplanar conformation between the imide 
and heterocycle, and in combination with the four methyl groups seem sufficient to limit access 
to N7 by the incoming sugar.  The "edge view" (Figure 1b) illustrates that the plane of the imide 
functionality is in fact rotated 52° relative to the plane of the heterocycle, and this rotation is 
necessary to prevent the steric clash between the imide carbonyls and the N7 nitrogen and C5 
carbon. 
 We next examined a number of adenine-based heterocycles for their ability to undergo 
glycosylation with M4SI as a directing/protecting group at the 6-position (Scheme 2) and 
compared these results with those obtained for the corresponding 6-chloropurine, when available 
(Table 1). Phthalimide-protected heterocycles 1b, 2b, and 3b showed a better directing efffect 
for N9 than did the 6-Cl derivatives, but only gave low to moderate yields; varying and poorly 
reproducible amounts of α-nucleosides were always isolated as well. The N7 and N9 
regioisomers could be separated but the α and β-diasteriosomers could not.  
 In contrast, glycosylation of M4SI-protected adenine 1c yielded only the N9 isomer. The 
best yield (71%) was obtained with phase transfer conditions using KOH/TDA-115 in comparison 
with NaH (54%). M4SI performed well with 3-deaza-3-substituted purines. 2c gave a 6.4:1 ratio 
of N9:N7 β-nucleosides, and this ratio increased to 7.59:1 for a 3-deaza analog bearing a silyl-
protected linker (4a). Although some coupling reactions generated small amounts of the 
unwanted regioisomer or diastereomers, with the M4SI group in place the desired β-N9 products 
could be resolved from the β-N7 and α-nucleosides by flash chromatography.  The α-nucleosides  
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result from anomerization of the chloro-sugar (structure illustrated in Scheme 2), which is 
accelerated in polar solvents.16 While the M4SI group is quite effective in  blocking access to N7, 
the 3-substituted purines such as 2c and 4a are more hindered nucleophiles; the reaction is then 
slower to reach completion and larger amounts of α-nucleosides are formed.  
 The M4SI group displayed the desired stability that phthalimide lacked. Treatment of the 
coupling products of 1c and 2c with NaOMe/MeOH or 7 M NH3/MeOH at room temperature 
removed the two toluoyl esters on the sugar but not the M4SI (64% and 82% yield respectively), 
and in 86% yeild for the coupling product of 4a (see Supporting Information). 
 Purine nucleosides with substituents at the 3-position are valuable to probe hydration 
effects in the DNA minor groove.  Even a simple methyl substituent at C3 will be directed into 
the minor groove of duplex DNA where it may disrupt or effect a reorganization of water 
structure.      
 As a further example of this protecting group’s utility we elaborated M4SI-protected 2′-
deoxy-3-deaza-3-methyladenosine, the coupling product of 2c, to the DMT-protected 
phosphoramidite for use in DNA solid-phase synthesis (see Supporting Information).  The M4SI 
can be cleanly removed with NH3/MeOH or conc. NH4OH at 55 °C overnight, both compatible 
with DNA synthesis protocols. The use of M4SI-protected phosphoramidites in solid-phase DNA 
synthesis will be reported elsewhere.  
 M4SI is a valuable new directing/protecting group that allows rapid access to β-N9 6-
aminopurine-2′-deoxynucleosides and functions as an effective base-labile protecting group. It is 
especially valuable for 3-substituted purines. It should also serve in other applications where 
bidentate amine protection is desired. 
  Acknowledgment  
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3.4 Experimental Details and Supporting Information 
  General Procedures  
 All reactions were carried out under an inert atmosphere with dry solvents under 
anhydrous conditions unless noted otherwise. Dry tetrahydrofuran (THF), diethyl ether (Et2O), 
N,N-dimethylformamide (DMF), pyridine (pyr), acetonitrile (MeCN), and dichloromethane 
(DCM) were obtained by passing commercially available pre-dried, oxygen-free formulations 
through activated alumina columns. Dry methanol (MeOH) was obtained by distillation from 
Mg(OMe)2. Yields refer to chromatographically and spectroscopically (1H NMR) homogeneous 
materials, unless otherwise stated. Reagents were purchased at the highest commercial quality 
and used without further purification, unless otherwise stated. Reactions were monitored by thin-
layer chromatography (TLC) carried out on 0.25 mm Silicycle TLG-R10011B-323 60 Å plates 
using UV light as visualizing agent and ceric ammonium molybdate (CAM) stain and heat as 
developing agents. Dynamic Adsorbents silica gel (60 Å, particle size 32-63 µm) was used for 
flash column chromatography. Difficult separations were carried out using “chromatospec silica 
gel” (E. Merck Chromatospec silica gel (60 Å, particle size 15-40 µm). NMR spectra were 
recorded on Varian VNMRS 400, VNMRS 500, VNMRS 600, or INOVA 500 instruments and 
calibrated using residual undeuterated solvent (CDCl3: δH = 7.26 ppm, δC = 77.16 ppm, acetone-
d6: δH = 2.05 ppm, δC = 29.84, DMSO-d6: δH = 2.50 ppm, δC = 39.52 ppm, methanol-d4: δH = 
3.31 ppm, δC = 49.00 ppm) as an internal reference. The following abbreviations are used to 
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designate the multiplicities: s = singlet, d = doublet, t = triplet, q = quartet, quin = quintet, m = 
multiplet, br = broad. High-resolution mass spectra (HRMS) were recorded on a Waters LCT 
Classic or JEOL AccuTOF mass spectrometer using ESI (electrospray ionization) or DART 
(direct analysis in real time). 
 
  Preparation of 3-deaza-3-substituted Purines  
 The 3-deaza-3-substituted purine analogs used in this work were prepared from known 3-
deazapurine analog 14 as shown in Scheme 1. The syntheses of 10 from 1, 11 from 3, and 13  
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from 3 were performed using essentially identical methodology, with the full synthesis of 13 
from 3 detailed herein. Treatment of 1 with anhydrous hydrazine followed by reduction with 
Raney nickel gave a mixture of 2 and 3, with 2 resulting from the dehalogenation of 
startingmaterial that sometimes remained even after extended reaction (>30 h) with hydrazine; 3 
was obtained in good to excellent yields but with somewhat variable reproducibility. M4SI 
protection of 3 using anhydride M4SA followed by Boc protection gave 5 as a mixture of 
regioisomers. Radical-mediated bromination of 5 gave 6 in 71% yield. Treatment of 6 with 
NaOAc in DMF at 60 °C displaced the bromide and surprisingly resulted in complete removal of 
the Boc group as well. The acetate 9 was not isolated, but hydrolyzed with NH3/MeOH at rt to 
afford 12 in 88% yield from 6. Silyl protection gave purine coupling partner 13 in 90% yield.  
 
  Glycosylations and Selective Deprotections  
 Full experimental details of the glycosylation and selective deprotection are included here 
for all M4SI-protected purines 4, 13, and 14. The synthesis of phosphoramidite 23 is also 
included; its use in DNA solid-phase synthesis will be reported elsewhere. Adenine was M4SI-
protected as described below to obtain coupling partner 14. As shown in Scheme 2, the protected 
purines 4, 13, and 14 were glycosylated by first treating with NaH or KOH/TDA-115 in MeCN 
followed by addition of α-chloro sugar 15, which was synthesized in three steps from 2-
deoxyribose according to the modifications to the Hoffer synthesis2 developed by Lhomme et 
al.3 The coupling products 16 and 17 were selectively deprotected by treatment with 7 M 
NH3/MeOH at rt for 4-8 h. The M4SI group could be cleaved by longer reaction (12-15 h) at rt, 
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or 5 h at 55 °C. NaOMe (2.5 equiv) in MeOH at rt was used to deprotect 18, and NH3/MeOH 
gave similar results. In general NaOMe gave a faster deprotection but slightly lower yields. 
 
Finally, compound 19 was elaborated to the corresponding phosphoramidite 23 employing 
standard methods of first DMT protection followed by phosphitylation (vide infra). 
 
 Experimental Procedures 
7-methyl-1H-imidazo[4,5-c]pyridine (2). Obtained in varying amounts with 3. This compound 
could also be obtained by treating 4-chloro-7-methyl-1H-imidazo[4,5-c]pyridine 14 (25 mg, 
0.149 mmol) with 200 mg of Raney Ni (CAUTION: pyrophoric, weighed under tared volume of 
water) in 3 mL of H2O at reflux with vigorous stirring for 18 h. The mixture was filtered and 
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purified as described below for 3 to afford 19 mg of 2 in nearly quantitative yield as a white 
amorphous powder. 2: Rf = 0.31 (silica gel, 9:1 DCM:MeOH with 0.7 M NH3); 1H NMR 
(DMSO-d6, 400 MHz) δ 12.95 (s, 1H), 8.78 (s, 1H), 8.38 (s, 1H), 8.12 (s, 1H), 2.48 (s, 3H) ppm; 
13C NMR (DMSO-d6, 101 MHz) δ 144.64, 141.81, 138.75, 14.85 ppm; HRMS (DART-TOF) 
calcd for C7H8N3H+ [M + H]+ 134.0718, found: 134.0712. 
7-methyl-1H-imidazo[4,5-c]pyridin-4-amine (3). To a flask containing 14 (1.50 g, 7.49 mmol) 
was added 25 mL of anhydrous hydrazine. The mixture was heated to reflux for 30 h (anhydrous 
conditions not needed). The hydrazine was removed in vacuo and co-evaporated with EtOH (3 x 
15 mL). Water (45 mL) and Raney nickel (2.25 g, CAUTION: pyrophoric, weighed under tared 
volume of water) were added and the mixture heated to reflux with vigorous stirring to prevent 
the Raney Ni from sticking to the stir bar. After 3 h the mixture was filtered, while still hot, 
through a pad of Celite and the pad washed with hot water (200 mL, CAUTION: prevent leftover 
Raney Ni from drying). Evaporation of the filtrate in vacuo afforded a brown solid. This was re-
dissolved in MeOH (30 mL) and silica gel (9 g) was added. After thorough drying of the mixture 
the resulting fine powder was loaded onto a flash column and purified by elution with 9:1 
DCM:MeOH containing 0.7 M NH3 to obtain 3 as a white amorphous powder (965 mg, 87%) 
and starting material (400 mg, 13%). Repetition of this procedure gave yields varying between 
60-87%, with most of the remainder being starting material and between a trace amount to 20% 
of 2. 3: Rf = 0.22 (silica gel, 9:1 DCM:MeOH with 0.7 M NH3); 1H NMR (DMSO-d6, 400 MHz) 
δ 12.55 (brs, 1H), 8.08 (s, 1H), 7.42 (s, 1H), 5.86 (brs, 2H), 2.26 (s, 3H) ppm; 13C NMR (DMSO-
d6, 101 MHz) δ 150.79, 140.69, 139.39, 126.57, 108.00, 14.55 ppm; HRMS (DART-TOF) calcd 
for C7H9N4H+ [M + H]+ 149.0827, found: 149.0834. 
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N-(7-methyl-1H-imidazo[4,5-c]pyridin-4-yl)-2,2,3,3-tetramethylsuccinimide (4). To a flask 
containing 7-methyl-1H-imidazo[4,5-c]pyridin-4-amine 3 (0.650 g, 4.38 mmol) and 2,2,3,3-
tetramethylsuccinic anhydride (1.37 g, 8.77 mmol) was added pyridine (45 mL) and DBU (1.97 
mL, 13.16 mmol). The mixture was heated to reflux for 18 h. Volatiles were removed in vacuo 
and the residue co-evaporated with toluene (3 x 10 mL) to remove residual pyridine. The 
resulting brown oil was purified by flash column chromatography eluting with 95:5 DCM:MeOH 
to obtain 1.14 g of white solid. The solid was thoroughly dried in vacuo and treated with 10 mL 
of SOCl2 at reflux for 2 h with a drying tube attached. Volatiles were removed in vacuo; co-
evaporation with EtOAc (3 x 10 mL) was used to remove residual SOCl2. The resulting off-white 
solid was then purified by flash column chromatography eluting with 95:5 DCM:MeOH to 
obtain 1.02 g (81%) of the title compound as a white amorphous powder. 4: Rf = 0.29 (silica gel, 
95:5 DCM:MeOH); 1H NMR (acetone-d6, 400 MHz) δ 8.27 (s, 1H), 8.12 (s, 1H), 2.57 (s, 3H), 
1.33 (s, 12H); 13C NMR (acetone-d6, 101 MHz) δ 182.63, 145.10, 142.18, 49.06, 22.47, 14.94; 
HRMS (DART-TOF) calcd for C15H19N4O2H+ [M + H]+ 287.1508, found: 287.1508. 
Note: 1H NMR (DMSO-d6) indicated that the product obtained before the SOCl2 treatment was a 
mixture of desired product and the amide. The presence of the amide was indicated by the CH3 
peak from the M4SI appearing at 1.1 ppm (s) in addition to 1.25 ppm (s) in a ~1:10 ratio. A small 
peak (brs) at 10.8 ppm was also present, the amide proton. However, the mixture was a single 
spot by TLC and MS only showed the m/z of 4. The final product was routinely isolated as the 
partial HCl salt after the SOCl2 treatment, as indicated by a small satellite peak slightly removed 
from each major peak in the 1H NMR spectrum; the CH3 peaks from the M4SI also appeared as a 
broad doublet instead of a sharp singlet. The HCl could be removed by suspending the title 
compound in acetone, adding solid K2CO3, and stirring for a few minutes. The suspension was 
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then filtered and washed with acetone; evaporation afforded the desired compound. It could be 
used in subsequent reactions without removing the HCl. 
tert-butyl 7-methyl-4-(3,3,4,4-tetramethyl-2,5-dioxopyrrolidin-1-yl)-1H-imidazo[4,5-
c]pyridine-1-carboxylate and tert-butyl 7-methyl-4-(3,3,4,4-tetramethyl-2,5-
dioxopyrrolidin-1-yl)-3H-imidazo[4,5-c]pyridine-3-carboxylate (5). To a flask containing 4 
(2.85 g, 9.95 mmol) was added Boc2O (3.04 g, 13.9 mmol) and DMAP (243 mg, 1.99 mmol). 
DCM (52 mL) was added and the mixture stirred at rt for 30 min (anhydrous conditions not 
needed). The starting material gradually dissolved to produce a yellow homogeneous solution. 
TLC (97:3 DCM: MeOH) indicated that a small amount of starting material remained. More 
Boc2O (1.1 g, 5 mmol) and DMAP (122 mg, 1 mmol) were added to drive the reaction to 
completion. After allowing the mixture to stir for another 15 min, TLC indicated that no starting 
material remained. Volatiles were removed in vacuo and the residue purified by flash column 
chromatography eluting with 97.5:2.5 DCM:MeOH to afford the desired product as a white foam 
(3.27 g, 85%, mixture of N7/N9 regioisomers). 5: Rf = 0.29, 0.36 (silica gel, 97:3 DCM:MeOH); 
1H NMR (CDCl3, 400 MHz): δ 8.41 (s, 0.5H), 8.39 (d, J = 0.8 Hz, 0.5H), 8.38 (s, 1H), 8.32 (d, J 
= 0.8 Hz, 1H), 2.73 (d, J = 0.8 Hz, 3H), 2.63 (d, J = 0.8 Hz, 1.5H), 1.64 (s, 9H), 1.60 (s, 4.4H), 
1.39 – 1.29 (m, 17.8H) ppm; 13C NMR (CDCl3, 101 MHz) δ 181.62, 181.46, 151.92, 146.67, 
146.31, 145.86, 145.27, 144.91, 143.76, 138.26, 137.65, 137.47, 130.87, 126.75, 121.55, 86.96, 
86.66, 81.05, 47.98, 46.73, 28.05, 27.98, 27.96, 27.81, 22.63, 21.66, 21.51, 18.87, 13.67 ppm; 
HRMS (ESI-TOF) calcd for C20H27N4O4H+ [M + H]+ 387.20323, found: 387.20368. 
tert-butyl 7-(bromomethyl)-4-(3,3,4,4-tetramethyl-2,5-dioxopyrrolidin-1-yl)-1H-
imidazo[4,5-c]pyridine-1-carboxylate and tert-butyl 7-(bromomethyl)-4-(3,3,4,4-
tetramethyl-2,5-dioxopyrrolidin-1-yl)-3H-imidazo[4,5-c]pyridine-3-carboxylate (6). To a 
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flask containing 5 (3.27 g, 8.46 mmol) was added N-bromosuccinimide (1.28 g, 7.2 mmol, 
recrystallized from hot H2O), benzoyl peroxide (131 mg, 0.54 mmol), and 175 mL of CCl4 
(reagent grade, not anhydrous). The mixture was heated to reflux with stirring. After 3 h 
additional NBS (301 mg, 1.69 mmol) and (BzO)2 (31 mg, 0.127 mmol) were added. The reaction 
was carefully monitored by TLC (97:3 DCM:MeOH) afterwards. After 6.5 h total the reaction 
was virtually complete, with only a trace of starting material and a trace of undesired 
dibrominated product. The reaction was allowed to cool to rt and filtered to removed 
succinimide. Volatiles were removed in vacuo and the residue purified by flash column 
chromatography eluting with DCM→97:3 DCM:MeOH to afford the desired product as a white 
foam (2.78 g, 71%, mixture of N7/N9 regioisomers), as well as the dibrominated product as an 
off-white solid (357 mg, 7.7%, mixture of N7/N9 regioisomers). 6: Rf = 0.36, 0.43 (silica gel, 
97:3 DCM:MeOH); 1H NMR (CDCl3, 400 MHz) δ 8.61 (s, 1H), 8.50 (s, 1H), 8.49 (s, 0.5H), 8.41 
(s, 0.5H), 5.13 (s, 1H), 4.90 (s, 2H), 1.70 (s, 4.5H), 1.62 (s, 9H), 1.42 – 1.30 (m, 18H) ppm; 13C 
NMR (101 MHz, cdcl3) δ 181.27, 181.08, 151.19, 146.01, 145.47, 144.84, 143.69, 139.70, 
132.91, 126.07, 125.29, 121.49, 87.70, 87.03, 48.02, 46.78, 29.46, 27.92, 27.88, 27.85, 23.84, 
22.45, 21.51, 21.37, 18.80 ppm; HRMS (DART-TOF) calcd for C20H25Br1N4O4H+ [M - Boc + 
H]+ 467.11170, found: 467.11272.  
N-(7-(hydroxymethyl)-1H-imidazo[4,5-c]pyridin-4-yl)-2,2,3,3-tetramethylsuccinimide (12). 
To a flask containing 6 (1.117 g, 2.406 mmol) and NaOAc (986 mg, 12.03 mmol) was added 
DMF (17 mL). The mixture was heated to 60-65 °C with stirring. Another 395 mg (4.812 mmol) 
of NaOAc was added after 4 h, and again after 6 h. After 9 h had passed TLC indicated complete 
consumption of starting material. The major product had Rf = 0.38 (silica gel, 95:5 
DCM:MeOH). Volatiles were removed in vacuo and 7 M NH3/MeOH (25 mL) were added. The 
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mixture was allowed to stir at rt for 8 h until TLC indicated complete conversion to 12. Volatiles 
were removed in vacuo, redissolved in MeOH (25 mL) and silica gel (10 g) was added. The 
slurry was thoroughly dried in vacuo and loaded onto a flash column. Elution with 91.5:8.5 
DCM:MeOH→9:1 DCM:MeOH afforded 639 mg (88%) of 12 as a white amorphous solid. 12: 
Rf = 0.16 (silica gel, 92.5:7.5 DCM:MeOH); 1H NMR (CD3OD, 500 MHz) δ 8.37 (s, 1H), 8.31 
(s, 1H), 5.02 (s, 2H), 1.38 (s, 12H) ppm; 13C NMR (101 MHz, CD3OD) δ 183.13, 172.37, 
146.58, 141.83, 118.92, 61.65, 21.85, 20.63 ppm; HRMS (ESI-TOF) calcd for C15H18N4O3H+ [M 
+ H]+ 303.14571, found: 303.14639.  
N-(7-((tert-butyldimethylsilyloxy)methyl)-1H-imidazo[4,5-c]pyridin-4-yl)-2,2,3,3-
tetramethylsuccinimide (13). To a flask containing 12 (100 mg, 0.331 mmol), TBSCl  (69 mg, 
0.463 mmol), and DMAP (2 mg, 0.0165 mmol) was added DCM (1.6 mL), DMF (0.4 mL), and 
DIPEA (86 µL, 0.496 mmol). The mixture was allowed to stir at rt for 20 h, then concentrated in 
vacuo and redissolved in EtOAc (10 mL). The organic layer was washed with water (2 x 5 mL) 
and brine (5 mL), then dried over Na2SO4, filtered, and evaporated. The residue was purified by 
flash chromatography eluting with 97:3 DCM:MeOH to obtain 124 mg (90%) of 13 as a white 
amorphous solid. 13: Rf = 0.36 (silica gel, 95:5 DCM:MeOH); 1H NMR (CD3OD, 500 MHz) δ 
8.38 (s, 1H), 8.35 (s, 1H), 5.17 (s, 2H), 1.38 (s, 12H), 0.96 (s, 9H), 0.15 (s, 6H) ppm; 13C NMR 
(CD3OD, 126 MHz) δ 183.26, 146.30, 139.31, 61.04, 26.33, 21.87, 19.22, -5.19 ppm; HRMS 
(ESI-TOF) calcd for C21H31N4O3SiNa+ [M + Na]+ 439.2141, found: 439.2138. 
N-(9H-purine-6-yl)-2,2,3,3-tetramethylsuccinimide (14). To an oven-dried flask containing 
adenine (150 mg, 1.11 mmol) and 2,2,3,3-tetramethylsuccinic anhydride (346 mg, 2.22 mmol) 
was added 7.5 mL of dry pyridine and DBU (0.497 mL, 3.33 mmol). The mixture was heated to 
reflux with stirring for 20 h. Volatiles were removed in vacuo and the residue co-evaporated with 
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toluene (3 x 3 mL) to remove residual pyridine. The resulting brown oil was purified by flash 
column chromatography eluting with 92.5:7.5 DCM:MeOH to obtain 305 mg of white foam. 1H 
NMR (DMSO-d6) indicated that this solid was a mixture of the desired product and the amide as 
indicated by signals at δ 12.23 (brs, ~0.3H), 1.17 (s, ~2.5 H), and 1.12 (s, ~2.5H) in addition to 
the signals reported below. This was dried in vacuo and treated with 5 mL of SOCl2 at reflux for 
2 h with a drying tube attached. Volatiles were removed in vacuo; co-evaporation with EtOAc (3 
x 3 mL) was used to remove residual SOCl2. The resulting off-white solid was then purified by 
flash chromatography eluting with 92.5:7.5 DCM:MeOH to obtain 236 mg (78%) of the title 
compound as a white amorphous powder. Crystals suitable for X-ray crystallographic analysis 
were obtained from slow addition of Et2O to a saturated solution of EtOH. 14: Rf = 0.61 (silica 
gel, 9:1 DCM:MeOH); 1H NMR (DMSO-d6, 500 MHz) δ 13.88 (brs, 1H), 8.95 (s, 1H), 8.68 (s, 
1H), 1.28 (s, 12H) ppm; 13C NMR (DMSO-d6, 101 MHz) δ 181.18, 152.82, 147.98, 48.60, 21.93 
ppm; HRMS (DART-TOF) calcd for C13H15N5O2H+ [M + H]+ 274.1297, found: 274.1304. 
1-[2-deoxy-3,5-di-O-(p-toluoyl)-β-D-erythro-pentofuranosyl]-4-(3,3,4,4-tetramethyl-2,5-
dioxopyrrolidin-1-yl)-7-methyl-1H-imidazo[4,5-c]pyridine (16). To a flask containing 4 (57 
mg, 0.199 mmol) and NaH (19.5 mg, 0.418 mmol, 50% dispersion in oil) was added 6 mL of 
MeCN. The mixture was allowed to stir for 1 h. Chlorosugar 152,3 (162 mg, 0.418 mmol) was 
added portionwise. Stirring was continued overnight, after which the reaction mixture was 
filtered. Volatiles were removed in vacuo and the resulting yellow foam was purified by flash 
chromatography employing chromatospec silica gel eluting with 98.25:1.75 DCM:MeOH to 
afford 75.4 mg (59%) of 16 as a white foam. Also obtained were 35 mg (27%) of a nearly 
inseparable mixture of α-N9, β-N7, and α-N7 products as a white foam in a 3.3:2.1:1 ratio as 
judged by 1H NMR. 16: Rf = 0.35 (silica gel, 97:3 DCM:MeOH); 1H NMR (acetone-d6, 600 
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MHz) δ 8.56 (s, 1H), 8.13 (d, J = 0.9 Hz, 1H), 8.05 – 7.96 (m, 2H), 7.93 – 7.83 (m, 2H), 7.40 – 
7.33 (m, 2H), 7.33 – 7.24 (m, 2H), 6.90 (dd, J = 7.8, 5.8 Hz, 1H), 5.86 (dt, J = 6.3, 3.1 Hz, 1H), 
4.76 (td, J = 4.7, 3.2 Hz, 1H), 4.71 – 4.60 (m, 2H), 3.26 (ddd, J = 14.4, 7.8, 6.7 Hz, 1H), 3.09 
(ddd, J = 14.3, 5.8, 3.0 Hz, 1H), 2.81 (s, 3H), 2.43 (s, 3H), 2.39 (s, 3H), 1.33 (d, J = 32.6 Hz, 
12H) ppm; 13C NMR (acetone-d6, 151 MHz) δ 181.76, 166.50, 166.36, 145.18, 144.78, 143.51, 
143.49, 140.30, 138.59, 138.34, 130.55, 130.38, 130.13, 130.11, 127.99, 127.91, 119.95, 86.26, 
83.39, 75.55, 64.81, 48.39, 38.59, 21.93, 21.72, 21.61, 21.57, 21.44, 15.51 ppm; HRMS (ESI-
TOF) calcd for C36H38N4O7Na+ [M + Na]+ 661.2638, found: 661.2629. 
 
Table 1. 1D NOE data for 16. Selected important NOEs are shown with red arrows. 
Proton Irradiated (δ, ppm)   NOE (%) 
3-CH3 (2.81)  H1′(1.5), H2(1.5) 
H1′(6.90) H8(0.4), H5′/H5′′(0.9), H2′(0.5), H2′′(2.8), 3-
CH3(3.5) 
H3′(5.86) H8(0.6), H1′(0.6), H4′(1.2), H5′/H5′′(2.1), 
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H2′(3.1) 
H4′(4.76) H1′(0.9), H3′(1.2), H2′′(0.3) 
 
1-[2-deoxy-3,5-di-O-(p-toluoyl)-β-D-erythro-pentofuranosyl]-4-(3,3,4,4-tetramethyl-2,5-
dioxopyrrolidin-1-yl)-7-((tert-butyldimethylsiloxy)methyl)-1H-imidazo[4,5-c]pyridine (17). 
Obtained by the same procedure as 16 except that a gradient of 4:1→1:1 Hex:EtOAc was used in 
the column chromatography; 17 was isolated in pure form in 76% yield as a white foam. The 
remaining isomers including 12% α-N9, 10.5% β-N7, and 1.5% α-N7 were obtained as a nearly 
inseparable mixture (white foam). 17: Rf = 0.16 (silica gel, 99:1 DCM:MeOH); 1H NMR 
(acetone-d6, 400 MHz) δ 8.61 (s, 1H), 8.35 (s, 1H), 8.01 (d, J = 8.1 Hz, 2H), 7.90 (d, J = 8.1 Hz, 
2H), 7.38 (d, J = 8.0 Hz, 2H), 7.30 (d, J = 8.0 Hz, 2H), 7.07 (dd, J = 8.3, 5.7 Hz, 1H), 5.92 – 5.79 
(m, 1H), 5.25 (dd, J = 47.2, 12.8 Hz, 2H), 4.73 (dd, J = 4.2, 2.5 Hz, 1H), 4.69 (d, J = 4.9 Hz, 
2H), 3.30 – 3.17 (m, 1H), 3.08 (ddd, J = 14.4, 5.6, 2.2 Hz, 1H), 2.44 (s, 3H), 2.39 (s, 3H), 1.34 
(d, J = 19.5 Hz, 12H), 0.88 (s, 9H), 0.13 (s, 3H), 0.12 (s, 3H) ppm; 13C NMR (acetone-d6, 101 
MHz,) δ 181.68, 166.53, 166.41, 145.25, 144.82, 143.99, 142.41, 140.31, 140.01, 138.70, 
130.58, 130.39, 130.13, 130.09, 128.00, 127.84, 122.67, 86.71, 83.56, 76.03, 65.02, 61.38, 48.48, 
39.15, 26.22, 21.89, 21.69, 21.62, 21.57, 21.42, 18.73, -4.88 ppm; HRMS (ESI-TOF) calcd for 
C42H53N4O8SiH+ [M + H]+ 769.3639, found: 769.3633. 
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Table 1. 1D NOE data for 17. Selected important NOEs are shown with red arrows. 
Proton Irradiated (δ, ppm)   NOE (%) 
3-CH2 (5.25)  H1′(3.1), H2(4.9), Si-CH3(1.4), Si-t-Bu(0.1) 
H1′(7.07) H8(1.2), 3-CH2(4.7), H4′(1.8), H2′(1.8), 
H2′′(3.7), Si-t-Bu(1.6) 
H2′(3.30-3.21) H8(8.7), H1′(2.3), H3′(7.4), H5′/5′′(3.0), 
H2′′(11.0) 
H2′′(3.08) H8(1.5), H1′(5.3), H3′(3.5), H2′(8.8) 
H3′(5.92-5.79) H8(1.0), H5′/5′′(4.2), H2′(4.3) 
H2 3-CH2(9.4), Si-t-Bu(4.2) 
 
9-[2-deoxy-3,5-di-O-(p-toluoyl)-β-D-erythro-pentofuranosyl]-6-(3,3,4,4-tetramethyl-2,5-
dioxopyrrolidin-1-yl)purine (18). To an oven-dried flask containing a suspension of powdered 
KOH (59 mg, 1.05 mmol) and TDA-1 (7 µL, 0.022 mmol) in MeCN (24 mL) was added 14 (120 
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mg, 0.439 mmol). The suspension was heated to 80 °C with stirring, then allowed to cool to 40 
°C. Chlorosugar 152,3 (188 mg, 0.483 mmol) was added and the reaction mixture allowed to stir 
at 40 °C for 20 min. The mixture was then filtered and evaporated. The crude white foam was 
purified by flash chromatography eluting with 98:2 DCM:MeOH to afford 18 as a white foam 
(195 mg, 71%). Also obtained was a small amount of α-N9 product as a white foam (16 mg, 
5.8%). 18: Rf = 0.33 (silica gel, 97:3 DCM:MeOH); 1H NMR (acetone-d6, 400 MHz) δ 8.88 (s, 
1H), 8.69 (s, 1H), 8.01 (d, J = 8.2 Hz, 2H), 7.92 (d, J = 8.1 Hz, 2H), 7.36 (d, J = 7.9 Hz, 2H), 
7.29 (d, J = 8.6 Hz, 2H), 6.79 (dd, J = 7.9, 6.1 Hz, 1H), 6.03 – 5.91 (m, 1H), 4.85 – 4.62 (m, 3H), 
3.57 (ddd, J = 14.4, 7.9, 6.5 Hz, 1H), 2.99 (ddd, J = 14.3, 6.1, 2.6 Hz, 1H), 2.42 (s, 3H), 2.39 (s, 
3H), 1.35 (s, 12H) ppm; 13C NMR (acetone-d6, 101 MHz) δ 181.25, 166.95, 166.77, 154.65, 
153.38, 147.36, 146.48, 145.52, 145.16, 132.35, 130.93, 130.80, 130.49, 130.44, 128.49, 128.34, 
86.67, 84.06, 76.38, 65.21, 49.29, 37.61, 22.00, 21.96, 21.88, 21.87 ppm; HRMS (ESI-TOF) 
calcd for C34H35N5O7Na+ [M + Na]+ 648.2445, found: 648.2417. 
1-[2-deoxy-β-D-erythro-pentofuranosyl]-4-(3,3,4,4-tetramethyl-2,5-dioxopyrrolidin-1-yl)-7-
methyl-1H-imidazo[4,5-c]pyridine (19). To an oven-dried flask containing 16 (91 mg, 0.144 
mmol) was added MeOH containing 7 M NH3 (1 mL). The flask was tightly stoppered and the 
mixture allowed to stir for 5 h. TLC indicated complete conversion to 19. Volatiles were 
removed in vacuo and the residue purified by flash chromatography eluting with 92.5:7.5 
DCM:MeOH to afford 19 as a white foam (47 mg, 82%). 19: Rf = 0.41 (silica gel, 92.5:7.5 
DCM:MeOH);  1H NMR (MeOH-d4, 400 MHz) δ 8.73 (s, 1H), 8.18 (s, 1H), 6.71 (t, J = 6.3 Hz, 
1H), 4.59 (dt, J = 6.1, 4.1 Hz, 1H), 4.07 (q, J = 3.7 Hz, 1H), 3.74 (ddd, J = 28.9, 12.1, 3.7 Hz, 
2H), 2.87 – 2.73 (m, 1H), 2.80 (s, 3H), 2.63 – 2.51 (m, 1H), 1.40 (s, 12H) ppm; 13C NMR 
(MeOH-d4, 101 MHz) δ 183.41, 145.50, 143.29, 141.25, 138.18, 137.73, 121.32, 89.40, 86.97, 
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71.95, 62.65, 41.90, 30.67, 29.53, 21.89, 21.85, 15.69 ppm; HRMS (ESI-TOF) calcd for 
C20H26N4O5Na+ [M + Na]+ 425.1801, found: 425.1794.  
1-[2-deoxy-β-D-erythro-pentofuranosyl]-4-(3,3,4,4-tetramethyl-2,5-dioxopyrrolidin-1-yl)-7-
((tert-butyldimethylsiloxy)methyl)-1H-imidazo[4,5-c]pyridine (20). Obtained according to the 
procedure for 19, except that the reaction mixture was evaporated after 6 h and purified by flash 
chromatography eluting with 94:6 DCM:MeOH. 20 was obtained in 86% yield as a white foam. 
20: Rf = 0.27 (silica gel, 94:6 DCM:MeOH); 1H NMR (MeOH-d4, 500 MHz) δ 8.77 (s, 1H), 8.33 
(s, 1H), 6.86 (t, J = 6.3 Hz, 1H), 5.17 (dd, J = 66.6, 12.8 Hz, 2H), 4.59 (dt, J = 6.1, 4.1 Hz, 1H), 
4.03 (q, J = 3.6 Hz, 1H), 3.72 (ddd, J = 33.7, 12.1, 3.6 Hz, 2H), 2.82 – 2.71 (m, 1H), 2.54 (ddd, J 
= 13.5, 6.2, 4.4 Hz, 1H), 1.38 (brs, 12H), 0.98 – 0.86 (m, 9H), 0.16 (s, 3H), 0.14 (s, 3H) ppm; 
13C NMR (MeOH-d4, 126 MHz) δ 183.29, 145.89, 142.17, 140.89, 139.47, 138.64, 123.94, 
89.36, 87.24, 72.02, 62.70, 61.50, 42.28, 26.32, 21.88, 21.82, 19.06, -5.02, -5.03 ppm; HRMS 
(ESI-TOF) calcd for C26H40N4O6SiNa+ [M + Na]+ 555.2592, found: 555.2603. 
9-[2-deoxy-β-D-erythro-pentofuranosyl]-6-(3,3,4,4-tetramethyl-2,5-dioxopyrrolidin-1-
yl)purine (21). To an oven-dried flask containing 18 (133 mg, 0.212 mmol) dissolved in dry 
MeOH (2 mL) was added a 25% w/w solution of NaOMe in MeOH (48 µL, 0.85 mmol). The 
mixture was allowed to stir for 8 h at rt. Volatiles were removed in vacuo and the residue 
purified by flash chromatography eluting with 95:5 DCM:MeOH to afford 21 as a white foam 
(53 mg, 64%). 21: Rf = 0.23 (silica gel, 95:5 DCM:MeOH); 1H NMR (acetone-d6, 400 MHz) δ 
8.93 (s, 1H), 8.73 (s, 1H), 6.63 (dd, J = 7.2, 6.3 Hz, 1H), 4.71 (dt, J = 5.9, 3.1 Hz, 1H), 4.10 (dd, 
J = 6.3, 3.3 Hz, 1H), 3.80 (ddd, J = 27.9, 12.0, 3.5 Hz, 2H), 2.95 (ddd, J = 13.3, 7.4, 5.8 Hz, 1H), 
2.55 (ddd, J = 13.4, 6.1, 3.2 Hz, 1H), 1.35 (s, 12H) ppm; 13C NMR (acetone-d6, 101 MHz) δ 
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180.91, 154.16, 152.75, 146.99, 146.02, 89.68, 86.36, 72.43, 63.07, 48.92, 41.28, 21.52, 21.49 
ppm; HRMS (DART-TOF) calcd for C18H23N5O5H+ [M + H]+ 390.1777, found: 390.1769. 
1-[5′-O-(4,4′-dimethoxytrityl)-2-deoxy-β-D-erythro-pentofuranosyl]-4-(3,3,4,4-tetramethyl-
2,5-dioxopyrrolidin-1-yl)-7-methyl-1H-imidazo[4,5-c]pyridine (22). To a flask containing 19 
(47 mg, 0.117 mmol) dissolved in pyridine (2.5 mL) was added TEA (23 µL, 0.164 mmol), 
DMTCl (47 mg, 0.140 mmol), and DMAP (0.7 mg, 6 µmol). The reaction was allowed to stir at 
rt for 3 h. TLC analysis indicated that some starting material remained, and so additional DMTCl 
(5 mg, 0.015 mmol) was added. TLC after another 4 h indicated complete consumption of 
starting material. Volatiles were removed in vacuo and the residue co-evaporated with toluene (3 
x 1 mL) to remove residual pyridine. The solid residue was then purified by flash 
chromatography (silica gel washed with 1% TEA in 97.5:2.5 DCM:MeOH, then eluted with two 
column volumes of solvent system without TEA before loading compound) eluting with 97.5:2.5 
DCM:MeOH to afford 22 as a white foam (71 mg, 87%). 22: Rf = 0.34 (silica gel, 95:5 
DCM:MeOH); 1H NMR (CDCl3/pyridine-d5, 400 MHz) δ 8.18 (d, J = 0.7 Hz, 1H), 8.16 (s, 1H), 
7.38 (dd, J = 8.2, 1.3 Hz, 2H), 7.31 – 7.11 (m, 7H), 6.79 (d, J = 8.9 Hz, 4H), 6.52 (t, J = 6.3 Hz, 
1H), 4.55 (dd, J = 9.0, 4.9 Hz, 1H), 4.16 (q, J = 4.5 Hz, 1H), 3.77 (s, 6H), 3.33 (ddd, J = 24.2, 
10.2, 4.7 Hz, 2H), 2.66 (s, 3H), 2.52 (t, J = 5.7 Hz, 2H), 1.37 (d, J = 4.6 Hz, 13H) ppm; 13C 
NMR (CDCl3/pyridine-d5, 101 MHz) δ 181.72, 181.69, 158.69, 146.05, 144.55, 143.13, 143.08, 
142.29, 142.25, 139.55, 137.39, 137.29, 135.68, 135.60, 130.13, 130.11, 130.02, 129.98, 129.14, 
128.33, 128.15, 128.05, 127.07, 125.41, 118.50, 113.35, 86.74, 86.30, 85.21, 85.16, 71.63, 63.77, 
55.34, 55.28, 47.98, 47.94, 46.24, 41.64, 21.91, 21.86, 21.80, 21.69, 21.54, 21.44, 21.37, 15.87, 
0.12 ppm; HRMS (ESI-TOF) calcd for C41H44N4O7Na+ [M + Na]+ 727.3073, found: 727.3094. 
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Cyanoethyl phosphoramidite 23. To a flask containing 22 (42 mg, 0.059 mmol) dissolved in 
MeCN (1.25 mL) was added tetrazole (0.125 mL of 0.45 M solution in MeCN, 0.056 mmol) 
followed by 2-cyanoethyl N,N,N,N-tetraisopropylphosphane (38 µL, 0.12 mmol) dropwise. The 
mixture was allowed to stir at rt for 6 h, after which TLC indicated that the reaction was 
complete. H2O (0.1 mL) was added and stirring continued for 10 min. The reaction mixture was 
diluted with DCM (5 mL) and washed with saturated NaHCO3 (2 x 2 mL) and brine (1 x 2 mL). 
The organic layer was separated and dried with Na2SO4, then filtered and dried in vacuo. The 
residue was purified by flash chromatography (silica gel washed with 1% TEA in 99.5:0.5 
DCM:MeOH, then eluted with two column volumes of solvent without TEA before loading 
compound) eluting with 99.5:0.5 DCM:MeOH to afford 23 as a white foam (46 mg, 85%, 1:1 
mixture of diasteriomers). 23: Rf = 0.41, 0.44 (silica gel, 97:3 DCM:MeOH); 1H NMR 
(CDCl3/pyridine-d5, 400 MHz) δ 8.21 (s, 1.5H), 8.18 (s, 0.5H), 7.44 – 7.33 (m, 2H), 7.33 – 7.15 
(m, 7H), 6.86 – 6.74 (m, 4H), 6.53 (dd, J = 7.4, 5.7 Hz, 1H), 4.72 – 4.55 (m, 1H), 4.34 – 4.20 (m, 
1H), 3.86 – 3.56 (m, 4H), 3.78 (s, 3H), 3.77 (s, 3H), 3.39 – 3.22 (m, 2H), 2.69 (dd, J = 4.6, 0.6 
Hz, 3H), 2.67 – 2.50 (m, 3H), 2.44 (t, J = 6.3 Hz, 1H), 1.38 (s, 6H), 1.37 (s, 6H), 1.23 – 1.14 (m, 
9H), 1.11 (d, J = 6.8 Hz, 3H) ppm; 31P NMR (CDCl3/pyridine-d5, 162 MHz) δ 149.44, 149.02 
ppm; HRMS (ESI-TOF) calcd for C50H61N6O8PNa+ [M + Na]+ 927.4186, found: 927.4208. 
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NMR Spectra 
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1H NMR (acetone-d6, 400 MHz)  
13C NMR (acetone-d6, 101 MHz) 
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1H NMR (CDCl3, 400 MHz) 
13C NMR (CDCl3, 101 MHz) 
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1H NMR (CDCl3, 400 MHz) 
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1H NMR (MeOH-d4, 500 MHz) 
13C NMR (MeOH-d4, 125 MHz) 
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1H NMR (MeOH-d4, 500 MHz) 
13C NMR (MeOH-d4, 125 MHz) 
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1H NMR (acetone-d6, 500 MHz) 
 
13C NMR (DMSO-d6, 101 MHz) 
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1H NMR (acetone-d6, 600 MHz) 
13C NMR (acetone-d6, 151 MHz) 
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1H NMR (acetone-d6, 400 MHz) 
13C NMR (acetone-d6, 101 MHz) 
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1H NMR (MeOH-d4, 500 MHz) 
 
 
1H NMR (MeOH-d4, 500 MHz) 
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1H NMR (CDCl3/pyridine-d5, 400 MHz) 
13C NMR (CDCl3/pyridine-d5, 101 MHz) 
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1H NMR (CDCl3/pyridine-d5, 400 MHz) 
31P NMR (CDCl3/pyridine-d5, 162 MHz) 
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ORTEP X-Ray Structure of 14 
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  Abstract 
 The purine nucleoside 2,6-diaminopurine-2′-deoxyriboside is prepared by the direct 
glycosylation of the 2,6-bis(tetramethylsuccinimide) derivative of the parent purine heterocycle 4 
with 2-deoxy-3,5-di-O-(p-toluoyl)-α-D-erythro-pentofuranosyl chloride 5 using the sodium salt 
method.  2′-Deoxyisoguanosine is prepared from 2,6-diaminopurine by a five-step procedure.  
The purine heterocycle isoguanine is prepared by selective diazotization of 2,6-diaminopurine 
and then converted to the N9-trityl derivative to increase solubility.  After silylation of the O2-
carbonyl with TMSCl the N6-amino group is protected as the tetramethylsuccinimide (M4SI).  
The O2 carbonyl is protected as the DPC derivative and the trityl group is removed. The 
resulting product is glycosylated in good yield to generate fully protected 2′-deoxyisoguanosine. 
Key Words:  Glycosylation, 2,6-Diaminopurine, Isoguanine 
  Introduction 
 Among their many roles, nucleoside analogues can be used to modulate stability for 
DNA, RNA or DNA/RNA duplexes.  2,6-Diaminopurine-2′-deoxyriboside or the corresponding 
ribonucleoside is often used in this role because of the presence of a minor groove amino group 
that can provide a third hydrogen bond for dA-dT base pairs, or corresponding RNA A-U base 
pairs, and enhance overall helix stability.1  2′-Deoxyisoguanosine has also been of interest for its 
hydrogen bonding capability but perhaps more so for the observation that it pairs with isoC and 
provides a fifth base pair to expand the genetic code in artificial genetic systems.2,3 
 An early description of the preparation of 2,6-diaminopurine riboside was a multistep 
pathway beginning with the N1-oxide of adenosine.4 A much simpler synthesis of the 2′-
deoxynucleoside and corresponding phosphoramidite was described by Gaffney and Jones;5 it 
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involved sulfonation of the O6 carbonyl of dG followed by treatment with trimethylamine and 
then  ammonia to generate the 2,6-diaminopurine-2′-deoxynucleoside.  That procedure has been 
improved by preparation of the O6-pentafluorophenyl derivative, which can be converted in high 
yield to 2,6-diaminopurine-2′-deoxyriboside by treatment with ammonia. They also report that 
this synthon can be incorporated into DNA and then converted to 2,6-diaminopurine.6 A recent 
report also describes the preparation of the ribonucleoside directly from guanosine in high yield 
under high pressure conditions using HMDS and triflic acid.7 One drawback to all of these 
procedures is that they use a nucleoside starting material, making them less cost-effective and 
less flexible if, for example, a nucleoside bearing a modified sugar were desired.   
 The alternative approach involves glycosylation of 2,6-diaminopurine or related 
derivative using for example, 2-deoxy-3,5-di-O-(p-toluoyl)-α-D-erythro-pentofuranosyl chloride8 
(5) to generate a precursor to the diaminonucleoside.  To achieve highly diastereomeric yields of 
2′-deoxynucleosides the sodium salt method9 is often used, requiring that the purine be activated 
by a base (commonly NaH).  This procedure is untenable when free amines or even amides are 
present, but this problem can be eliminated by using 2,6-dichloropurine (available from 
xanthine) for glycosylation.8,10,11 Treatment of chloropurines with NaH generates the tautomeric 
N9/N7 salt, which upon reaction with the chlorinated carbohydrate typically results in a mixture 
of N9 and N7 purine nucleosides.  The major product is the N9-β-isomer, the minor product is 
the N9-α-isomer.8 The sodium salt method requires polar solvents, which can accelerate the 
anomerization of the chloro-sugar and generate some of the diastereomeric α-nucleoside.  
Reaction of the product 2,6-dichloropurine nucleoside with ammonia displaces the chlorine at 
the C6 position, but not the one at C2.11 The latter site requires a harsher hydrazine treatment 
followed by Raney nickel reduction.  Alternatively, NaN3 can be used to displace the chlorines at 
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both positions; the product diazide can then be reduced to the desired 2,6-diaminopurine 
nucleoside.10 One drawback with this overall approach is the larger number of steps needed, first 
to eliminate the amines and then to regenerate them in order to obtain the desired 2,6-
diaminopurine-2′-deoxyriboside. 
    Syntheses of 2′-deoxyisoguanosine12 and isoguanosine suffer from similar issues.  
Reported syntheses generally employ a nucleoside starting material.  For example, after 
preparing the N1-oxide of 2′-deoxyadenosine a photolytic rearrangement generates the desired 
2′-deoxyisoguanosine13,14 in a reported 42% yield.15 A second reported synthesis requires four 
steps from guanosine to generate 2-iodoadenosine, which could then be photolyzed to 
isoguanosine in a reported 55% yield.16 The other common approach to obtain the isoguanine 
nucleosides is to selectively deaminate 2,6-diaminopurine riboside or the 2′-deoxy derivative 
with nitrous acid.14,17,18 These deaminations still require a costly nucleoside starting material and 
are limited to ribose or 2′-deoxyribose sugars. 
    Reported procedures for the glycosylation of isoguanine are limited.  To the best of our 
knowledge there has been no report of direct glycosylation of isoguanine to prepare 2′-
deoxyisoguanosine.  Bookser and Raffaele describe19 a Vorbrüggen glycosylation using 
microwave acceleration to generate isoguanosine in 38% yield and in 79% purity; the noted 
purity results from product isolation by precipitation.  The absence of other reports for 
isoguanine glycosylations likely stems from the extremely poor solubility of isoguanine, 
estimated to be 2.2 mg/liter of water,20 and virtual insolubility in organic solvents. 
    Here we describe simple and straightforward procedures involving glycosylation of 
protected aminopurine derivatives to generate the fully protected nucleosides of 2,6-
diaminopurine (1) and isoguanine (2) (Figure 1).  The use of the tetramethylsuccinimide (M4SI) 
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protecting group21 affords purine derivatives that display excellent solubility and are excellent 
coupling partners in the sodium salt procedure.   These derivatives can be further elaborated to 
DMT-protected nucleoside phosphoramidites for DNA synthesis, or can be fully deprotected to 
generate the parent nucleosides 2,6-diaminopurine-2′-deoxyriboside and 2′-deoxyisoguanosine.  
 
Figure 1. Protected derivatives of (a) 2,6-diaminopurine-2′-deoxyriboside and (b) 2′-deoxyisoguanosine 
resulting from glycosylation of the corresponding purines. 
 
 
  Results and  Discussion 
    Glycosylation reactions to form purine 2′-deoxynucleosides commonly use the sodium 
salt method9 whereby the purine is treated with base (e.g., NaH) and the purine salt thus formed 
performs an SN2 displacement of chloride from 2-deoxy-3,5-di-O-(p-toluoyl)-α-D-erythro-
pentofuranosyl chloride (5, Scheme 1); the reaction usually generates a mixture of N9 and N7 
nucleosides in the β-configuration, with α-anomers sometimes formed due to anomerization of 
the sugar.  Purines containing free amines or amides generally have poor solubility and give low 
product yield with the sodium salt method.   
 We wished to avoid the use of the costly 2,6-dichloropurine glycosylation partner and 
examine direct glycosylation of the readily available 2,6-diaminopurine.  To accomplish this 
task, we needed to protect the exocyclic amines in such a manner that sodium hydride treatment 
generated only the N7/N9 purine salt.  We chose to use tetramethylsuccinic anhydride (M4SA)21 
to form the bis(tetramethylsuccinimide) of 2,6-diaminopurine.  After refluxing in the presence of 
129 
 
DBU for 22 h we obtained the fully protected purine heterocycle 4 (Scheme 1) as a mixture with 
approximately 10% of the corresponding amide.  After partial purification, this mixture was fully 
converted to 4 in an overall yield of 74% by refluxing in anhydrous pyridine an additional 8 h.  
 
Scheme 1 
 
 The glycosylation of 4 occurred under standard conditions using sodium hydride to 
activate the fully protected heterocycle and 2.1 equivalents of the glycosylating sugar 5.  Under 
these conditions and at ambient temperature we obtained the β-N9 product 1 in 93% yield 
(Scheme 1).  None of the N7 glycosylation product and neither of the possible α-anomers were 
observed. 
The toluoyl groups could be removed from 1 using ammonia/methanol (Scheme 2), but during 
this reaction partial deprotection of the N6-M4SI was observed (→6).  However, it was possible 
to convert 1 to 6 employing aq. NaOH in 2:1 pyridine/ethanol, and after purification protect the 
exocyclic amine as the dimethylformamidine derivative (7).  The material obtained in this 
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manner can be converted to a DMT-protected nucleoside phosphoramidite using standard 
protocols. The coupling product 1 could also be fully deprotected to yield the 2′-deoxynucleoside 
8. 
 
Scheme 2 
 
 Glycosylation of isoguanine has proven difficult with but a single report noted above 
using high temperatures facilitated by microwave treatment.19  2,6-Diaminopurine (Scheme 3) is 
a readily available starting material for 2′-deoxyisoguanosine, and similar to reports14,17,18 for the  
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Scheme 3 
corresponding nucleoside, we could selectively deaminate it by dripping a solution of 2,6-
diaminopurine in aqueous NaOH/NaNO2 into an acidic solution and then heating at 60 °C for 
one hour.  Precipitation gave isoguanine (9) in excellent yield.  Owing to its poor solubility, 
 isoguanine was treated with excess HMDS under reflux and then treated with trityl chloride to 
generate 10.  The N9-trityl derivative of isoguanine exhibited much improved solubility but the 
exocyclic amine could not be protected with M4SA; the low reactivity of the amino group of 
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isoguanosine has also been noted by Seela.22  Transient protection of isoguanosine by treatment 
with TMSCl has been reported to enhance the reactivity of N6,22 presumably as the result of 
silylation of the O2-carbonyl. We adopted a similar course of action and treated 10 with TMSCl 
and DBU followed by M4SA and obtained 11 in 67% yield.  Removal of the trityl group from 11 
with acetic acid followed by glycosylation of the resulting the M4SI-protected nucleobase 
generated at least four different products, suggesting the presence of reactive nucleophiles in 
addition to N9.  This observation is also consistent with reactions described by Seela22 who noted 
that alkylation could take place at N1, N3 and N9, suggesting extensive delocalization of the 
isoguanyl anion. 
    As an alternative, the DPC group (one of the preferred O2-protecting groups for 
monomers of isoguanine used in DNA synthesis protocols13) was introduced at O2 (→12) and the 
trityl group removed.  We then glycosylated the fully protected heterocycle (12) using 5.  
Glycosylation of 12 proceeded smoothly to generate a quantitative yield of coupling products 
with 70-79% of the desired β-N9 product, 5-15% α-N9, and 15% α/β-N7 in an approximately 1:1 
ratio. The wide variation in yield of the α-N9 product prompted us to optimize the reaction 
conditions to both minimize this product and render the reaction more reproducible.  
The same amount of α-N9 (12-15%) was produced with either acetonitrile or 
dichloromethane as the solvent after allowing 1 h for formation of the purine sodium salt with 
NaH and followed with an overnight (16 h) reaction time after addition of 5. Stopping the 
reaction at 1 h, 5 h, or 16 h after addition of the sugar indicated that the highest yield of couple 
products (quantitative) was obtained after 5 h; the same amount of α-N9 (12-15%) was obtained 
in each case. To our surprise, the least amount of α-N9 (4-5%) was produced when the reaction 
time of 12 with NaH was minimized (20 min) and all other conditions kept identical, while 
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allowing 1 h or more for reaction with NaH gave the most α-N9 product. Either acetonitrile or 
dichloromethane could be used as the reaction solvent with identical yields and identical ratios of 
products obtained. Therefore, the reaction time after addition of the sugar was not important 
except in terms of the overall yield. This result is surprising given that the sugar 5 anomerizes at  
 
Scheme 4 
a faster rate in polar solvents23 and thus should yield increasing amount of α-nucleosides with 
increasing reaction time. This rationale does not adequately explain our observed trend in 
coupling product ratios; it may be that another factor such as aggregation of the sodium salt of 12 
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during long reaction times with NaH leads to the observed effect. No similar effects were 
observed either with coupling of 4 or with other M4SI-protected purine substrates.21The final step 
of the synthesis required the selective cleavage of the toluoyl esters (Scheme 4), but this proved 
infeasible.  Under a number of conditions (NH3/MeOH, NaOH at 0 °C or K2CO3 at ambient 
temperature), as the M4SI group was the most labile protecting group.  The DPC group was 
stable enough that 13 could be isolated in ~50% yield.   However,  Seela has reported24 that 13 
cannot be converted to the amidine derivative (14).  Therefore the simplest course of action was 
to fully deprotect 2 using ammonia in methanol at 60 °C overnight to obtain 15.  The conversion 
of 2′-deoxyisoguanosine (15) to the fully protected DMT-nucleoside phosphoramidite (Scheme 
4) has been described.15,24  
 
  Conclusions 
    We describe simple and straightforward procedures for the glycosylation of protected 
derivatives of 2,6-diaminopurine and isoguanine.  Both procedures rely upon the use of the 
bidentate protecting group M4SI. The bidentate nature of the M4SI group eliminates any side 
reactions that result from proton abstraction at the exocyclic amines (or corresponding amides); 
it also provides enhanced solubility for purine heterocycles, particularly for isoguanine.  The 
M4SI protecting group exhibits exceptional directing ability such that high ratios of the N9 vs. 
N7 glycosylation products result.  These valuable  nucleosides can be further elaborated to 
generate nucleoside phosphoramidites for solid-phase DNA syntheses using standard protocols. 
 
3.6 Experimental Details and Supporting Information 
  Experimental Details 
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 General Procedures. All reactions were carried out in oven-dried glassware under an 
inert atmosphere with dry solvents and anhydrous conditions, unless otherwise noted. Dry 
tetrahydrofuran (THF), diethyl ether (Et2O), N,N-dimethylformamide (DMF), pyridine (pyr), 
acetonitrile (MeCN), and dichloromethane (DCM) were obtained by passing commercially 
available pre-dried, oxygen-free formulations through activated alumina columns. Dry methanol 
(MeOH) was obtained by distillation from Mg(OMe)2. Yields refer to chromatographically and 
spectroscopically (1H NMR) homogeneous materials, unless otherwise stated. Reagents were 
purchased at the highest commercial quality and used without further purification, unless 
otherwise stated. Reactions were monitored by thin-layer chromatography (TLC) carried out on 
0.25 mm Silicycle TLG-R10011B-323 60 Å plates using UV light as visualizing agent and ceric 
ammonium molybdate (CAM) stain and heat as developing agents. Dynamic Adsorbents silica 
gel (particle size 32-63 µm) was used for flash column chromatography. Difficult separations 
were carried out using “chromatospec silica gel” (E. Merck Chromatospec silica gel (60 Å pore 
size, particle size 15-40 µm). NMR spectra were recorded on Varian VNMRS 400, INOVA 500, 
VNMRS 500, or VNMRS 600 instruments and calibrated using residual undeuterated solvent 
(CDCl3: dH  = 7.26 ppm, dC  = 77.16 ppm, acetone-d6: dH = 2.05 ppm, dC = 29.84, DMSO-d6: dH 
= 2.50 ppm, dC = 39.52 ppm, methanol-d4: dH = 3.34 ppm, dC = 49.00 ppm) as an internal 
reference. The following abbreviations are used to designate the multiplicities: s = singlet, d = 
doublet, t = triplet, q = quartet, quin = quintet, m = multiplet, br = broad. High-resolution mass 
spectra (HRMS) were recorded on a Waters LCT Classic or JEOL AccuTOF mass spectrometer 
using ESI (electrospray ionization) or DART (direct analysis in real time). Infrared spectra were 
recorded on a Mattson Galaxy 5000 spectrometer. UV spectra were recorded on a Perkin-Elmer 
spectrophotometer.  
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N,N′-(9H-purine-2,6-diyl)bis(2,2,3,3-tetramethylsuccinimide) (4). To a flask containing 2,6-
diaminopurine 3 (257 mg, 1.71 mmol) and 2,2,3,3-tetramethylsuccinic anhydride (1.604 g, 10.27 
mmol) was added 13 mL of pyridine and 1.02 mL of DBU (6.84 mmol). The mixture was heated 
to reflux with stirring for 20 h. The starting material gradually dissolved as the reaction 
proceeded. TLC (9:1 DCM:MeOH containing 0.7 M NH3) indicated that some starting material 
remained. Another 267 mg (1.71 mmol) of anhydride was added and heating continued for 
another 10 h. TLC showed that no starting material remained. Volatiles were removed in vacuo 
and the residue co-evaporated with toluene (3 x 3 mL). The resulting brown oil was purified by 
flash chromatography eluting with 95:5 DCM:MeOH) to obtain 738 mg of white solid. This 
material contained the amides (~10% by 1H NMR) that co-eluted with the desired product. The 
solid was thoroughly dried in vacuo and treated with SOCl2 (3 mL) at reflux for 2 h with a 
drying tube attached, or dissolved in anhydrous pyridine (10 mL) and heated to reflux for 8 h. 
Volatiles were removed in vacuo and the residue co-evaporated with EtOAc or toluene, 
respectively (3 x 3 mL). The residue was purified by flash chromatography eluting with 95:5 
DCM:MeOH to obtain 546 mg (74%) of 4 as a white amorphous powder. 4: Rf = 0.7 (silica gel, 
9:1 DCM:MeOH); 1H NMR (DMSO-d6, 400 MHz) δ 14.25 (brs, 1H), 8.84 (brs, 1H), 1.29 (s, 
12H), 1.24 (s, 12H) ppm; 13C NMR (DMSO-d6, 101 MHz) δ 180.53, 180.07, 146.45, 47.72, 
47.25, 21.09, 20.94 ppm; HRMS (ESI-TOF) calcd for C21H26N6O4Na+ [M + Na]+ 449.1940, 
found: 449.1920. 
9-[2-deoxy-3,5-di-O-(p-toluoyl)-β-D-erythro-pentofuranosyl]-2,6-di-(3,3,4,4-tetramethyl-2,5-
dioxopyrrolidin-1-yl)purine (1). To a flask containing 4 (200 mg, 0.467 mmol) and NaH (45 
mg, 0.984 mmol, 50% dispersion in oil) was added 20 mL of MeCN. The mixture was allowed 
to stir for 1 h, then 2-deoxy-3,5-di-O-p-toluoyl-α-D-erythro-pentofuranosyl chloride 5 (382 mg, 
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0.984 mmol) was added. Stirring was continued overnight. The reaction mixture was filtered 
through Celite and the filter cake washed with acetone (25 mL). The filtrate was evaporated in 
vacuo and the resulting yellow foam was purified by flash column chromatography eluting with 
98.25:1.75 DCM:MeOH to obtain 338 mg (93%) of 1 as a white foam. 1: Rf = 0.55 (silica gel, 
97:3 DCM:MeOH); 1H NMR (acetone-d6, 400 MHz) δ 8.79 (s, 1H), 7.97 (d, J = 8.2 Hz, 2H), 
7.87 (d, J = 8.2 Hz, 2H), 7.34 (d, J = 8.2 Hz, 2H), 7.26 (d, J = 8.1 Hz, 2H), 6.80 (s, 1H), 5.99 (s, 
1H), 4.79 (dd, J = 10.5 Hz, J = 5.0 Hz, 1H), 4.74 – 4.59 (m, 2H), 3.55 – 3.42 (m, 1H), 3.01 (ddd, 
J = 14.5, 6.6, 3.4 Hz, 1H), 2.42 (s, 3H), 2.38 (s, 3H), 1.35 (s, 12H), 1.31 (s, 12H) ppm; 13C NMR 
(acetone-d6, 101 MHz) δ 180.90, 180.61, 166.50, 166.24, 155.19, 148.66, 148.33, 147.20, 
145.08, 144.70, 131.75, 130.51, 130.37, 130.07, 130.01, 128.08, 127.94, 86.64, 83.70, 76.03, 
65.03, 48.99, 48.42, 37.09, 21.60, 21.55, 21.52, 21.47, 21.42 ppm; HRMS (ESI-TOF) calcd for 
C42H46N6O9Na+ [M + Na]+  801.3224, found: 801.3207. 
6-amino-9-[2-deoxy-β-D-erythro-pentofuranosyl]-2-(3,3,4,4-tetramethyl-2,5-
dioxopyrrolidin-1-yl)purine (6). Note: anhydrous conditions not needed. To a flask containing 
1 (123 mg, 0.158 mmol) dissolved in 2:1 pyr:EtOH (1.4 mL) at 0 °C was added 1 M NaOH (0.7 
mL) dropwise. The mixture was allowed to stir at 0 °C for 2 h. The reaction was quenched by 
adding NH4Cl (45 mg, 0.19 mmol). Volatiles were removed in vacuo, and the residue was re-
dissolved in minimal MeOH. Silica gel (700 mg) was added, and volatiles removed in vacuo. 
The thoroughly-dried powder was loaded onto a flash column and purified by elution with 9:1 
DCM:MeOH then 6:1→5:1 DCM:EtOH to obtain 45 mg (72%) of 6 as a white foam. 6: Rf = 
0.13 (silica gel, 9:1 DCM:MeOH); 1H NMR (acetone-d6, 500 MHz) δ 8.27 (s, 1H), 7.01 (brs, 
2H), 6.41 (dd, J = 8.8, 5.7 Hz, 1H), 5.00 (brs, 1H), 4.59 (m, 1H), 4.42 (brs, 1H), 4.05 (dd, J = 
4.2, 2.6 Hz, 1H), 3.74 (dd, J = 12.3, 2.4 Hz, 1H), 3.68 – 3.56 (m, 1H), 2.83 (ddd, J = 13.2, 8.9, 
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5.4 Hz, 2H), 2.35 (s, 1H), 1.26 (s, 12H) ppm; 13C NMR (acetone-d6, 126 MHz) δ 181.08, 158.35, 
150.77, 148.63, 142.38, 90.24, 87.40, 73.21, 63.73, 48.06, 41.35, 21.60, 21.42 ppm; HRMS 
(ESI-TOF) calcd for C18H24N6O5Na+ [M + Na]+ 427.1706, found: 427.1709. 
9-[2-deoxy-β-D-erythro-pentofuranosyl]-6-{[1-(dimethylamino)ethylidene]amino}-2-(3,3,4,4-
tetramethyl-2,5-dioxopyrrolidin-1-yl)purine (7). To a flask containing 6 (36 mg, 0.089 mmol) 
was added MeOH (0.5 mL) followed by N,N-dimethylformamide dimethylacetal (18 µL, 0.133 
mmol). The mixture was allowed to stir at rt for 24 h, at which time TLC indicated that all 
starting material had been consumed. Volatiles were removed in vacuo and the residue purified 
by flash chromatography eluting with 9:1 DCM:MeOH to obtain 35 mg (85%) of 7 as a white 
foam. 7: Rf = 0.29 (silica gel, 9:1 DCM:MeOH); 1H NMR (acetone-d6, 500 MHz) δ 8.98 (s, 1H), 
8.39 (s, 1H), 6.46 (dd, J = 8.8, 5.7 Hz, 1H), 4.92 (brs, 1H), 4.65 – 4.56 (m, 1H), 4.46 (brs, 1H), 
4.07 (dd, J = 4.5, 2.7 Hz, 1H), 3.76 (dd, J = 12.3, 2.6 Hz, 1H), 3.65 (d, J = 11.9 Hz, 1H), 3.26 (s, 
3H), 3.21 (d, J = 0.6 Hz, 3H), 2.86 (ddd, J = 13.2, 8.8, 5.4 Hz, 1H), 2.37 (ddd, J = 13.1, 5.8, 1.9 
Hz, 1H), 1.28 (d, J = 1.1 Hz, 12H) ppm; 13C NMR (acetone-d6, 126 MHz) δ 181.25, 162.16, 
159.92, 152.78, 148.12, 143.58, 127.27, 90.14, 87.20, 73.20, 63.72, 48.10, 41.35, 41.27, 35.07, 
21.60, 21.45 ppm; HRMS (ESI-TOF) calcd for C21H29N7O5Na+ [M + Na]+ 482.2128, found: 
482.2122. 
Isoguanine (6-amino-1H-purin-2(9H)-one) (9). 2,6-diaminopurine (2.0 g, 13.3 mmol) was 
dissolved in 1.67 M NaOH (20 mL) and NaNO2 (1.19 g, 17.3 mmol) was added. The resulting 
solution was transferred to an addition funnel and added dropwise over 1 h, with stirring, to a 
flask containing 78% H2SO4 (8 mL) immersed in a water bath at 20 °C. The temperature was 
carefully regulated at 20 °C during this time. After the solution of 2,6-diaminopurine had been 
added the temperature was raised to 60 °C and allowed to stir for 1 h. The mixture was allowed 
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to cool to room temperature and filtered to remove the precipitate that had formed. The 
precipitate was washed with 10 mL H2O, air-dried, then re-dissolved in 0.9 M NaOH (40 mL). 
To this solution was added NaHSO3 (122 mg). The solution was heated to 90 °C with stirring 
and slowly neutralized to pH 7-8 by adding 50% H2SO4 dropwise. A precipitate formed, and 
after allowing the neutralized mixture to cool to room temperature it was filtered. The precipitate 
was washed with 50 mL H2O and dried overnight in a vacuum oven at 50 °C to yield 9 as an off-
white amorphous solid (1.837 g, 91%). The product was virtually insoluble in organic solvents 
and H2O but readily soluble in alkali. The physical data were in agreement with those reported.25 
9: m.p. >360 °C; UV λmax = 283 (0.1 M NaOH) (8.0); IR (KBr pellet): 3051, 2785, 1828, 1698, 
1666, 1524, 1450, 1398, 1236, 1179, 1119, 1028, 940, 852, 775 cm-1. 
6-amino-9-trityl-1H-purin-2(9H)-one (10). To an flask containing isoguanine 9 (530 mg, 3.50 
mmol) and (NH4)2SO4 (35 mg, 0.26 mmol) was added HMDS (53 mL). The mixture was heated 
to reflux with stirring for 18 h. The excess HMDS was removed in vacuo and the flask purged 
with nitrogen. Trityl chloride (988 mg, 3.54 mmol) and MeCN (53 mL) were added and the 
mixture allowed to stir for 8 h at rt under inert atmosphere. Volatiles were removed in vacuo and 
the residue purified by flash chromatography eluting with 9:1 DCM:MeOH to obtain 1.268 g 
(92%) of 10 as a white amorphous powder. 10: Rf = 0.38 (silica gel, 9:1 DCM:MeOH); 1H NMR 
(DMSO-d6, 400 MHz) δ 10.21 (brs, 1H), 7.39 – 7.23 (m, 12H), 7.18 – 7.11 (m, 6H) ppm; 13C 
NMR (DMSO-d6, 101 MHz) δ 141.43, 129.40, 127.84, 127.33, 74.16 ppm; HRMS (ESI-TOF) 
calcd for C24H19N5OH+ [M + H]+ 394.1668, found: 394.1662. 
N-(2-oxo-9-trityl-2,9-dihydro-1H-purin-6-yl)-2,2,3,3-tetramethylsuccinimide (11). To a flask 
containing 10 (593 mg, 1.51 mmol) and DBU (0.9 mL, 6.03 mmol) in 16 mL of anhydrous 
pyridine at 0 °C was added TMSCl (476 µL, 3.77 mmol) dropwise by syringe. The mixture was 
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allowed to stir for 30 min. The ice bath was removed and the mixture allowed to stir for another 
30 min. 2,2,3,3-tetramethylsuccinic anhydride (823 mg, 5.27 mmol) was added and the mixture 
heated to reflux for 12 h. Volatiles were removed in vacuo and the residue co-evaporated with 
toluene (3 x 5 mL). The residue was re-dissolved in DCM (15 mL) and washed with sat. 
NaHCO3 (2 x 5 mL) and brine (1 x 5 mL). The organic layer was dried with Na2SO4, filtered, 
and evaporated. The residue was purified by flash chromatography eluting with 98.25:1.75 
DCM:MeOH to obtain 700 mg of a white foam. The product contained 23% of the unreacted 
anhydride M4SA by weight as determined by 1H NMR; the yield of 11 was thus 539 mg (67%). 
Some of the anhydride could be removed by repeated chromatography, but 11 could be used in 
subsequent reactions without further purification. An analytical sample of 11 was obtained by 
recrystallization from acetone containing a small amount of MeOH. 11: Rf = 0.44 (silica gel, 97:3 
DCM:MeOH);  1H NMR (CDCl3, 400 MHz) δ 10.27 (brs, 1H), 7.93 (s, 1H), 7.36 – 7.25 (m, 9H), 
7.24 – 7.08 (m, 6H), 1.28 (s, 12H) ppm; 13C NMR (CDCl3, 101 MHz) δ 180.11, 159.93, 157.12, 
145.80, 145.26, 140.65, 129.94, 128.23, 128.11, 126.04, 76.39, 48.32, 21.41 ppm; HRMS (ESI-
TOF) calcd for C32H29N5O3Na+ [M + Na]+ 554.2168, found: 554.2147. 
6-(3,3,4,4-tetramethyl-2,5-dioxopyrrolidin-1-yl)-9H-purin-2-yl diphenylcarbamate (12). To 
a flask containing 11 (781 mg, 77% 11 by weight, 1.13 mmol) and diphenylcarbamoyl chloride 
(289 mg, 1.25 mmol) was added pyridine (8 mL) and DIPEA (0.4 mL, 2.26 mmol). The mixture 
was allowed to stir at room temperature.  Full conversion to a UV-active spot with Rf = 0.32 in 
99:1 DCM:MeOH was observed by TLC after 1.5 h. Water (5 mL) was added and stirring 
continued for 10 min. Volatiles were removed in vacuo and the residue co-evaporated with 
toluene (3 x 3 mL). CHCl3 (not anhydrous, 20 mL) and AcOH (4 mL) were added and the 
mixture heated to reflux with stirring until TLC indicated consumption of starting material (20 
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h). Volatiles were removed in vacuo. The residue was re-dissolved in DCM (25 mL) and washed 
with sat. NaHCO3 (3 x 8 mL) and brine (10 mL). The organic layer was dried with Na2SO4, 
filtered, and evaporated. The residue was purified by flash chromatography eluting with 
97:3/95:5 DCM:MeOH to obtain 508 mg (93%) of 12 as a white foam. 12: Rf = 0.42 (silica gel, 
95:5 DCM:MeOH); 1H NMR (CDCl3, 400 MHz) δ 12.13 (s, 1H), 7.97 (s, 1H), 7.34 (m, 8H), 
7.30 – 7.15 (m, 2H), 1.32 (s, 12H) ppm; 13C NMR (CDCl3, 101 MHz,) δ 180.11, 155.82, 155.44, 
151.98, 146.03, 145.81, 141.51 (br), 129.41, 128.03, 127.50 (br), 126.27 (br), 48.40, 21.43 ppm; 
HRMS (ESI-TOF) calcd for C26H24N6O4Na+ [M + Na]+ 507.1757, found: 507.1745. 
9-[2-deoxy-3,5-di-O-(p-toluoyl)-β-D-erythro-pentofuranosyl]-6-(3,3,4,4-tetramethyl-2,5-
dioxopyrrolidin-1-yl)-9H-purin-2-yl diphenylcarbamate (2). To a flask containing 12 (201 
mg, 0.414 mmol) and NaH (41 mg, 0.871 mmol, 50% dispersion in oil) was added 20 mL of 
DCM. The mixture was allowed to stir for 20 min, then 5 (338 mg, 0.871 mmol) was added. 
Stirring was continued for 5 h, after which the reaction mixture was filtered through Celite and 
the filter cake washed with acetone (25 mL). The filtrate was evaporated in vacuo and the 
resulting yellow foam was purified by flash chromatography (20 x 5 cm column, chromatospec 
silica gel) eluting with 98.25:1.75 DCM:MeOH to obtain 273 mg (79%) of 2 as a white foam. 
Also obtained were 17 mg (5%) of α-N9 product and 55 mg (16%) of α/β-N7 products. 2: Rf = 
0.38 (silica gel, 97:3 DCM:MeOH); 1H NMR (acetone-d6, 400 MHz) δ 8.66 (s, 1H), 8.00 (d, J = 
8.3 Hz, 2H), 7.87 (d, J = 8.3 Hz, 2H), 7.53 (d, J = 7.5 Hz, 4H), 7.43 – 7.32 (m, 6H), 7.32 – 7.19 
(m, 4H), 6.75 (t, J = 6.8 Hz, 1H), 6.06 (dt, J = 6.4, 3.2 Hz, 1H), 4.84 (dd, J = 10.5, 4.5 Hz, 1H), 
4.76 – 4.61 (m, 2H), 3.47 (dt, J = 14.0, 6.8 Hz, 1H), 3.01 (ddd, J = 14.4, 6.5, 3.4 Hz, 1H), 2.43 
(s, 3H), 2.37 (s, 3H), 1.34 (s, 12H) ppm; 13C NMR (acetone-d6, 101 MHz) δ 180.50, 166.58, 
166.37, 156.59, 155.65, 151.95, 147.56, 147.13, 145.11, 144.73, 143.15, 130.57, 130.40, 130.10, 
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130.04, 128.03, 127.97, 127.80 (br), 86.37, 83.61, 76.00, 64.96, 48.98, 37.14, 21.62, 21.58, 
21.48, 21.48; HRMS (ESI-TOF) calcd for C47H44N6O9Na+ [M + Na]+ 859.3067, found: 
859.3039. 
9-[2-deoxy-β-D-erythro-pentofuranosyl]-6-amino-9H-purin-2-yl diphenylcarbamate (13). 
Obtained in approx. 50% yield by deprotection of 2 in NH3/MeOH at rt for 15 h. Purification of 
the residue by flash chromatography eluting with 92.5:7.5 DCM:MeOH gave 13 as a white foam. 
Physical data were in agreement with those reported.23 
2′-deoxyisoguanosine (15).14,26 To a flask containing 2 (212 mg, 0.253 mmol) was added 7 M 
NH3/MeOH (8 mL). The mixture was allowed to stir at 60 °C for 15 h and volatiles removed in 
vacuo. The residue was washed with DCM (2 x 5 mL) and EtOAc (2 x 5 mL) and dried in vacuo 
to yield 58 mg of impure product. This off-white solid was recrystallized from MeOH to yield 49 
mg (73%) of 15 as an off-white powder. 
 
Acknowledgments: We thank Dr. Nick Greco for critical discussions.  This work was supported 
by an award from the NSF to LWM (MCB 0451488).  
 
Supporting Information Available: 1H-NMR spectra. This material is available free of charge 
via the Internet at http://pubs.acs.org.  
 
References  
 
(1) Strobel, S. A.; Cech, T. R.; Usman, N.; Beigelman, L. Biochemistry 1994, 33, 13824-
13835. 
143 
 
(2) Piccirilli, J. A.; Kauch, T.; Moroney, S. E.; Benner, S. A. Nature 1990, 343, 33-37. 
(3) Switzer, C. Y.; Moroney, S. E.; Benner, S. A. Biochemistry 1993, 32, 10489-96. 
(4) Tohru, U.; Kazunobu, M.; Tsuguo, K. Chem. Pharm. Bull. (Tokyo) 1978, 26, 2122-2127. 
(5) Gaffney, B. L.; Marky, L. A.; Jones, R. A. Tetrahedron 1984, 40, 3-13. 
(6) Gao, H.; Fathi, R.; Gaffney, B. L.; Goswami, B.; Kung, P. P.; Rhee, Y.; Jin, R.; Jones, R. 
A. J. Org. Chem. 1992, 57, 6954-6959. 
(7) Ross, B. S.; Springer, R. H.; Ravikumar, V. T. Nucleosides, Nucleotides & Nucleic Acids 
2008, 27, 67-69. 
(8) Wright, G. E.; Hildebrand, C.; Freese, S.; Dudycz, L. W.; Kazimierczuk, Z. J. Org. 
Chem. 1987, 52, 4617-4618. 
(9) Kazimierczuk, Z.; Cottam, H. B.; Revankar, G. R.; Robins, R. K. J. Am. Chem. Soc. 
1984, 106, 6379-6382. 
(10) Naval, M.; Thibaut, M.; Vasseur, J. J.; Debart, F. Biorg. & Med. Chem. Lett. 2002, 12, 
1435-1438. 
(11) Christensen, L. F.; Broom, A. D. J. Med. Chem. 1972, 15, 735-739. 
(12) Kazimirczuk, Z.; Mertens, R.; Seela, F. Helv. Chim. Acta 1991, 74, 1742-1752. 
(13) Roberts, C.; Bandaru, R.; Switzer, C. Tet. Lett. 1995, 36, 3601-3604. 
(14) Seela, F.; Gabler, B. Helv. Chim. Acta 1994, 77, 8322-8323. 
(15) Roberts, C.; Bandaru, R.; Switzer, C. J. Am. Chem. Soc. 1997, 119, 4640-4649. 
(16) Nair, V.; Young, D. J. Org. Chem. 1985, 50, 406-408. 
(17) Jurczyk, S. C.; Kodra, J. T.; Park, J. H.; Benner, S. A.; Battersby, T. R. Helv. Chim. Acta 
1999, 82, 1005-1014. 
(18) Davol, J. J. J. Am. Chem. Soc. 1951, 73, 3174-3179. 
144 
 
(19) Bookser, B. C.; Raffaele, N. B. J. Org. Chem. 2006, 72, 173-179. 
(20) Bendich, A.; Brown, G. B.; Philips, F. W.; Thiersch, J. B. J. Biol. Chem. 1950, 267-277. 
(21) Arico, J. W.; Calhoun, A. K.; Salandria, K. J.; McLaughlin, L. W. Org. Lett. 2010, 12 (1), 
120–122. 
(22) Seela, F.; Wei, C.; Kazimierczuk, Z. Helv. Chim. Acta 1995, 78, 1843-1854. 
(23) Kotick, M. P.; Szantay, C.; Bardos, T. J. J. Org. Chem. 1969, 34, 3806-3811. 
(24) Seela, F.; Wei, C. Helv. Chim. Acta 1997, 80, 73-85. 
(25) Chern, J. W.; Lee, H. Y.; M., H.; Shish, F. J. Tetrahedron Lett. 1987, 28, 2151-2154. 
(26) Kazimierczuk, Z.; Mertens, R.; Kawczhnski, W.; Seela, F. Helv. Chim. Acta 1991, 74, 
1742-1752. 
 
 
 
 
 
   
145 
 
Electronic Supporting Information 
Preparation of the 2′-Deoxynucleosides of 2,6-Diaminopurine and 
Isoguanine by Direct Glycosylation 
 
Joseph W. Arico, Amy K. Calhoun, and Larry W. McLaughlin* 
Department of Chemistry, Merkert Chemistry Center, Boston College, Chestnut Hill, 
Massachusetts 02467 
*E-mail: mclaughl@bc.edu 
Table of Contents 
1H and 13C NMR Spectra of 4         S2 
1H and 13C NMR Spectra of 1         S3 
1H and 13C NMR Spectra of 6         S4 
1H and 13C NMR Spectra of 7         S5 
1H and 13C NMR Spectra of 10         S6 
1H and 13C NMR Spectra of 11         S7 
1H and 13C NMR Spectra of 12         S8 
1H and 13C NMR Spectra of 2         S9 
146 
 
 
 
 
1H NMR (DMSO-d6, 400 MHz) 
13C NMR (DMSO-d6, 101 MHz) 
147 
 
 
 
 
 
1H NMR (acetone-d6, 400 MHz) 
13C NMR (acetone-d6, 101 MHz) 
148 
 
 
 
 
 
1H NMR (acetone-d6, 500 MHz) 
13C NMR (acetone-d6, 126 MHz) 
149 
 
 
 
 
 
1H NMR (acetone-d6, 500 MHz) 
13C NMR (acetone-d6, 126 MHz) 
150 
 
 
 
 
 
1H NMR (DMSO-d6, 400 MHz) 
13C NMR (DMSO-d6, 101 MHz) 
151 
 
 
 
 
 
1H NMR (CDCl3, 400 MHz) 
13C NMR (CDCl3, 101 MHz) 
152 
 
 
 
 
 
1H NMR (CDCl3, 500 MHz) 
13C NMR (CDCl3, 126 MHz) 
153 
 
 
 
 
 
1H NMR (acetone-d6, 400 MHz) 
13C NMR (CDCl3, 101 MHz) 
154 
 
Chapter 4: Synthesis of Novel Nucleoside Analog dhm3c3A and Studies of 
DNA Hydration in the Minor Groove 
4.1 Introduction 
 The minor groove of B-form DNA presents a wide array of interesting structural features. 
In particular A-tracts—sections of DNA containing multiple A-T base pairs in a row—are rich 
with structural peculiarities such as narrowing of the minor groove,1 axial bends,2 high propeller 
twists,3 localized cations,4 and highly ordered hydration motifs.5 While there is little specific 
ordering of water molecules around the internucleotide phosphates on the edge of the minor 
groove, a string of water molecules can localize in the narrow floor of the minor groove in A-T 
rich sequences. This so-called spine of hydration has been observed in numerous X-ray 
structures1a,5 such as the Dickerson dodecamer,1a the self-complementary sequence 
d(CGCGAATTCGCG)2, which shows the primary shell of hydration engaging in hydrogen 
bonding in the A2T2 tract between the N3 nitrogen of dA and the O2 carbonyl of the dT in the 
adjacent base pair over a distance of approximately 3.7 Å6 (Figure 1). The width of the minor 
groove in such sequences narrows from ~4 Å in G-C rich areas to as little as 2.8 Å in the A-tract, 
as measured by a recent high-resolution crystal structure containing an A3T3 tract.7  The 
residence time of these strand-bridging water molecules in solution can be quite long.8 This 
hydration pattern is not possible in a random or G-C rich sequence because the N2 amino group 
of dG prevents a water molecule from hydrogen bonding with its N3.  
 The stabilities of A-form and B-form DNA are both explained in terms of hydration 
effects.6 The A-form structure is generally less hydrated than the B-form; indeed, dehydrating 
conditions such as addition of salt9 or organic solvents10 can induce B-form duplexes to undergo 
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a cooperative transition to A-form. The minor groove spine of hydration is not present in A-form 
DNA. Instead, the phosphate groups show well-ordered hydration, being bridged by one to three 
 
 
Figure 1. Top: Crystal structure of the Dickerson dodecamer showing the spine of hydration in 
the AATT tract of the minor groove. Bottom: Cartoon depiction of the spine of hydration looking at 
each base pair edge-on from the minor groove. 
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water molecules. Also, the major groove is more narrow, and its stability might be enhanced by 
water molecules bridging between the phosphates across the major groove.6 The spine of 
hydration may account for the fact that the B-form → A-form transition is difficult to induce in 
A-T rich sequences, and has never been reported for poly(dA)•poly(dT) sequences. 
 As mentioned in Section 1.2, hydration in the major groove is more dynamic and less 
ordered, and its contribution to the stability of B-form DNA cannot be described in the sequence-
specific manner attributed to A-tracts in the minor groove. Nevertheless, there are conserved  
 
 
 
sites of water and cation binding. Shakked and co-workers found 10 conserved hydration sites in 
the major groove of the trp operator that were crucial for recognition and binding of the trp 
Figure 2. Top: Gumport's 2′-deoxy-7-deaza-7-hydroxymethyladenosine water-modeling nucleoside. 
Bottom: Three dG analogs used by Ganguly and co-workers to model hydration and cation binding in the 
major groove. 
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repressor.11 Crystal structures have shown high-occupancy sites for cation binding in the major 
groove, including the N7 and/or O6 of dG nucleotides.4d,12 Gumport and co-workers used 2′-
deoxy-7-deaza-7-hydroxymethyladenosine 1 to model a bound water molecule into the crystal 
structure of a crystal structure of the tryptophan (trp) repressor/operator complex, showing that 
the analog places the oxygen of the hydroxymethyl group in nearly the same position as the 
oxygen contributed by the water in the protein/DNA complex. (Figure 2).13 Ganguly and co-
workers used dc7G (2′-deoxy-7-deazaguanosine, 2), 2′-deoxy-7-deaza-7-
hydroxymethylguanosine 3, and 2′-deoxy- 7-deaza-7-aminomethylguanosine14 4 to model the 
removal of hydrogen-bonding contacts, an N7-water contact, and an N7-cation contact in the 
major groove, respectively (Figure 2).15 They showed that removal of the cation-binding N7 by 
substitution with 2 or 3 was destabilizing to the duplex, while the 7-aminomethyl cation model 4 
stabilized the duplex relative to a control sequence, quantifying the importance of cation binding 
at the N7 and O6 of G nucleotides in the major groove. 
 
 
 The next step in understanding the importance of the spine of hydration was to observe 
its dynamics directly and measure its contribution to overall duplex stability. There has been 
progress toward the former goal employing NMR studies8 and theoretical analyses.16  The major 
Figure 3. Guanine N7/O6 binds cations, basic protein side chains, and water in the major groove. 
Figure from reference 15. 
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approach to the latter goal by this laboratory17 and others18 has been the use of nucleoside 
analogs that eliminate or alter interactions in the minor groove involved in the spine of hydration. 
Crosstick and co-workers examined the introduction of dc3A in place of dA (Figure 4) in several 
8-mer duplexes.18 They found that the TM values of the duplexes were highly dependent on pH 
due to the high basicity of dc3A (6.80 relative to 3.62 for dA). Protonation of the N1 of dc3A at 
low pH would disrupt Watson-Crick base pairing and destabilize duplexes incorporating the 
analog. The dc3A analog decreased the stability of the duplex with each incorporation, but the 
short sequences used and limited number of duplexes examined did not allow the authors to 
distinguish between destabilization due to protonation of the basic heterocycle, differences in 
base stacking, or the disruption of interactions with water molecules composing the spine of 
hydration as proposed. At physiological pH, almost one pH unit above the pKa of its protonated  
 
 
form, dc3A should behave as a normal dA residue in terms of base pairing. In support of this 
view, computational studies undertaken in this laboratory have found no significant differences 
Figure 4. Top: Illustration of a normal A-T base pair. Bottom: The dc3A-dm32P base pair, an analog base 
pair that removes minor groove functional groups. 
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between dc3A and dA in terms of interstrand hydrogen bonding and changes in dipole 
moment.17b Thus dc3A is a good mimic of dA except for lacking the N3 hydrogen-bond acceptor.  
 Work in this laboratory undertaken by Tao Lan employed dc3A as well as the dT analog 
3-methyl-2-pyridone 2′-deoxyriboside (dm32P)19 to probe the importance of the spine of 
hydration to B-form structure and duplex stability.17 A series of duplexes were prepared 
incorporating increasing numbers of A-dm32P, dc3A-T, or dc3A-dm32P base pairs. Initial work 
examined modifications to the self-complementary Dickerson Dodecamer. Surprising results  
 
 
were obtained when four or more analog nucleotides were positioned in the four core base pairs 
of the dodecamer. TM studies revealed two thermally induced transitions (Figure 6) in the UV 
absorbance vs. temperature curve of the dodecamer containing a fully-modified core (Table 1, 
entry 4), one near 20 °C and another near 70 °C. This is not unlike behavior for duplexes 
containing a central core of non Watson-Crick base pairs,20 and part b of Figure 6 shows that the 
melting curve of a self-complementary dodecamer containing four T-T mismatches in its core is 
essentially identical to that observed for the sequence with four modified base pairs. For the self-
complementary sequences that did form a duplex as their most stable form, two 5 analogs in the 
Figure 5. Structures of nucleoside analogs used in probing interactions in the minor groove of DNA. 
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Figure 6. Self-complementary sequences examined by Tao Lan in ref. 17. Surprisingly, sequences 
containing four or more analogs in the four core base pairs preferred the monomolecular hairpin to 
the duplex.  
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the retention of duplex stability when a single isolated substitution is made amongst a G-C rich 
sequence shows that the analogs do not affect the fundamental duplex properties of base pairing 
and base stacking. Disruption of these fundamental properties would destabilize G-C rich 
sequences just as A-T rich sequences. Instead, A-T tracts are destabilized by the disruption of 
hydration and/or metal ion binding in the minor groove. As further proof of this, monitoring of  
 
 
 
the UV melting curve at 297 nm, the λmax of 5, showed that the thermal transition—representing 
the unstacking of 5—occurred at significantly lower temperatures than the melting of the rest of 
Figure 7. Cartoons of interactions in the minor groove with multiple dm3c3A residues (Top) and 
dhm3c3A residues (Bottom). 
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the duplex. This shows that the analog base pairs that are not stabilized by hydration are the first 
to unstack and become unpaired. 
 The next question was whether an analog such as dm3c3A 7 placing a more bulky and 
non-polar functionality into the minor groove would be tolerated, further destabilize the duplex, 
or render duplex formation impossible. It is possible that the 5-6 base pair may support a degree 
of hydration engaged in non-ordered contacts, such as hydrogen bonding with the sugar oxygens 
or phosphates, and that 7 might crowd out water molecules from the minor groove entirely 
(Figure 7, top), leading to bulge formation where the 7-dT base pairs would dissociate entirely, 
perhaps even at room temperature.  
 Having asked this question, and bearing Gumport’s13 and Ganguly’s15 work in mind, we 
wished to investigate if a 3-deaza-3-hydroxymethylpurine analog would be able to model or 
mimic a water molecule engaged in hydrogen bonding to the N3 such that a measure of duplex 
stability would be restored. If correctly placed, the hydroxymethyl group would be able to orient 
itself such that the hydroxyl would bridge to the adjacent dT residue on the opposite strand and 
hydrogen bond with the O2 carbonyl (Figure 7, bottom). Analog 8 (Figure 1) places its hydroxyl 
group in nearly the same place, at least in terms of bond distances, as a water molecule engaging 
the N3 nitrogen of dA in a hydrogen bond. We undertook its synthesis and incorporation into 
DNA oligos to test whether it would restore some or all of the native stability of A-T tracts. 
    
  4.2 Improved Synthesis of dm3c3A and Its Phosphoramidite Employing the M4SI 
Protecting Group 
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 We were interested in using the adenosine analog 2′-deoxy-3-deaza-3-methyladenosine 
(dm3c3A or 3mddA) as a probe for important biological interactions. As an extension of Lan’s 
work described in Section 4.1, placing dm3c3A in an A-T rich sequence would be significantly 
more disrupting to the spine of hydration than dc3A. In addition to removing a hydrogen bonding 
contact, dm3c3A would place a bulky and hydrophobic methyl group in the constrained and 
hydrophilic minor groove. The extent to which this modification could be tolerated would give 
us further information about the importance of the spine of hydration in stabilizing A-T tracts, 
and about the ability of the minor groove to accommodate non-natural functional groups. 
 The analog dm3c3A21 (7) maintains normal Watson-Crick base pairing though like 6 it is 
more electron-rich and basic than dA. Its pKa has not been measured but is likely to be close to 7, 
much like analog 6 (6.80).18 Originally synthesized as an anti-fixed dA analog—the methyl 
group prevents rotation about the glycosylic bond, as measured by NOE experiments21—the 
published synthesis begins with commercially available 3-methyl picoline N-oxide 9. The 
original synthesis as described had a number of deficiencies, and during the course of this work 
conditions for several steps were optimized. The optimized conditions and yields are described 
here. In addition to these improvements, the latter part of the synthesis was changed to employ 
the M4SI directing/protecting group,22 leading to a more efficient and high-yielding synthesis of 
the important dm3c3A phosphoramidite (vide infra). 
 Nitration with concentrated H2SO4 and fuming HNO3 gave 10 in 70% yield after 
neutralization and precipitation of product. Reduction of the nitro group and concomitant 
removal of the N-oxide with Raney Ni/H2 in a Parr shaker at 65 psi gave aminopyridine 11. 
Since strong nitrating conditions led only to decomposition,21 the amino group was nitrated with 
cooling to give nitroamine 12 after neutralization and precipitation with conc. ammonia. 
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Dissolving 12 carefully in H2SO4 and stirring for 12–48 h at room temperature resulted in a 
rearrangement to give 13 in moderate yield. Violent decomposition of 12 took place if care was 
not taken during its dissolution, and the neutralization-precipitation to isolate 13 was extremely 
pH-sensitive. Drastic decreases in yield resulted if the final pH was not 6.5–7. The reaction was 
poorly reproducible, sometimes complete in 8 h and sometimes requiring 48 h or more. Starting  
 
 
material could not generally be recovered. 1H NMR analysis of neutralized aliquots was 
sufficient to monitor reaction progress. The next step was also problematic. The reported yield of 
the reduction-chlorination of 13 to 14 was 29% with numerous side products.21 Furthermore, 100 
mL/g of conc. HCl was used, an untenable amount for large scale preparations such as we 
required. The optimized conditions used more SnCl2 (4.9 vs. 1.6 equiv), 5 mL/g of HCl, and 
reproducibly gave 70% isolated yield without the need for chromatography. The reported 
cyclization to 15 using only triethylorthoformate, CH(OEt)3, gave a 67% yield with several side 
products, but use of a 1:1 mixture of orthoformate and Ac2O afforded 15 in 96% yield with 
purification possible by passing the crude product through a silica plug. Nucleobase 15 proved to 
Scheme 1. Synthesis of key nucleobase 15. Optimized conditions are shown. 
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be a key compound not only for the synthesis of the phosphoramidite of 7, but also in the 
successful synthesis of novel analog dhm3c3A (8). 
 As discussed in Section 3.2, coupling of 15 gives an excellent overall yield of 90–100% 
with no α-anomers detected but with a 1:2.2 ratio of N9:N7 products (Scheme 2), translating to 
25–30% isolated yield of the desired N9 product. We found that the undesired 17b could be 
recycled back to 15 by cleavage of the sugar with AcOH/AcCl followed by a simple 
precipitation.23 While this approach was sufficient to allow the synthesis of the dm3c3A  
 
 
phosphoramidite, it represented a sticking point in our approach to 8 (vide infra). Use of the 
M4SI protecting group22 (Scheme 2, see also Section 3.3) resulted in an improvement of the 
coupling ratio from 1:2.2 β-N9:β-N7 to 6.4:1 while maintaining a similar overall yield. The 
Scheme 2. Coupling and recycling of 15; Synthesis of M4SI-protected nucleobase 21. 
168 
 
disadvantage to this procedure is that 18–20% yield of the two α-nucleoside products was 
obtained, making purification more challenging.  
 Amination of 15 proceeded somewhat sluggishly, requiring at least 24 h in refluxing 
anhydrous hydrazine. Evaporation of the hydrazine and reduction with Raney nickel gave a 
mixture of 18 and 19, with small amounts of starting material usually recovered as well. A test 
reaction with 15 exposed to Raney Ni showed that it dehalogenated to form 18, but since the 
hydrazine step cannot be monitored, it was not possible to ascertain when 15 had fully reacted to 
form the intermediate hydrazide. Extending the reaction time beyond 30 h did not significantly 
improve the yield. Despite the variable yield, the reaction was reliable enough to obtain plentiful 
19 to continue the synthesis. Treatment of 19 with M4SA gave a mixture of 20/21 (Section 3.2) 
which was treated with SOCl2 to afford 21 in 81% isolated yield as the partial HCl salt. 
 Coupling of 21 proceeded smoothly as described22 and the remaining steps to the 
phosphoramidite are described with experimental details in Section 3.3. This phosphoramidite 
recently became commercially available, but considering its price (Berry & Associates 2009 
Product Catalog, $1495/250 mg), the 13-step improved synthesis described here should be 
considered. 
 
4.3 Successful Approach to dhm3c3A and Its Phosphoramidite  
 Over the course of this work several approaches to 8 were attempted. Initial work focused 
on transformation of a protected 3-deaza-3-halopurine24 intermediate by a Negishi coupling with 
an alkoxyzinc iodide25 or Bouveault aldehyde synthesis26 as the key step to install the 
hydroxymethyl functionality. These efforts ultimately were unsuccessful as described in Chapter 
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2. Since 7 only differs from 8 in a formal oxidation of the 3-methyl group, we investigated 
whether a benzylic oxidation of 7 or a precursor was possible. While efforts to directly install an 
oxygen failed, 3-deaza-3-methyl nucleobase 15 proved to be an excellent substrate for a benzylic 
bromination (Scheme 3). The polar, crystalline 15 was first Boc-protected to increase its 
solubility in organic solvents. Bromination with NBS in CCl4 using benzoyl peroxide as a radical  
 
 
initiator gave 22 in 63% yield with a small amount of the dibrominated product. Heating with 
NaOAc in DMF displaced the bromide to form the acetate; surprisingly, the Boc group was also 
lost to give 23 in 68% yield. Glycosylation using the sodium salt method27 gave a mixture of 
Scheme 3. Benzylic bromination of 22 as an approach to dhm3c3A (8). 
170 
 
regioisomers with excellent β-selectivity and 85% overall yield, but the desired 24 was 
disfavored 2.3:1. Furthermore, the separation of the two regioisomers was extremely difficult; 
only partial separation was possible on silica gel, requiring multiple flash columns to obtain pure 
material. A selective deprotection of 24 was not possible as the acetate proved nearly as resistant 
to hydrolysis as the toluoyl esters, but we planned to use a bridging silyl protection to selectively 
protect the sugar28 (27). Full deprotection with NaOMe/MeOH gave 25, which was treated with 
hydrazine at reflux followed by Raney nickel reduction to install the amine. This displacement 
was sluggish, and extended reaction times resulted in decomposition of 25. Allowing 15 h for the 
hydrazine step resulted in a 30% yield of dhm3c3A 8, but most of the remaining starting material 
was dehalogenated by the Raney nickel to give 26. While 8 had been successfully obtained, the 
efficiency of the synthesis was not practical for obtaining sufficient quantities of the 
phosphoramidite. 
 The problems associated with the glycosylation and the amination led us to pursue the 
route shown in Scheme 4.  We began with phthaloyl protection of 19 using phthalic anhydride in 
refluxing pyridine followed by SOCl2 to close the partially reacted amide,22 then Boc protection 
and bromination in similar yields to those in Scheme 1 to obtain 28. The bromide was displaced 
with several different sodium salts in search of an optimal protecting group for the 
hydroxymethyl functionality that could be removed without affecting the toluoyl esters of the 
sugar. The phthaloyl group of 28 was surprisingly labile, and 29a–c were obtained in poor and 
variable yields. Several impurities stemming from opening of the phthaloyl imide were often 
observed. As before, the Boc group was lost. The reaction was sluggish at temperatures lower 
than 50–55 °C. While 29a and c could be purified, 29b decomposed on silica due to loss of the 
chloroacetyl group. Fortunately it could be coupled to the sugar in crude form.  
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 Coupling of 29a–c gave 60–80% yields of crude coupling products in similar ratios of 
~1.2:1 N9:N7, but varying amounts of α-nucleoside products were present and the mixture could 
not be fully purified on silica. Like 29b, 30b decomposed on silica and had to be used in crude 
form. Fortunately, 30a–c rapidly deprotected in 3 M NH3/MeOH to 31 in 10 min at room 
temperature, with 30c giving the cleanest reaction and best yield. Since the formyl ester of 30c is 
intermediate in stability between the acetate and chloroacetate esters, it had ideal characteristics 
in balancing stability and selectivity of removal. 31 could be separated from the N7 isomers, but 
there were always varying quantities of α-N9 nucleoside isolated with 31. This impurity could 
not be removed at this stage, nor over subsequent steps of silyation, benzoylation, and 
deprotection to 32. With 10–15% of the corresponding α-N9 nucleoside present in the 
phosphoramidite, incorporation into DNA and purification of the oligos would be greatly 
complicated, as would the interpretation of any subsequent studies.  
Scheme 4. Phthaloyl directing/protecting group approach to dhm3c3A (8). 
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 At this juncture we recently had begun investigating the M4SI directing/protecting group 
for regioselective purine glycosylations,22 and we sought to employ it in our synthesis of 8. 
M4SI-protected 3-deaza-3-methyl nucleobase 33 could be Boc protected as an inconsequential 
4:1 mixture of regioisomers in excellent yield. and underwent benzylic bromination in 71% yield 
with only a trace of dibrominated product. The M4SI group of 34 was not thermally labile like  
 
 
the phthaloyl group of 28 and reacted cleanly with NaOAc to give a single product followed by 
smooth hydrolysis with 7 M NH3/MeOH at room temperature to give 35 in 88% yield. TBS 
protection gave 36 in 90% yield. There was some concern that the relatively bulky TBS group 
would decrease the yield of N9 product or lead to a sluggish glycosylation, but treatment of 36 
with NaH in MeCN followed by addition of 16 and stirring for 5 h led to a quantitative yield of 
coupling products. The desired β-N9 coupling product 37 was obtained in 76% yield, a 7.6:1 
Scheme 5. Successful approach to dhm3c3A phosphoramidite 39. 
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ratio of N9:N7. Considering that ~12% α-N9 is also obtained, the coupling occurs with excellent 
regioselectivity (>8.3:1) for glycosylation at N9. In this case, the separation of the four coupling 
products also was straightforward (flash chromatography, 4:1 Hex:EtOAc). The M4SI group of 
37 proved to be quite robust, as the sugar esters were selectively removed with 7 M NH3/MeOH 
at room temperature in 86% yield to afford 38. Protection of the 5′-OH with the acid-labile DMT 
group followed by phosphitylation as described (Section 3.3) in 84% and 73% yield, 
respectively, led to the target phosphoramidite of dhm3c3A, 39.  
 
4.4 Investigation of the Effect of 3-Deaza-3-modified Purines on Hydration in the Minor 
Groove of DNA 
 With the phosphoramidite 39 in hand, we undertook the synthesis of several DNA oligos 
incorporating one, two, or four hm3c3A analogs replaced dA (Figure 7). These modified 
sequences were then annealed with a complementary sequence and their stability was measured 
by thermal denaturation (TM) studies.  
 39 is fully compatible with standard DNA solid-phase synthesis protocols, but there were 
some potential pitfalls that were considered. The M4SI group had not been used in DNA 
synthesis before, so it was important to verify the conditions required to deprotect it and whether 
these conditions were compatible with DNA oligos. M4SI is base-labile, and standard 
deprotections of synthetic DNA oligos to remove protecting groups and cleave the sequence 
from the CPG beads use concentrated ammonia at 55 °C for 12–16 h. Deprotection of a small 
amount of 38 showed that its M4SI was stable in 7 M NH3/MeOH at room temperature for at 
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least 24 h, but that it was completely deprotected in conc. NH3 in 8 h at 55 °C. The TBS group 
was stable to these conditions. Deprotection of the TBS group was examined next. Only one 
 
 
 
report of a DNA synthesis using a TBS-protected 5-hydroxymethyluracil 2′-deoxyriboside has 
appeared in the literature,29 and the authors were able to deprotect the TBS group by extending 
the standard detritylation conditions for DMT-on oligos, i.e. oligos in which the last DMT group 
is left intact on the 5′ terminus as a hydrophobic handle to aid in HPLC purification, (80% 
AcOH, 0 °C, 30 min) to 1 h at room temperature. Enzymatic digest confirmed that the TBS 
group was fully cleaved. These conditions were not likely to succeed in our case, as treatment of 
38 with 80% AcOH at room temperature achieved ~30% deprotection after 1 h. A longer acid 
treatment was likely to degrade the precious DNA oligo by depurination, so another method was 
sought. 
Figure 7. Sequences of oligos synthesized. The sequences of 2–8 were identical 
except for the four core bases. 
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 Synthesis of RNA frequently employs TBS-protection for the 2′-OH of the 
phosphoramidite building blocks,30 although recently the TOM ([(Triisopropylsilyl)oxy]methyl) 
protecting group has become more widely used, as it does not undergo migration during RNA 
synthesis.31  Solid-phase synthesis of RNA is followed by deprotection in ammonia32 or 
methylamine31 and desilylation in separate steps off the synthesizer. The DMT can be left on33 or 
cleaved during the desilyation as needed. Precipitation from butanol or Et2O is sufficient to 
desalt the oligo, and HPLC or gel purification of the crude RNA follows.34 
 Desilylation of RNA oligos is commonly performed using TBAF in THF35 but problems 
associated with the interference of residual moisture have led to a general preference for newer 
methods using triethylamine trihydrofluoride, 3HF•TEA.36 This method gives highly 
reproducible results and is insensitive to the water content of the reaction mixture.36a It is 
typically performed by dissolving the lyophilized oligo in anhydrous DMSO, adding 3HF•TEA, 
and heating at 65 °C for 2.5 h, then cooling and precipitating by addition of butanol or Et2O (see 
experimental details, Section 4.6).  
 The above methods use a large excess of fluoride to ensure complete deprotection of the 
RNA, given that the presence of a single protecting group can alter the biological properties of 
the oligo and give inaccurate results. DNA is generally much more robust than RNA37 and thus 
the RNA deprotection conditions were likely to work well for the oligos modified with 8. There 
were some problems encountered along the way, however.  
 The DNA solid-phase synthesis was straightforward for Sequences 3 and 4 containing the 
phosphoramidites of 6 and 7, respectively. Both phosphoramidites coupled in essentially the 
same yield as the commercially available phosphoramdities of the natural nucleosides. The 
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synthesis of these sequences and control sequences 1 and 2 was carried out as described in 
Section 4.6.  
 The hydroxymethyl phosphoramidite 39 did not couple well using the standard wait time 
of 2 minutes for the coupling step of solid-phase synthesis. If the wait time was increased to 15 
minutes the coupling proceeded in 70–80% yield. Increasing the wait time to 60 minutes resulted 
in coupling efficiencies between 85–90% as monitored by the DNA synthesizer, which 
quantifies the DMT cation released after each coupling to calculate the efficiency per coupling. 
These yields are not ideal, but sufficient for the synthesis of short DNA oligos containing a few 
dhm3c3A analogs at most. Generally phosphoramidites must couple in >98% per base to afford 
reasonable quantities of full-length oligo at the end of the run. The low coupling yields for 39 are 
likely due to the TBS-protected hydroxymethyl group’s bulk near the 3′-phosphoramidite. The 
presence of bulky groups on the N2 amino group of dG, for example, interferes with the reaction 
of the phosphoramidite moiety, lowering the coupling efficiencies, even after extended wait 
times.38 Given that the 3-position is even more proximal to the phosphoramidite moiety, and that 
the purity of 39 had been carefully ascertained by 1H and 31P NMR as well as HRMS (see 
Section 4.6), we considered steric hindrance the most likely explanation. Improvement of these 
coupling efficiencies would necessitate a smaller protecting group for the hydroxymethyl 
functionality. 
 Oligos 5–8 were obtained in reasonable average coupling efficiencies and were 
deprotected and cleaved from the resin according to the method in Section 4.6. HPLC traces of 
the crude oligos are shown in Figure 8. The full-length oligo is generally the largest peak with 
the longest retention time, due to the presence of the 5′ terminal DMT group. In Figure 8A the  
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Figure 8. A) HPLC trace of oligo unmodified 12-mer. B) Sequence 5 containing one 
dhm3c3A residue. C) Sequence 6 with two modifications. D) Sequence 8 with four 
modifications. 
A 
DC 
B
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trace of an unmodified oligo with 99% average yield is shown; 8B shows Sequence 5 (1 
modification), which is clearly obtained in high yield. With two or four modifications (8C and 
D), however, the   presence of failure sequences is increasingly evident, and the retention time 
increases from 15 min to 19 min (8C) to 24 min (8D). Each sequence except for Sequence 8 
(Figure 8D) was cleanly isolated from several HPLC runs, desilylated, and precipitated. These 
oligos then used without further purification in the TM experiments described below. Sequence 8 
was collected as cleanly as possible and desilylated as DMT-on by a procedure which uses 
additional TEA to alter the pH of the deprotection.33 It was then precipitated and re-purified by 
reverse-phase HPLC (Figure 9) which gave a major peak with retention time 7.3 min. This  
 
 
retention time is rather short for a DMT-on oligo, and we suspected that detritylation might have 
occurred inadvertently. The major peak was nonetheless subjected to detritylation in 80% AcOH 
Figure 9. HPLC trace of fully-deprotected oligo containing four dhm3c3A residues (Sequence 8). 
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at 0 °C for 30 min, as with normal DNA oligo synthesis, then desalted by Sephadex G-10 
column. 
 As Sequences 3–8 represent modified oligos, their purity and the presence of the fully 
deprotected analogs must be verified. MALDI is a well-established method of verifying that an 
oligo is full-length, and together with enzymatic digest are sufficient to prove the correct 
sequence of the synthetic oligo.39 These efforts are currently underway (Professor Nicholas J. 
Greco, Western Connecticut State University) and will be reported as soon as possible. 
 Table 3 compares the TM values obtained for the control sequence compared with the 
various modified oligos. In comparison to Tao Lan’s sequences, they are not self-complementary 
and contain a core region of four dA (or analog) nucleotides instead of an AATT core region. 
The sequences used here are reasonably similar to the Dickerson dodecamer and have the A-T 
rich center region flanked by exclusively G-C pairs, which provide very stable regions on either 
side of the region of interest. The G-C regions also have no involvement in the spine of 
hydration, helping to simplify the interpretation of results. The TM values compared are at a total 
strand concentration of 3 µM with a pH was 7.5, chosen to ensure that the three dA analogs 6, 7, 
and 8 would all engage in normal Watson-Crick base pairing with virtually no protonation of the 
heterocycle. 
 Tao Lan’s control sequence17 (Table 3, entry 1) is nearly identical to ours (entry 5) with 
nearly identical conditions used. The melting temperatures of entry 1 and entry 5 are 63.4 and 
62.2 °C, respectively. The substitution of two 5-6 analog base pairs reduces the TM by 10.7 °C, a 
moderate reduction, but replacement of all four base pairs in the core sequence (entry 3) 
drastically reduces the duplex stability (TM of 37.0 °C, or a reduction of -26.4 °C). Spreading 
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four analogs over the core sequence (entry 4) has a similar effect as entry 2, reducing the TM by 
11.7 °C. As expected, substitution of all four dA nucleotides for dc3A 6 decreases the TM by 11.3 
°C, very similar to entries 2 and 4. 
 
 
 
Table 3. TM results comparing Lan’s work17 (entries 1–4) with oligos incorporating either 6, 
7, or 8. 
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 The 3-deaza-3-methyl derivative 7 had a highly destabilizing effect on the duplex. With 
four 7 analogs placed in the core sequence the TM fell by 20.8 °C to 41.4 °C. This is nearly as 
large an effect as removal of all minor groove functional groups in the core sequence (entry 4), 
which showed a ΔTM = -26.4 °C. The UV melting curves of duplexes containing four 7 analogs 
were notably more broad and less clear than for the other duplexes examined. The transition was 
poorly defined, being broad and gradual as opposed to the sharp transitions normally seen for 
stable duplexes under high salt conditions such as we employed. 
 Finally, the introduction of dhm3c3A (8) nucleotides (entries 8–10) tested whether the 
hydroxymethyl group would prove an effective water mimic or a bulky, destabilizing intrusion 
into the minor groove. One 8 substitution (entry 8) destabilized the duplex more than one 6 
substitution (1.9 °C vs. 0.6 °C), but the TM for entry 8 was 60.3 °C, nearly as high as the control. 
Two substitutions (entry 9) reduced the TM to 57.9 °C, a decrease of 4.3. However, with the full 
core sequence substituted by 8 the duplex displayed greater stability than either entry 6 or 7 (6 or 
7 in the core sequence, respectively). The TM of entry 10 was 54.5 °C, or 3.6 °C higher than entry 
6 with a full core of 6 replacing dA, and 13.1 °C higher than the duplex containing four 7 
nucleotides. Clearly, the hydroxymethyl group is engaging in a stabilizing interaction that is 
impossible for the 3-deaza-3-methyl derivative. Furthermore, considering that the 
hydroxymethyl group is much bulkier than the C-H of the 3-deazapurine 6 the stability of the 
fully 8-substituted duplex is remarkable. A further point is that the first two hydroxymethyl 
substitutions are successively more destabilizing (-1.9 °C, -4.3 °C), but the fully substituted 
sequence is only destabilized by a total of 7.7 °C relative to the control. 
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 This may be explained by the differences in geometry between 8 and a normal dA 
nucleotide engaged in a hydrogen bond with a water molecule: (1) of necessity, the 3-aryl-CH2 
bond of 8 is shorter and nearly linear, while a hydrogen bond need not be linear and is longer 
than the C-C bond; (2) analog 8 must account for the steric demand of its methylene group in the 
constrained space of the minor groove, while a water molecule has no such steric demand; (3) 
the entropic advantage of the covalently-bound hydroxylmethyl group might counteract the loss 
of stability due to (2); (4) differences in base stacking between 8 and dA, an as yet unknown 
factor.  
 One or two hydroxymethyl analogs appear to disrupt the spine of hydration, but four 
analogs in a row are able to engage in a cooperative hydrogen-bonding network similar to but 
probably geometrically different than the spine of hydration. While one or two analogs interfere 
with the spine of hydration for the normal dA nucleotides, the core fully substituted with 8 does 
not interfere with the hydration of its neighbors; instead, each hydroxymethyl analog is able to 
cooperatively hydrogen bond to the opposite strand’s dT in a similar fashion to the spine of 
hydration. This network may not engage the secondary shell of hydration in the same way as the 
primary shell normally present. 
 The dependence of the TM on duplex concentration was plotted for all sequences 
described above at 1, 3, 5, 8, and 10 µM. The linear relationship between 1/TM and lnCT can be 
used to extract the thermodynamic properties for each duplex and is a valuable tool for 
understanding the structure and properties of DNA duplexes.40 The van’t Hoff transition 
enthalpies and entropies was calculated from the slope and the intercept of the 
line,respectively.41 The control, a duplex of Sequences 1 and 2 (Figure 10) had a ΔG of -15.6 
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Sequence M B  ΔH, kcal/mol ΔS, 
cal/molK 
ΔG, kcal/mol 
2 -2.906E-05 2.629E-03 -68.4 -177 -15.5 
3 -2.364E-05 2.806E-03 -84.1 -233 -14.6 
4 -4.511E-05 2.615E-03 -44.0 -112 -10.5 
5 -2.320E-05 2.718E-03 -85.6 -230 -17.1 
8 -2.29E-05 0.0027773 -86 -238 -15.7 
      
 
kcal/mol, while replacing 2 with Sequence 3 was slightly lower at -14.6 kcal/mol. As expected, 
Sequence 4 was markedly lower at -10.5 kcal/mol. The ΔG for Sequence 5 was -17.1 kcal/mol, a  
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Figure 10. Dependence of TM on duplex concentration for sequences 2 (control), 3, and 4. 
Table 4. Preliminary thermodynamic data for several of the sequences used. 
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bit surprising since this would seem to indicate that duplex formation is more thermodynamically 
favored than for the control sequence even though its TM or thermal stability is lower. Finally, 
the ΔG for Sequence 8 was -15.7 kcal/mol, slightly more stable than the control. Additional 
collection of data for Sequences 6 and 7 is being undertaken, as is the gathering of additional 
points for Sequence 5. The differences between 6 and 7 should help shed light on the finer details 
of whether 8 engages in an altered interstrand hydrogen bonding network that interferes with the 
spine of hydration. Placing two 8 analogs next to each other might be expected to have a slightly 
higher stability than separating them, as in Sequence 6. 
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Figure 10. Dependence of TM on duplex concentration for sequences 5,7, and 8. 
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4.5 Conclusion and Outlook 
 The M4SI directing/protecting group may not represent a final solution to the problem of 
glycosylation regioselectivity for all purines, but is a significant advancement toward a solution. 
It has allowed for the efficient and regioselective synthesis of many purine 2′-deoxyribosides, in 
particular adenine and 2,6-diaminopurine heterocycles, where no N7 product whatsoever is 
observed. Selective deprotection of the sugar is possible for most purines after the glycosylation, 
and the resulting M4SI-protected nucleoside is only two steps from the phosphoramidite for 
solid-phase DNA synthesis. This obviates the need for an additional protection step, typically the 
transient protection protocol, to re-protect the exocyclic amine. Furthermore, the M4SI protecting 
group has made possible glycosylations that were not possible before (diaminopurine, 
isoguanine) as well as greatly increasing the efficiency and selectivity for many difficult purine 
substrates such as the 3-deaza-3-modified purines. The direct use of M4SI-protected 
aminopurines in glycosylations also is more cost-effective for most purines, eliminating the need 
to use expensive chloropurines. 
 M4SI should also be considered as a protecting group for primary amines where bidentate 
protection is needed. This remains to be investigated, but it is possible that the properties of M4SI 
protection could complement or even improve on the widely-used phthaloyl group. Deprotection 
of primary amines is likely to require harsher conditions than for nucleosides, just as is the case 
for the phthaloyl group, which is removed with NH3/MeOH at room temperature for nucleosides, 
but requires hydrazine and heat to remove from primary aliphatic amines. 
 Key brominated and M4SI-protected nucleobase 34 allows the synthesis of many 
different 3-deaza-3-modified purines that were not accessible before this work began. Current 
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efforts underway include the synthesis of 3-azido, 3-aminomethyl and 3-thiomethyl derivatives. 
Azide-modified nucleosides have been used for the post-synthetic modification of DNA, 
attaching such groups as dyes, linkers, and other labels in a bioorthogonal manner using click 
chemistry.42 The aminomethyl modification, similar to the work of Ganguly and co-workers15, 
would model a cation bound to the minor groove of DNA and provide valuable insight into the 
role of cation binding in stabilizing the structure of the minor groove. The thiol linker could be 
used to conjugate a wide variety of fluorophores or dyes to the minor groove in a more non-
invasive manner than has been accomplished in the past.43  
 Though the synthetic work has occupied the most time, advancements in the 
understanding of B-form DNA hydration in the minor groove has been made possible by that 
work. The novel dA analog, 2′-deoxy-3-deaza-3-hydroxymethyladenosine, has been shown by 
preliminary studies to be a reasonably good mimic of a water molecule bound in the minor 
groove. Ongoing work will provide additional thermodynamic data for this important 
contribution to our understanding of DNA structure. 
 
4.6 Experimental Details and Supporting Information 
4-Nitro-3-picoline N-oxide (10).21 To a flask containing 3-picoline N-oxide 9 (20 g, 183 mmol) 
was slowly added 100 mL of concentrated H2SO4. While keeping the temperature below 80 °C, 
40 mL of 90% fuming HNO3 was added. The reaction mixture was then carefully heated to 100 
°C until an exothermic reaction was observed with evolution of a brown gas. The flask was 
removed from heat until the bubbling had subsided, then heated at 120 °C for 2 h, after which it 
was cooled to room temperature and poured over 300 g of crushed ice. This mixture was placed 
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in an ice bath and titrated with concentrated NH4OH until a yellow precipitate formed at basic 
pH. The mixture was filtered and the solid collected and dried to yield 19.74 g (70%) of 10. This 
compound could be used directly for the next step; recrystallization from methanol yielded 
analytically pure material. 1H NMR (400 MHz, acetone-d6): δ 8.29 (s, 1H), 8.19 (m, 1H), 8.11 
(d, J=12 Hz, 1H), 2.59 (s, 3H); MS (ESI): m/z 154 (M+). 
4-Amino-3-methylpyridine (11).21 Raney nickel 2800 (8.0 g; CAUTION: pyrophoric; weighed 
under tared volume of water) was added to 100 mL of methanol and pre-reduced in a Parr shaker 
with H2 at 60 psi for 5 min. Compound 10 (8.0 g, 52 mmol) was added and reduced at 65 psi for 
4 h. The mixture was then filtered through Celite, washed thoroughly with methanol and dried in 
vacuo to obtain 5.34 g (95%) of a slightly green solid. Compound 11 is oxidized easily; therefore 
it was purged with argon and stored at 4 °C until used. 1H NMR (400 MHz, acetone-d6): δ 7.96 
(s, 1H), 7.94 (d, J = 4.8 Hz, 1H), 6.55 (d, J=4.8 Hz), 5.24 (bs, 2H), 2.08 (s, 3H); MS (ESI): m/z 
108 (M+). 
4-Nitramino-3-methylpyridine (12).21 Compound 11 (6.80 g, 63 mmol) was dissolved in 
51 mL of concentrated H2SO4 and cooled to 5 °C in a dry ice/ethanol bath. 70% HNO3 (21 mL) 
was added slowly to maintain the reaction temperature below 10 °C. The reaction mixture was 
allowed to stir at 10 °C for 1 h and then poured onto 200 g of crushed ice. Concentrated NH4OH 
was then added until a creamy off-white precipitate was formed at pH 7. The mixture was 
filtered and the precipitate recrystallized from hot water to yield 8.11 g (84%) of 12. 1H NMR 
(400 MHz, DMSO-d6): δ 8.15 (d, 2H), 8.00 (d, J = 6.6 Hz, 1H), 2.08 (s, 1H); MS (ESI): 
m/z = 153 (M+). 
3-methyl-5-nitropyridin-4-amine (13).21 Compound 12 (2.00 g, 13 mmol) was added to 19 mL 
of concentrated H2SO4 in small portions to avoid decomposition of the starting material. The 
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mixture was allowed to stir at room temperature for 18-48 h until complete (reaction was 
monitored by removing aliquot, neutralizing with NH4OH, filtering, and analyzing the precipitate 
by 1H NMR) and then quenched by pouring over 200 g of crushed ice. This mixture was then 
slowly titrated with concentrated NH4OH while cooling in an ethanol/dry ice bath. When the 
mixture reached pH 6.5-7 a yellow precipitate formed. This was filtered and dried to yield 1.02 g 
(54%) of 13. 1H NMR (400 MHz, DMSO-d6): δ 8.87 (s, 1H), 8.09 (s, 1H), 7.66 (bs, 2H), 2.12 (s, 
3H). MS (ESI): m/z 153 (M+). 
2-chloro-5-methylpyridine-3,4-diamine (14).21 Anhydrous stannous chloride (12.64 g,  66.7 
mmol,) was added to 51 mL of concentrated HCl followed by 13 (3.4 g, 22 mmol) was added 
and the reaction mixture heated at 90 °C for 1.5 h. TLC (9:1 DCM:MeOH) of an aliquot (pH 
adjusted to 12 and extracted with EtOAc) showed complete consumption of starting material. 
The reaction mixture was allowed to cool to room temperature and poured over 475 g of crushed 
ice. The pH was adjusted to 12 with 7 M NaOH and the reaction mixture extracted with EtOAc 
(4 x 200 mL). The combined organic layers were dried with MgSO4, filtered, and dried in vacuo 
to afford 2.46 g (70%) of white solid. In most cases the crude product was pure enough to be 
used directly in the next step; otherwise, flash column chromatography eluting with 9:1 
DCM:MeOH gave pure 14. 1H NMR (400 MHz, DMSO-d6): δ 7.20 (s, 1H), 5.47 (bs, 2H), 4.63 
(bs, 2H), 1.95 (s, 3H). MS (ESI): m/z 157 (M+). 
4-chloro-7-methyl-1H-imidazo[4,5-c]pyride (15).21 Under argon atmosphere, 20 mL of 
anhydrous triethylorthoformate (distilled from Na) and 20 mL acetic anhydride (fractionally 
distilled) was added to 4.0 g (25.4 mmol) of 14 and refluxed for 1 h. The reaction was cooled to 
room temperature and dried in vacuo. The residue was purified by passing through a short (6 cm) 
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column of silica gel with 9:1 DCM:MeOH to yield 3.84 g (96%) of 15. 1H NMR (400 MHz, 
DMSO-d6): δ 13.3 (bs, 1H) 8.45 (s, 1H), 7.91 (s, 1H), 2.44 (s, 3H). MS (ESI): m/z 167 (M+). 
4-chloro-7-methyl-1H-imidazo[4,5-c]pyride (15)21 from N7 product (17b).  To a pressure tube 
containing 17b (0.5 g, 0.96 mmol) was added AcOH (42 mL) and AcCl (0.41 mL, 1.1 equiv). 
The tube was sealed and the mixture heated at 65 °C for 11 h with stirring. All volatiles were 
removed in vacuo and the residue washed with DCM (5 mL) then dissolved in minimal 0.1 M 
NaOH. The solution was filtered to remove black solid residue to give a homogeneous dark 
solution. CO2 gas was bubbled through the solution until a fine white precipitate appeared. After 
15 min additional bubbling of CO2 the mixture was filtered and the white solid dried in vacuo to 
yield 159 mg (94%) of 15. This compound was analytically pure and identical in all respects to 
15 obtained above. 
7-methyl-1H-imidazo[4,5-c]pyridine (18).22 Obtained in varying amounts with 19. This 
compound could also be obtained by treating 4-chloro-7-methyl-1H-imidazo[4,5-c]pyridine 154 
(25 mg, 0.149 mmol) with 200 mg of Raney Ni (CAUTION: pyrophoric, weighed under tared 
volume of water) in 3 mL of H2O at reflux with vigorous stirring for 18 h. The mixture was 
filtered and purified as described below for 19 to afford 19 mg of 18 in nearly quantitative yield 
as a white amorphous powder. 18: Rf = 0.31 (silica gel, 9:1 DCM:MeOH with 0.7 M NH3); 1H 
NMR (DMSO-d6, 400 MHz) δ 12.95 (s, 1H), 8.78 (s, 1H), 8.38 (s, 1H), 8.12 (s, 1H), 2.48 (s, 3H) 
ppm; 13C NMR (DMSO-d6, 101 MHz) δ 144.64, 141.81, 138.75, 14.85 ppm; HRMS (DART-
TOF) calcd for C7H8N3H+ [M + H]+ 134.0718, found: 134.0712. 
7-methyl-1H-imidazo[4,5-c]pyridin-4-amine (19).22 To a flask containing 154 (1.50 g, 7.49 
mmol) was added 25 mL of anhydrous hydrazine. The mixture was heated to reflux for 30 h 
(anhydrous conditions not needed). The hydrazine was removed in vacuo and co-evaporated with 
190 
 
EtOH (3 x 15 mL). Water (45 mL) and Raney nickel (2.25 g, CAUTION: pyrophoric, weighed 
under tared volume of water) were added and the mixture heated to reflux with vigorous stirring 
to prevent the Raney Ni from sticking to the stir bar. After 3 h the mixture was filtered, while 
still hot, through a pad of Celite and the pad washed with hot water (200 mL, CAUTION: 
prevent leftover Raney Ni from drying). Evaporation of the filtrate in vacuo afforded a brown 
solid. This was re-dissolved in MeOH (30 mL) and silica gel (9 g) was added. After thorough 
drying of the mixture the resulting fine powder was loaded onto a flash column and purified by 
elution with 9:1 DCM:MeOH containing 0.7 M NH3 to obtain 19 as a white amorphous powder 
(965 mg, 87%) and starting material (400 mg, 13%). Repetition of this procedure gave yields 
varying between 60-87%, with most of the remainder being starting material and between a trace 
amount to 20% of 18. 19: Rf = 0.22 (silica gel, 9:1 DCM:MeOH with 0.7 M NH3); 1H NMR 
(DMSO-d6, 400 MHz) δ 12.55 (brs, 1H), 8.08 (s, 1H), 7.42 (s, 1H), 5.86 (brs, 2H), 2.26 (s, 3H) 
ppm; 13C NMR (DMSO-d6, 101 MHz) δ 150.79, 140.69, 139.39, 126.57, 108.00, 14.55 ppm; 
HRMS (DART-TOF) calcd for C7H9N4H+ [M + H]+ 149.0827, found: 149.0834. 
2-(7-methyl-1H-imidazo[4,5-c]pyridin-4-yl)isoindoline-1,3-dione (from 19).22 To a dry flask 
containing 15 (1.21 g, 8.17 mmol) and phthalic anhydride (2.42 g, 16.33 mmol) under inert 
atmosphere was added 80 mL of anhydrous pyridine. The reaction mixture was heated to reflux 
for 3 h, at which time TLC (9:1 DCM:MeOH containing 0.7 M NH3) indicated that all starting 
material had been consumed. All volatiles were removed in vacuo and the residue purified by 
flash chromatography (92.5:7.5 DCM:MeOH). The amide coeluted with the desired imide. The 
mixture of products weighed 2.02 g. Excess thionyl chloride (10 mL, ReagentPlus grade, 
Aldrich) was added and the mixture heated to reflux for 2 h. The solvent was removed to afford 
the title compound as an off-white solid in 86% yield. The product was pure enough to be used 
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in the next step. 1H NMR (DMSO-d6, 400 MHz) δ 13.51 (s, 1H), 9.25 (s, 1H), 8.42 (s, 1H), 8.20 
– 7.91 (m, 3H), 2.66 (s, 2H) ppm; 13C NMR (101 MHz, DMSO) δ 166.77, 145.62, 142.77, 
141.44, 135.87, 132.06, 130.36, 124.60, 122.85, 14.63, 14.57 ppm; HRMS (ESI-TOF): calcd for 
C15H10N4O2H+ 279.088, found: 279.089. 
tert-butyl 4-(1,3-dioxoisoindolin-2-yl)-7-methyl-1H-imidazo[4,5-c]pyridine-1-carboxylate 
(from 19). To a flask containing 2-(7-methyl-1H-imidazo[4,5-c]pyridin-4-yl)isoindoline-1,3-
dione (1.12 g, 4.03 mmol) was added Boc2O (4.39 g, 20.15 mmol) followed by DMAP (123 mg, 
1 mmol) and dichloromethane (20 mL). The mixture was allowed to stir for 45 min, at which 
time TLC (97:3 DCM:MeOH) showed that all starting material had been consumed. It was 
sometimes necessary to add additional Boc2O and DMAP to achieve full conversion. Volatiles 
were removed in vacuo and the residue purified by flash chromatography (97:3 DCM:MeOH) to 
afford the title compound as a white foam (1.34 g, 84%, mixture of regioisomers). 1H NMR 
(CDCl3, 400 MHz) δ 8.48 – 8.43 (m, 1H), 8.41 (d, J = 6.3 Hz, 1H), 7.97 (ddd, J = 12.6, 5.4, 3.1 
Hz, 1H), 7.81 – 7.76 (m, 1H), 2.78 (s, 1H), 2.70 (s, 1H), 1.68 (d, J = 2.1 Hz, 4H), 1.47 (s, 3H) 
ppm; 13C NMR (CDCl3, 101 MHz) δ 166.84, 166.75, 166.23, 151.97, 151.78, 151.21, 146.70, 
146.47, 146.35, 146.20, 145.26, 145.02, 144.89, 143.90, 140.61, 138.40, 137.86, 136.99, 134.49, 
134.26, 132.65, 132.37, 132.10, 130.37, 130.09, 128.49, 126.90, 126.39, 125.88, 125.16, 124.13, 
123.85, 121.62, 117.11, 87.26, 86.97, 86.47, 83.61, 29.90, 29.49, 28.27, 28.15, 27.84, 27.68, 
19.03, 13.83 ppm; HRMS (ESI-TOF) calcd for C20H18N4O4H+ 379.1306, found: 379.1398.  
tert-butyl 7-(bromomethyl)-4-(1,3-dioxoisoindolin-2-yl)-1H-imidazo[4,5-c]pyridine-1-
carboxylate (28). Obtained by the same procedure as 34. Purification by flash column 
chromatography (49:1 DCM:MeOH) ) afforded 28 as a white foam in 68% yield. 1H NMR 
(CDCl3, 400 MHz) δ 8.67 (s, 1H), 8.56 (s, 0.3H), 8.51 (s, 1H), 8.44 (s, 0.3H), 7.98 (ddd, J = 15.3, 
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5.4, 3.1 Hz, 2.6H), 7.81 (dt, J = 5.3, 2.5 Hz, 2.6H), 5.17 (s, 0.6H), 4.94 (s, 2H), 1.72 (s, 3H), 1.47 
(s, 9H) ppm; 13C NMR (CDCl3, 101 MHz) δ 166.51, 166.40, 151.32, 146.43, 146.09, 145.98, 
145.71, 144.91, 143.97, 139.40, 138.34, 137.06, 134.65, 134.46, 132.55, 132.49, 132.25, 130.12, 
126.26, 125.50, 124.26, 123.99, 121.60, 88.08, 87.45, 29.68, 28.24, 28.13, 27.82, 27.66, 24.11 
ppm; HRMS (ESI-TOF) calcd for C20H17BrN4O4H+ 457.0511, found: 456.0516. 
1-[5′-O-(4,4′-dimethoxytrityl)-2-deoxy-β-D-erythro-pentofuranosyl]-4-(3,3,4,4-tetramethyl-
2,5-dioxopyrrolidin-1-yl)-7-methyl-1H-imidazo[4,5-c]pyridine (from 38). To a flask 
containing 38 (394 mg, 0.741 mmol) dissolved in pyridine (7.5 mL) was added TEA (144 µL, 
1.04 mmol), DMTCl (301 mg, 0.889 mmol), and DMAP (18.1 mg, 0.148 mmol). The reaction 
was allowed to stir at rt for 3 h. TLC analysis indicated that some starting material remained, and 
so additional DMTCl (50 mg, 0.148 mmol) was added. TLC after another 4 h indicated complete 
consumption of starting material. Volatiles were removed in vacuo and the residue co-evaporated 
with toluene (3 x 2 mL) to remove residual pyridine. The solid residue was then purified by flash 
chromatography (silica gel washed with 1% TEA in 97.5:2.5 DCM:MeOH, then eluted with two 
column volumes of solvent system without TEA before loading compound) eluting with 97.5:2.5 
DCM:MeOH to afford the title compound as a white foam (520 mg, 84%). Title compound: Rf = 
0.34 (silica gel, 95:5 DCM:MeOH); 1H NMR (CDCl3/pyridine-d5, 500 MHz) δ 8.32 (s, 1H), 8.22 
(s, 1H), 7.45 – 7.33 (m, 2H), 7.33 – 7.11 (m, 7H), 6.87 – 6.69 (m, 5H), 5.02 (dd, J = 98.3, 12.8 
Hz, 3H), 4.59 (q, J = 5.2 Hz, 1H), 4.16 (q, J = 4.6 Hz, 1H), 3.76 (s, 6H), 3.34 (qd, J = 10.2, 4.6 
Hz, 2H), 2.53 (dd, J = 8.8, 3.9 Hz, 3H), 1.38 (s, 6H), 1.36 (s, 6H), 0.90 (s, 9H), 0.11 (s 3H), 0.9 
(s, 3H) ppm; 13C NMR (CDCl3/pyridine-d5, 125 MHz) δ 181.4, 158.5, 144.5, 142.5, 141.7, 139.3, 
138.9, 137.6, 135.7, 135.5, 130.01, 129.98, 128.1, 127.9, 126.9, 121.3, 113.2, 86.5, 85.9, 85.2, 
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71.2, 63.7, 60.8, 55.2, 47.9, 46.2, 41.6, 25.8, 21.7, 21.2, 18.2, -5.1, -5.2. ppm; HRMS (ESI-TOF) 
calcd for C41H44N4O7Na+ [M + Na]+ 857.3922, found: 857.3903. 
Cyanoethyl phosphoramidite 39. To a flask containing 5′-O-DMT-protected 38 (300 mg, 0.349 
mmol) dissolved in MeCN (6 mL) was added tetrazole (0.74 mL of 0.45 M solution in MeCN, 
0.332 mmol) followed by 2-cyanoethyl N,N,N,N-tetraisopropylphosphane (211 µL, 0.664 mmol) 
dropwise. The mixture was allowed to stir at rt for 6 h, after which TLC indicated that the 
reaction was complete. H2O (1 mL) was added and stirring continued for 10 min. The reaction 
mixture was diluted with DCM (20 mL) and washed with saturated NaHCO3 (2 x 5 mL) and 
brine (1 x 5 mL). The organic layer was separated and dried with Na2SO4, then filtered and 
evaporated in vacuo. Compound 39 could not be purified effectively by flash chromatography 
due to decomposition. Precipitation by slow addition of the crude mixture dissolved in minimal 
DCM to 120 mL vigorously stirring hexanes followed by cooling at 0 °C for 30 min afforded 39 
as a white solid (263 mg, 73%, 1:1 mixture of diasteriomers). 39: Rf = 0.41, 0.44 (silica gel, 97:3 
DCM:MeOH); 1H NMR (CDCl3/pyridine-d5, 500 MHz) δ  ppm; 31P NMR (CDCl3/pyridine-d5, 
203 MHz) δ 149.51, 149.42 ppm; HRMS (ESI-TOF) calcd for C56H75N6O9PSiH+ [M + H]+ 
1035.5181, found: 1035.5179. 
 
  DNA Synthesis  
The native and modified 12-mers were prepared by solid-phase DNA synthesis and 
deprotected using standard protocols except those containing 39. The analog nucleotides could 
be incorporated into DNA strands with essentially the same coupling efficiency as the common 
nucleotides except for 39, which coupled in 70-80% yield using the standard wait time of 2 min 
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during the coupling cycle. Increasing the wait step of the coupling cycle to 1 hour for each 
introduction of 39 resulted in coupling efficiencies of 85–90%. All newly-synthesized oligos 
were deprotected and cleaved from the CPG beads by 12–14 h treatment with concentrated 
ammonia at 55 °C. The solutions were then decanted and evaporated by speedvac, then 
redissolved in 4-6 mL H2O for purification. 
Initial purification of native and modified oligonucleotides, Sequences 1–8, was 
accomplished by HPLC (Oligo R3 reverse-phase C18 column, trityl on), starting with 100% A 
for 1 min, using a linear gradient from 0 to 50% B over 25 min [A:  1 M TEAA (pH 7) in 5% 
acetonitrile; B: 1 M TEAA (pH 7) in 70% acetonitrile]. The DMT-protected 12-mers had 
retention times of about 17.5 minutes, except for Sequence 8, which had a retention time of 24 
min due to the presence of a TBS group remaining on the hydroxymethyl group of each residue 
of 39 (four total). The collected oligonucleotides were then reduced in volume and detritylated 
and/or desilylated.  
Sequences 1–4 were detritylated in 80% acetic acid for 30 min at 0 °C. The resulting 
oligonucleotides were then desalted (Sephadex G-10) and lyophilized. Sequences 1–3 were 
desalted by elution through a Sephadex G-10 column with H2O. Purification of the c3A-modified 
oligonucleotide (Sequence 3) was accomplished by 20% denaturing gel (1x TBE buffer, 16W for 
5 hr). The oligonucleotide was visualized by UV-shadowing, bands were excised from the gel, 
and extracted into 0.5 M ammonium acetate buffer overnight. The resulting solution was filtered 
(Bio Rad poly-prep chromatography column) and desalted using a Sep-Pak cartridge (Waters 
Corporation, MA).  
Sequences 5–7 were not detritylated with AcOH because the TBS groups were not fully 
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cleaved after 1 h treatment at rt. Instead, after DMT-on HPLC purification the sequences were 
lyophilized and dissolved in 100 µL anhydrous DMSO. Then 125 µL of NEt3•3HF were added 
and the mixture heated at 65 °C for 2.5 h (DMT-off conditions). Sequence 8 was desilylated by 
dissolving in 115 DMSO, followed by addition of 60 µL TEA then 75 µL NEt3•3HF and then 
heating (DMT-on conditions). Desalting of Sequences 5–8 was accomplished by precipitation 
from butanol: after cooling the desilyation mixture briefly in a freezer, 1 mL of 1-butanol was 
added, followed by 25 µL of 3 M NaOAc. After vortexing for 30 sec the mixture was cooled at -
70°C for 30 minutes. This was followed by centrifugation for 10 min at 12,500 rpm. The butanol 
was decanted using a sterile pipette. The residue was rinsed with 0.75mL ethanol twice, then 
dried under high vacuum in a speed-vac to remove traces of butanol. Sequence 8 was purified 
again by HPLC (Oligo R3 as above) before use; sequences 5–7 were used without further 
purification.  
 
  Nucleoside Analysis 
 Sequence 3 (2 nmol) was digested into monomeric units with snake venom 
phosphodiesterase, nuclease P1, and calf intestinal alkaline phosphatase overnight at 37 °C. An 
aliquot of this mixture was analyzed by HPLC [C18 column, 0.1 M TEAA (pH 8) in 5% 
acetonitrile (isocratic)]. 
  
  Thermal Denaturation Studies 
 Thermal denaturation studies were performed in solutions of 20 mM NaH2PO4 (pH 7.5) 
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and 1 M NaCl with varying the concentrations of duplex (1 to 10 μM). Absorbance and 
temperature values were measured with an AVIV 14DS UV-visible spectrophotometer equipped 
with digital temperature control.  The temperature of the cell compartment was increased in 1.0 
°C steps (from 10 to 95 °C), and when equilibrium was reached, temperature and absorbance 
data were collected.  The TM values were determined from the absorbance versus temperature 
plots using the first derivative of the mathmatically smoothed curve. 
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1H NMR (2-(7-methyl-1H-imidazo[4,5-c]pyridin-4-
yl)isoindoline-1,3-dione (from 19). 
13C NMR (2-(7-methyl-1H-imidazo[4,5-c]pyridin-4-
yl)isoindoline-1,3-dione (from 19). 
NMR Spectra 
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1H NMR (tert-butyl 4-(1,3-dioxoisoindolin-2-yl)-7-
methyl-1H-imidazo[4,5-c]pyridine-1-carboxylate 
(from 19). 
13C NMR (tert-butyl 4-(1,3-dioxoisoindolin-2-yl)-7-
methyl-1H-imidazo[4,5-c]pyridine-1-carboxylate 
(from 19). 
199 
 
 
 
1H NMR of 28. 
13C NMR of 28. 
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1H NMR of 29c (impure). 
1H NMR of 30c (inseparable mixture of coupling products). 
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13C NMR of 30c (inseparable mixture of coupling products). 
1H NMR of 5′-O-DMT-protected 38. 
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13C NMR of 5′-O-DMT-protected 38. 
1H NMR of 39. 
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31P NMR of 39. 
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